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Abstract
Despite the decline in its incidence in the past decade, malaria remains an
important public health problem in Peru. A challenge faced by the National Malaria
Control Programme (NMCP) is the ability to efficiently target and eliminate the
remaining parasite reservoir in endemic areas, where malaria transmission is
low, seasonal and increasingly focal. Two cross-sectional surveys that combined
parasitological (PCR, microscopy) and serological metrics (seroprevalence,
seroconversion rates) were conducted to characterize malaria transmission
dynamics in low endemic areas of the Pacific northern coast and the Amazon
region in Peru. Besides the serological evidence for high heterogeneity in malaria
exposure, both to Plasmodium falciparum and Plasmodium vivax, at micro-
geographical level and over time, PCR results confirmed that most malaria
infections in the study areas were asymptomatic and sub-microscopic, and
therefore unlikely to be detected by the routine passive case detection (PCD)...
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Malaria remains an important public health problem in Peru. Two parasitologi-
cal and serological surveys were conducted to characterize malaria transmission 
in endemic areas of the Pacific northern coast (2010) and the Amazon region 
(2012) in Peru. Results showed high heterogeneity in malaria exposure at micro-
geographical level and over time, and that most malaria infections were asymp-
tomatic and sub-microscopic. Since focal screening and treatment (FSAT) has 
been introduced to overcome the limitations of routine passive case detection 
for detecting asymptomatic infections, a modelling approach was developed to 
assess the potential impact of this strategy on the P. falciparum transmission in 
the Amazon. Although model predictions suggest that FSAT enabled to reach 
elimination levels, the progression rates to those levels varied substantially ac-
cording to different operational criteria used for the intervention.  The asymp-
tomatic reservoir calls for an immediate shift in the malaria policy in Peru from 
detecting and controlling clinical malaria to targeting and eliminating all malaria 
infections. 
Le paludisme reste un problème important de santé publique au Pérou. Deux enquêtes para-
sitologiques et sérologiques ont été effectuées pour caractériser la transmission palustre dans 
les zones endémiques de la côte Pacifique Nord (2010) et la région de l’Amazonie Péruvienne 
(2012). Les résultats ont montré une forte hétérogénéité de l’exposition au paludisme, au ni-
veau micro-géographique ainsi que dans le temps, et que la plupart des infections palustres 
étaient asymptomatiques et sub-microscopiques. Le dépistage focal et traitement (DFT) ayant 
été introduit récemment afin de surmonter les limites de la détection passive afin de détecter 
les infections asymptomatiques, une approche de modélisation a été développée pour évaluer 
l’impact potentiel de cette stratégie sur la transmission de P. falciparum en Amazonie. Bien que 
les prédictions du modèle suggèrent que la DFT permette d’atteindre les niveaux d’élimination, 
les taux de progression vers ces niveaux varient sensiblement selon les différents critères opé-
rationnels utilisés pour l’intervention. L’existence de ce réservoir asymptomatique nécessite 
une réponse immédiate  de la politique de control du paludisme au Pérou, afin de passer de 
la détection et de contrôle des cas cliniques au ciblage et l’élimination de toutes les infections 
palustres.
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SUMMARY 
Despite the decline in its incidence in the past decade, malaria remains an important public 
health problem in Peru. A challenge faced by the National Malaria Control Programme 
(NMCP) is the ability to efficiently target and eliminate the remaining parasite reservoir in 
endemic areas, where malaria transmission is low, seasonal and increasingly focal.  
Two cross-sectional surveys that combined parasitological (PCR, microscopy) and 
serological metrics (seroprevalence, seroconversion rates) were conducted to characterize 
malaria transmission dynamics in low endemic areas of the Pacific northern coast and the 
Amazon region in Peru. Besides the serological evidence for high heterogeneity in malaria 
exposure, both to Plasmodium falciparum and Plasmodium vivax, at micro-geographical 
level and over time, PCR results confirmed that most malaria infections in the study areas 
were asymptomatic and sub-microscopic, and therefore unlikely to be detected by the routine 
passive case detection (PCD).  Since the NMCP has recently introduced focal screening and 
treatment (FSAT) to overcome the limitations of PCD for detecting asymptomatic carriers, a 
modelling approach was developed to assess the potential impact of this strategy on the P. 
falciparum transmission in the Amazon region and to provide insights for the best criteria for 
its implementation. Although model predictions suggest that combined interventions enabled 
to reach elimination levels, the progression rates to those levels varied substantially according 
to different operational criteria (timing, duration, diagnostic tool) used for the intervention.  
The uncovered asymptomatic and sub-patent reservoir calls for an immediate shift in the 
malaria control policy in Peru from detecting and controlling clinical malaria to targeting and 
eliminating all malaria infections (both asymptomatic and symptomatic). The combination 
of molecular and serological tools have repeatedly proved their added value in accurately 
understanding the local malaria epidemiology, determining risk factors, describing spatial 
heterogeneity in transmission, detecting malaria hotpots for targeted interventions as FSAT, 
and identifying recent changes in malaria transmission in the study areas. 
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1. INTRODUCTION 
1.1. Rationale 
Despite several decades of intense control efforts, malaria remains an important public 
health problem in Peru [1]. After malaria resurgence in the late 90s, with a peak of more 
than 200,000 slide confirmed cases in 1998 associated with the El Niño Southern 
Oscillation (ENSO) [1,2], the annual incidence decreased and stabilized at around 70,000-
90,000 cases between 2000 and 2005 [3]. Between 2005 and 2010, increased support 
from international donors, e.g. the Global Fund-PAMAFRO Project [4], allowed the 
scale-up of comprehensive malaria control strategies [5,6].  During this period, malaria 
declined drastically in Peru from 87,805 reported clinical cases in 2005 to 29,355 and 
23,075 cases in 2010 and 2011, respectively. Since 2011, following the reduction of 
financial support allocated to the malaria control, malaria started to increase again with a 
doubling of clinical cases in 2013, highlighting the potential risk of rapid malaria 
resurgence, especially in the Amazon Region [7]. 
In Peru, the significant overall reduction in malaria incidence over the past decade has 
modified the epidemiological profile of the disease in the country, especially in their most 
affected regions (i.e. Pacific northern coast and the Amazon region) [1] where 
transmission is seasonal and currently highly concentrated in a small proportion of their 
total communities [7,8]. Implementing malaria control measures in low endemic areas 
with seasonal and increasingly focal transmission, represents a major challenge to the 
National Malaria Control Programmes (NMCPs) [9]. Single communities or groups of 
households within communities in which the malaria transmission risk is significantly 
higher as compared to surrounding areas (called “hotspots”) need to be identified and 
targeted in order to efficiently eliminate the remaining parasite reservoirs [9,10]. 
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Moreover, targeted interventions should be evaluated to demonstrate whether they 
achieved expected outcomes and impact.   
Both the identification of hotspots for targeting the malaria control, and the monitoring 
and evaluation (M&E) of targeted interventions require that malaria transmission is 
accurately measured [11,12]. Historically, NMCPs have used the number of reported 
malaria cases (microscopically confirmed infections in Peru) to stratify the malaria risk, 
prioritize intervention areas, and monitor the impact of control interventions [13].  
However, as malaria transmission decreases, measuring the incidence of clinical malaria 
becomes increasingly difficult and insensitive [14], mainly due to the substantial 
proportion of asymptomatic infections not identified by passive case detection (PCD) 
[15].   
Accurately measuring malaria transmission in low endemicity areas is not a 
straightforward undertaking, and different factors (such as costs, sensitivity-specificity, 
feasibility, acceptability, seasonal variations) must be taken into account before choosing 
adequate metrics [11,16]. Though the entomological inoculation rate (EIR) is usually 
considered as the gold standard for quantifying malaria transmission, this metric has 
proven to be inaccurate and non-cost-effective in low transmission areas [16,17]. 
Although determining the malaria parasite rate (i.e., the prevalence of malaria infections, 
both symptomatic and asymptomatic) through a large community survey seems to be a 
more accurate and cost-effective method, only repeated surveys using the same methods 
in the same population at similar time periods would provide sufficient precision for 
monitoring changes in malaria transmission [16,18]. Additionally, low-parasite-density 
infections would only be detected by highly sensitive tests such as polymerase chain 
reaction (PCR) [19]. Conversely, cross-sectional surveys using serological markers are 
increasingly proposed as useful alternatives for estimating malaria transmission intensity 
in low transmission settings. Age-stratified seroprevalence data have been used to model 
seroconversion rates (SCR) which closely correlated with EIR, parasite prevalence [20-
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22] as well as related changes over time following specific interventions [22], seasonal 
or behavioural changes [23]. 
In addition to tracking the progress of control efforts with appropriate malaria 
transmission metrics, NMCPs should be able to anticipate and evaluate diverse threats 
that can appear during the scale-up of malaria control interventions (e.g., drug resistance, 
insecticide resistance, sub-optimal coverage, sub-optimal use of preventive measures, 
etc.) for an opportune programme reorientation [14]. Moreover if the programme 
reorientation involves the incorporation of new malaria control strategies or tools, 
NMCPs should be able to evaluate them in terms of geographic scope and long-term 
feasibility [14,24]. Since these types of evaluation cannot always be done experimentally, 
mathematical modelling has emerged as an important tool for understanding malaria 
transmission dynamics and assessing short and long term impacts of different control 
measures [25,26]. Modelling can build on available data, test multiple scenarios and 
combination of interventions, and make verifiable predictions on the expected impact and 
timeline of different strategies.  
This thesis research aimed to characterize malaria transmission in two different ecological 
settings in Peru (i.e., the northern coast and the Amazon region), and to assess the 
elimination potential of different interventions using modelling approaches. The two 
main topics addressed in the thesis (i.e., malaria transmission metrics in low transmission 
areas, and modelling potential impact of different strategies for malaria decision-making) 
are in line with important needs identified by the research community and decision-
makers in preliminary forums about the relevance and feasibility of a national malaria 
elimination program in Peru: the need to  redefine surveillance and control strategies in 
the perspective of low transmission, and to strengthen M&E activities in order to better 
inform malaria control and elimination efforts [27]. 
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1.2. Objectives 
 
The main objective of the thesis is: 
 To characterize malaria transmission in two different ecological settings in Peru 
and to assess the elimination potential of different interventions using modelling 
approaches.  
 
The specific objectives of the thesis are: 
 To measure malaria transmission intensity and identify related risk factors in the 
Pacific northern coast and the Amazon region of Peru using parasitological and 
serological metrics; 
 To characterize the heterogeneity in malaria transmission in the Pacific northern 
coast and the Amazon region through the use of spatial analysis, and identify past 
changes in transmission using age-specific seroconversion rates; 
 To develop a simple mathematical model able to simulate an existing baseline 
scenario of seasonal malaria transmission in an endemic community of the Amazon 
region, and to improve this model to predict the potential for elimination of focal 
screening and treatment (FSAT) in addition to the routine PCD. 
 
 
 
 
 
 
 
 
Introduction 
5 
 
 
1.3. Thesis outline 
The thesis is organised in seven chapters. 
Chapter 1 presents the rationale and the objectives of the thesis.  
Chapter 2 describes the global malaria burden and revises briefly the past and current 
control and elimination efforts. Then, it provides a background on transmission metrics 
and on advantages and disadvantages of their use in low transmission settings. Next, it 
focuses on the basic malaria mathematical models and how these can be used in 
describing the influence of control and elimination interventions on the transmission of 
the disease. And finally, it presents a detailed overview of the malaria control strategies 
in Peru. 
Chapter 3 reports on population-based estimates of P. falciparum and P. vivax 
prevalence and seroprevalence in an area of low endemicity in the north-west coast of 
Peru, providing insights into the residual transmission dynamics. 
Chapter 4 characterizes the malaria transmission dynamics in three sites of the Peruvian 
Amazon region through the use of a single cross-sectional survey that combined 
parasitological and serological metrics.  Current malaria transmission patterns, hotspots 
of high malaria risk and changes in species-specific malaria transmission are identified in 
the study area. 
Chapter 5 describes a mathematical model developed to simulate an existing baseline 
scenario of seasonal malaria transmission in an endemic community of the Amazon 
Region, and how it was improved to predict the potential effect of adding FSAT 
interventions to ongoing PCD. 
Chapter 6 includes an ongoing work that complements the characterization of malaria 
transmission in the northern coast (Chapter 3) by identifying spatial clusters of malaria 
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risk using survey data, and evaluates whether these spatial clusters are able to detect future 
malaria hotspots of clinical malaria incidence. 
Chapter 7 discusses the main findings of the thesis research, the implications of them for 
the malaria control in Peru, and provides perspectives for future research.   
Chapter 8 lists the bibliographic references, and chapter 9 includes the chapter annexes.
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2. BACKGROUND 
2.1. Malaria, the global burden 
The remarkable increase of financing and coverage of NMCPs overall has resulted in a 
wide-scale reduction in the reported malaria incidence and mortality rates since 2000 
(Figure 2.1). Based on an assessment of trends of reported malaria cases, 64 of a total of 
the 106 countries with malaria transmission in 2000 were meeting the Millennium 
Development Goal (MDG) target of reversing the incidence of malaria in 2013. Of these 
64 countries, 55 were on track to meet the World Health Assembly (WHA) and Roll Back 
Malaria (RBM) targets of reducing malaria case incidence rates by 75% in 2015. 
However, most of those 55 countries had low numbers of cases in 2000, accounting for 
only 6% of the total estimated cases in that year [28]. 
 Figure 2.1.  Projected changes in malaria incidence rates, by country, 2000-2015.  
Source: World Malaria Report 2014 [28].  
 
Considering the WHO classification of countries by stage of malaria elimination (Table 
2.1), among the 106 countries with malaria transmission in 2000, ten countries are 
currently in the pre-elimination phase (Capo Verde, Belize, El Salvador, Costa Rica, 
Mexico, Ecuador, Paraguay, Bhutan, Democratic People’s Republic of Korea, Malaysia), 
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nine countries are in the elimination stage (Algeria, Argentina, Iran,  Saudi Arabia, 
Azerbaijan, Tajikistan, Turkey, Sri Lanka, Republic of Korea), seven countries in the 
prevention of malaria reintroduction phase (Egypt, Oman, Iraq, Syrian Arab Republic, 
Georgia, Kyrgyzstan, Uzbekistan), and four countries have recently been certified as 
malaria free countries by WHO (Morocco in 2010, United Arab Emirates in 2007, 
Turkmenistan in 2010, and Armenia in 2011). 
Box 2.1. Definitions for stages towards malaria elimination [29,30] 
 Malaria control programmes are implemented in countries for reducing the malaria disease burden 
(incidence, prevalence, morbidity, and mortality rates) to a level at which it is no longer a public health 
problem. Continued intervention measures are required to maintain the reduction. 
Pre‐elimination programmes are implemented in countries to reorient their NMCP between the 
sustained control and elimination stages. During this period, high coverage with good‐quality 
laboratory and clinical services should be reached, reporting and surveillance should be reinforced, 
followed by other programme adjustments to halt transmission nationwide. 
Prevention of reintroduction programmes are implemented in countries that have either recently 
achieved zero cases and aim to maintain the situation, or in countries that are generally considered 
non‐endemic, having been malaria‐free for well over a decade, that have experienced recent outbreaks 
of locally acquired malaria subsequent to importation of parasites.  The main activity is vigilance 
(surveillance and response) by the general health services, which can be combined with vector control 
and other interventions to reduce receptivity in vulnerable areas. 
Malaria elimination is the complete interruption of the local mosquito-borne malaria transmission, 
i.e., reduction to zero of the incidence of infection caused by human malaria parasites in a defined 
geographical area as a result of deliberate efforts. Continued measures are required to prevent 
reestablishment of transmission. 
Certification of malaria elimination is the official recognition of malaria-free status granted by 
WHO after it has been proven beyond reasonable doubt that the chain of local human malaria 
transmission by Anopheles mosquitoes has been fully interrupted in an entire country for at least 3 
consecutive years. 
Re-introduction of transmission is the renewed presence of a constant measurable incidence of cases 
and mosquito-borne transmission in an area over a succession of years. An indication of the possible 
re-establishment of transmission would be the occurrence of three or more introduced and/or 
indigenous malaria infections in the same geographical focus, for 2 consecutive years for P. 
falciparum and for 3 consecutive years for P. vivax. 
Malaria eradication is the permanent reduction to zero of the worldwide incidence of infection 
caused by a particular malaria parasite species as result of deliberate efforts. Intervention measures 
are no longer needed once eradication has been achieved. 
Despite the good progress over the past decade, malaria remains the most important 
human arthropod-borne disease worldwide. Over three billion people live at risk of being 
infected with malaria and developing disease. According to the last estimates, 198 million 
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cases and about 584,000 deaths occurred globally in 2013 representing a decrease in 
malaria case incidence and mortality rates of 30% and 47% since 2000, respectively [28].  
However, the distribution is not equal: the African continent is a highly-endemic region 
accounting for most of the worldwide overall malaria cases (82%) and deaths (about 90%) 
compared to regions like the American continent which contributed with only a minor 
percentage of the global malaria burden with 427,000 confirmed cases (about 700,000 
estimated cases) and 82 reported deaths (about 800 estimated deaths) in 2013 [28]. 
Approximately 120 million people in 21 American countries live at risk of malaria 
infection within the context of hypo-endemic and unstable transmission [28,31,32]. The 
Amazon basin shows the greatest transmission involving five countries (Brazil, 
Venezuela, Colombia, Guyana, and Peru) accounting for about 90% of the malaria burden 
in the continent (Figure 2.2). P. vivax accounts for 74% of the cases, P. falciparum for 
about 26%, and a limited number of cases (0.1%) are caused by P. malariae [28]. 
 Figure 2.2. Distribution of malaria in the Americas according to the Annual Parasite 
Index in 2012. Source: Pan American Health Organization (PAHO) 
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2.2. Global malaria control and elimination efforts 
A mathematical model demonstrating the effective interruption of parasite transmission 
through adult mosquito control was the scientific basis for the past malaria eradication 
efforts [33,34].  Encouraged by the early success of using dichloro-diphenyl-
trichloroethane (DDT) against malaria vectors, WHO embarked on the Global Malaria 
Eradication Program (GMEP) in 1955. Eradication was defined as “the ending of the 
transmission of malaria and the elimination of the reservoir of  infective cases in a 
campaign limited in time and carried out to such a degree of perfection that when it comes 
to an end, there is no resumption of transmission” [35]. Taking into account the particular 
outcomes of regional malaria control campaigns evidencing almost complete interruption 
of malaria transmission in selected areas (Greece, Italy, Cyprus, Venezuela, Argentina 
and the United States) [36], WHO designed a four-phased Eradication plan for NMCPs 
which was limited in duration (5-10 years) and in geographic scope. First as preparatory 
phase, a National Malaria Eradication Service (NMES) was established in each 
participating country to coordinate and execute all phases of the programme. Second, an 
attack phase was implemented in endemic regions involving deployment of antimalarial 
drugs (primarily chloroquine (CQ)) to reduce infection prevalence in human populations, 
and extensive spraying of DDT to shorten mosquito vector viability.  Third, once the 
surveillance data confirmed the interruption of transmission, a consolidation phase based 
on intense active case detection (ACD) allowed the identification and elimination of the 
remaining malaria infections. If no autochthonous cases appeared for three years, malaria 
was recognized as being eradicated from that region. At that point, the region would enter 
the maintenance phase, during which malaria surveillance responsibilities were 
transferred to the national health services.  
GMEP campaigns succeeded in altering the global distribution of malaria, reducing 
radically the morbidity and mortality in many endemic areas of Europe, North America, 
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the Caribbean, Asia and South-Central America [37] and eliminating the disease in over 
30 countries (mostly developed countries) [38].   The remarkable success in these areas 
was aligned with the improvement of the local public health infrastructure, the 
commitment of financial and human resources that were not realized until after the 
Second World War, and the sustained political commitment.  However their limited 
effectiveness in high transmission areas such as the sub-Saharan Africa demonstrated that 
the total eradication of malaria through single strategies was not feasible [39]. In addition, 
the development of insecticide resistance, the operational and financial limitations to 
sustain the intensive eradication efforts in some regions, and the reallocation of funds to 
more pressing public health problems in other regions where malaria had successfully 
been reduced but not eliminated resulted in the WHO abandoning the global eradication 
program 1969 [36].  
From 1969 to 1991 the malaria control strategy changed to containment which was mainly 
focused on technical issues against a background of rising malaria cases, on the research 
and development of new tools (e.g. vector control and insecticide-treated nets), as well as 
on the better understanding of the social, economic and cultural dimensions of malaria. 
During this post-eradication period, newly independent states of Africa struggled to 
establish broad-based health systems and primary health care, and did not receive enough 
support for the malaria control.  
By 1992, the combination of a worsening malaria situation and promising technical 
developments led to renewed global focus on malaria control. In 1998, WHO launched 
Roll Back Malaria (RBM) initiative as a mechanism for improving control interventions 
and attracting money for malaria control [35].  In 2000, the Abuja Declaration defined 
the progressive intervention coverage targets for reducing the malaria disease burden, 
emphasizing the fact this could only be achieved through vastly strengthened local health 
systems [37]. 
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Since 2003, the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), the 
World Bank’s Booster Program (WBBP), the US President’s Malaria Initiative (PMI) and 
many other donors have been supporting the widespread implementation of malaria 
control measures such as long-lasting insecticide-treated bed nets (LLINs), indoor 
residual spraying (IRS), the use of malaria rapid diagnostic tests (RDTs) and the provision 
of efficacious anti-malarial treatments based on artemisinin-based combination therapy 
(ACT). The early evidence of decreasing malaria transmission in regions with high 
coverage of interventions renewed the optimism for malaria elimination programmes.  
Thus, following declarations at the Malaria Forum in 2007 convened by the Bill & 
Melinda Gates Foundation, and subsequent support voiced by the WHO, the RBM 
Partnership, and many other organizations, the paradigm of malaria control and 
elimination has been extended to encompass an ultimate goal of malaria eradication 
[29,40]. 
 Figure 2.3. WHO malaria elimination continuum  
Source: Global Malaria Action Plan. RBM, 2008. 
 
In 2008, the RBM unveiled the Global Malaria Action Plan (GMAP) [29], which became 
the first single comprehensive blueprint for global malaria control and elimination [41]. 
The Plan characterizes different phases of malaria control as NMCPs progressively 
Background 
13 
 
reduce transmission, though it is understood that these phases are part of a continuum 
rather than abrupt shifts (Figure 2.3). At high levels of transmission, initial efforts are 
focused on scaling up control strategies for impact. LLINs, IRS, preventive treatment for 
pregnant women and access to effective treatment with ACT are considered as primary 
strategies. Sustained control efforts subsequently lead to further transmission reduction. 
As very low levels of transmission are reached, NMCPs move from control to pre-
elimination and elimination, and finally the prevention of reintroduction once elimination 
is reached. 
In 2015, WHO aims to launch a new technical strategy for 2016–2030 [42] which will set 
milestones and goals for burden reduction and elimination beyond 2015, the WHO vision 
being “A world free of malaria”. This can be achieved through country-by-country (and 
later regional) elimination of malaria infection, followed by global malaria eradication.  
2.3. Transmission metrics in low transmission areas  
Many factors have been described as potential causes of the limited success of GMEP 
campaigns, including the collapse of funding [36,38].  Retrospective analysis of 
eradication efforts have also revealed  that there were failures of national monitoring and 
evaluation (M&E) systems in providing guidelines  for establishing  quantitative (i.e., 
metrics) and operationally definitions and milestones for measuring progress towards 
control in a range of contexts [14].   
As NMCPs reduce malaria transmission in their respective countries, they will need to 
use metrics that ensure an accurate description of the malaria heterogeneity and 
measurement of changes in the malaria transmission intensity across appropriate 
geographical scales.  Those metrics should be chosen taking into account different factors 
(such as costs, sensitivity-specificity, feasibility, acceptability, seasonal variations) 
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[11,16].  Table 2.1 summarizes the advantages and disadvantages of four different 
transmission metrics in low transmission settings. 
   
Table 2.1. Advantages and disadvantages of the use of transmission metrics in low 
transmission areas 
Metrics Advantages Disadvantages 
 Entomological 
inoculation 
rate (EIR) 
 -Gold standard for measuring 
malaria transmission intensity. 
-Familiar to decision-makers 
 -Validity affected by the spatial, temporal 
and seasonal variability in vector density. 
-Variation in sampling methods for 
mosquitoes.  
- Data collection is resource-intensive 
and time-consuming.  
Incidence rate 
of clinical 
malaria 
confirmed by 
microscopy 
-Obtained from routine surveillance. 
-Able to be integrated with other 
programmatic data.  
-Familiar to decision-makers. 
-Validity affected by factors that 
influence PCD effectiveness and case 
notification, e.g. high proportion of 
asymptomatic infections, access to health 
facilities, treatment-seeking behaviour, 
quality of microscopic diagnosis, 
information systems, etc.  
Parasite rate 
(PR) 
-Common used as metric of 
endemicity. 
-Metric obtained from cross-
sectional surveys. 
-Familiar to decision-makers 
-Provide information about current 
infection. 
-Validity affected by the sensitivity of the 
malaria diagnostic test used. 
-Affected by seasonal variations. 
-Large sample sizes are needed at low 
levels of infections (increase in costs and 
resources).  
 
Seroconversion 
rate (SCR) 
-Easy sample collection during 
cross-sectional surveys.  
-Cheap laboratory techniques.  
-Provide information about past 
infection.  
-Less affected by seasonal variations. 
-Not used by decision-makers. 
-Require previous validation of antigens 
(multiple) for detection of antibodies. 
 
 
The Entomological inoculation rate (EIR) is the number of infectious bites received per 
person per period of time (typically year) [43], and can be estimated using direct 
measurements of the human biting rate (HBR, the number of bites per person per time 
unit) and the sporozoite rate (SR, the proportion of mosquitoes that are infectious) 
supplemented by models of mosquito populations. Measuring HBR involves capturing 
and counting the number of mosquitoes that attempt to feed on a human, while the 
determination of SR requires the identification of sporozoites in salivary glands of the 
captured mosquitoes.  
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EIR is usually considered as gold standard for measuring malaria transmission and 
commonly used by NMCP managers. However, the precision and accuracy of EIR 
estimates can be affected by the spatial, temporal and seasonal variability in the vector 
density, as well as by the lack of standardization of available methods for measuring both 
HBR (i.e. human-landing catches, exit traps, CDC light traps) and SR (i.e., dissection, 
enzyme-linked immunosorbent assays-ELISA,  Polymerase chain reaction-PCR) [17].  
Although repeated sampling over time and at multiple locations can overcome the 
heterogeneity in the mosquito dispersal and feeding behaviour, and increase the 
sensitivity of EIR [44]; this sampling strategy would not be cost-effective in low 
transmission areas given the large number of mosquitoes to collect before finding one 
that is infected [17].    
The incidence rate of clinical malaria is the rate at which new episodes of clinical 
malaria (fever plus confirmed parasitaemia) occur in a population. Throughout the thesis, 
the term “incidence”  refers only the number of new cases, while the term “incidence 
rate” takes into account the variable time periods during which individuals are disease-
free and thus “at risk” of developing malaria. In its calculation, the numerator is the 
number of new malaria episodes that occur in a defined time period, and the denominator 
is the population at risk of experiencing the event during this period [45]. Since it may 
not be possible to measure disease-free periods precisely, the denominator is often 
calculated approximately by multiplying the average size of the study population by the 
length of the study period. This is reasonably accurate if the size of the population is large 
and stable and incidence is low. NMCPs frequently use a proxy measure of the incidence 
rate, i.e., the annual parasite index (API), which is expressed as the total number of 
cases per 1000 person per year at risk. It results from the product of the slide positivity 
rate (SPR) and the annual blood examination rate (ABER) divided by 10 [11,36].  SPR is 
the proportion of individuals examined by light microscopy (LM) or RDTs who test 
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positive for parasitaemia, while ABER is the proportion of the total population examined 
for parasitaemia.    
Since SPR and ABER can be obtained from the routine surveillance data, they allow 
NMCPs to rapidly detect changes in incidence rates, and to easily integrate this metric 
with other types of data to help evaluate and improve programmes [16].  API ascertained 
through passive case detection (PCD) alone only records those symptomatic individuals 
who are detected at health facilities, underestimating the intensity of transmission for the 
entire population.  Other factors related to PCD that can affect the accuracy of API include 
the access to the health facilities with LM or RDTs [46], the quality of microscopy-based 
diagnosis [47], and social and cultural factors that influence treatment seeking behaviors 
at community level [48]. Adding ACD to detect symptomatic individuals who do not seek 
for attention as well as asymptomatic infections may generate more accurate API, but is 
costly and logistically more challenging since it involves repeated scheduled visits of 
targeted populations [49].     
Parasite rate (PR), the proportion of individuals with parasitaemia at given point in the 
time, is one of the most widely used metrics of endemicity [50]. PR is commonly 
measured in cross-sectional surveys by examining blood samples using LM or RDTs of 
a representative sample of the population. While the operational utility of these diagnosis 
tests cannot be discounted, there is enough accumulated data that suggest that LM and 
RDT diagnoses underestimate the PR [51]. Epidemiological studies using molecular 
methods such as PCR have detected on average two fold more infections than detected 
by LM, uncovering an important proportion of very low-parasite-density infections 
particularly in low transmission areas [52-54].  
Besides the method used for parasite detection, the accuracy of PR can also be affected 
by the distribution of both parasite infections and parasite densities in the population at 
the time of the blood sample collection.  Since that distribution can vary according to the 
malaria transmission season [16,18], the level of immunity at the population [55], and the 
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recent history of anti-malarial drug use, it is unlikely that a single cross-sectional could 
accurately capture PR [56].  Repeated surveys using the same methodology in the same 
population at similar time periods can give enough precision for monitoring changes in 
malaria transmission, but not in all epidemiological contexts.  The detection of the impact 
of malaria control efforts in low transmission areas become very difficult when PR 
estimates are below 1-5% [11]. In addition with low levels of positive tests, surveys will 
require large sample sizes to achieve an appropriate degree of statistical power; thereby 
increasing the resources and costs required for the measurement.  
Seroconversion rate (SCR) is defined by the percentage of population that develop 
antibodies against malaria over a fixed time period. It is calculated by fitting a reverse 
catalytic model to age-specific prevalence of antibody responses to a single or defined set 
of recombinant malaria proteins expressed by various stages of the parasite lifecycle [20]. 
More details about the reverse catalytic model are presented in Box 2.2.   Blood samples 
for generating seroprevalence data can be collected in cross-sectional surveys [57], school 
surveys or in health facilities taking into account the advantages and disadvantages of 
each survey type.   Experimentally, the quantification of antibodies on blood samples 
collected on tubes or filter paper is relatively easy to perform using simple and cheap 
laboratory techniques such as ELISA [58].  
Since seroprevalence represents cumulative exposure to infection [59], SCR is able to 
reconstruct the history of exposure in the study population even without knowing 
previous baseline data [21,22]. Its accuracy increases when serological surveys include 
enough individuals of different ages, and the detection of antibodies is performed using 
multiple antigens given the possibility of heterogeneous immunity in the population 
[16,60].  SCR as metric for malaria transmission intensity may be particularly suited to 
low endemic areas as antibodies remain in the blood longer than malaria parasites and are 
thus easier to detect and less subject to seasonal variations than other measures [57].  
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Box 2.2. Catalytic models 
 
 Catalytic models were first used to model age-
specific changes in the force of infection, the rate at 
which individuals who are susceptible (S) become 
infected (I).  For common viral diseases such as 
measles the presence of antibodies indicates that the 
person has been infected and become immune to 
subsequent infection, then the seroconversion rate 
(SCR, λ) or force of infection can be estimated 
directly from the age-seroprevalence data using a 
simple catalytic model and maximum likelihood 
methods.  
 
Reversible catalytic models describe the infectious 
process where a susceptible (S) host becomes 
infected (I), and then reverts to the state of 
susceptibility after the infection is self-limited or 
cured by medical interventions.     
The model generates a seroconversion rate (SCR,  λ), 
which represents the rate at which people become 
seropositive, and a rho (ρ) which represents the rate 
at which people revert back to seronegativity 
(seroreversion rate). Despite its simplicity, this model 
have been frequently used for estimate the force of 
infection of malaria in well-defined areas. 
 
The main assumptions of the model are: population is 
constant, migration is negligible, there are no 
individual differences in SCR between subjects, and 
the disease transmission in the population is at an 
endemic steady-state; i.e., SCR is assumed constant 
over time. 
  
Formulas and schematic 
representations  
of catalytic models 
 
 
 
Simple catalytic model 
 
 
 
  
 
 
Reversible catalytic model 
 
 
 
 
Pt is the proportion of 
individuals  
aged t that are seropositive 
 
 
 
 
 
 
Background 
19 
 
2.4. Modelling for malaria control and elimination 
A considerable number of modelling studies have addressed the transmission of 
infections throughout populations [61]. The traditional epidemiological approach 
consists of compartmentalizing the total host (human) population into susceptible (S), 
exposed (E), infected (I) and recovered (R) sub-populations, and/or the total vector 
population into susceptible (U), exposed (L), and infected (V) sub-populations [62].  
Many variations of this paradigm have been proposed over the past century. 
 
Figure 2.4. Malaria life cycle. During a blood meal, a malaria-infected female Anopheles 
inoculates sporozoites into the human host (1). Sporozoites infect liver cells (2) and mature into 
schizonts (3), which rupture and release merozoites (4). In Plasmodium vivax a dormant stage 
“hypnozoites” can persist in the liver and cause relapses weeks, or even years later. After this initial 
replication in the liver (exo-erythrocytic schizogony [A]), parasites undergo asexual multiplication 
in the erythrocytes (erythrocytic schizogony [B]). Merozoites infect red blood cells (5). The ring 
stage trophozoites mature into schizonts, which rupture releasing merozoites (6). Some parasites 
differentiate into sexual erythrocytic stages (gametocytes) (7). Blood stage parasites are responsible 
for the clinical manifestations. The gametocytes, male (microgametocytes) and female 
(macrogametocytes), are ingested by an Anopheles mosquito during a blood meal (8). The parasites' 
multiplication in the mosquito is known as the sporogonic cycle [C]. While in the mosquito's 
stomach, the microgametes penetrate the macrogametes generating zygotes (9). The zygotes in turn 
become motile and elongated (ookinetes) (10) which invade the midgut wall of the mosquito where 
they develop into oocysts (11). The oocysts grow, rupture, and release sporozoites (12), which make 
their way to the mosquito's salivary glands. Inoculation of the sporozoites into a new human host 
perpetuates the malaria life cycle (1). Source: Parasite Image Library. 
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Modelling malaria transmission require a good knowledge and understanding of the 
malaria life cycle (Figure 2.4) and the first malaria transmission models originated with 
Sir Ronald Ross. While working at the Indian Medical Service in 1890's, Ross 
demonstrated the life-cycle of the malaria parasite in mosquito, and was one among the 
first to publish a series of papers using mathematical functions to study malaria 
transmission  in the early 1900s [63-65]. In 1915, Ross introduced the first deterministic 
differential equation model intended to explain the relationship between the incidence of 
malaria in the human and mosquito population [66].  
After about forty years, George Macdonald [34] in 1950s expanded the Ross model by 
introducing information about the time Plasmodium spends growing and multiplying 
inside the female mosquito before it harbours infectious sporozoites in its salivary glands 
(“sporogonic cycle”= about 10 days). Since the mosquito needs to survive beyond this 
latent period to be able to transmit the disease, mosquito survival was recognized as the 
most critical parameter to maintain malaria transmission. This approach provided the 
rationale for GMEP campaigns focused on the use of DDT to kill mosquitoes [33,36].  
Then in 1991, Anderson and May added to Macdonald's model the time (about 21 days) 
lag a person exposed to P. falciparum needs to become infectious with gametocytes in 
the blood (“latency”) [67].  
Summarizing, the three basic models use the simplest scenario for predicting the 
progression of malaria infections in the host and mosquito population through the 
compartmentalization of populations and the incorporation or not of the latency periods 
of Plasmodium in the mosquito and the human, assuming that total populations remain 
constant over time (Box 2.3).  As shown in Figure 2.5, the inclusion of latency periods in 
mosquitoes and humans not only reduces the long-term prevalence of infected mosquitoes 
(V) and humans (I), but it also reduces the rates of progression to these infections. See 
Annex (Chapter 9, text S2.1) for R codes of basic malaria models. 
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Box 2.3. Basic malaria models 
Ross model divides the human population (N)
in susceptible (S) and infected (I) sub-
populations, and the mosquito population (M)
in susceptible (U) and infected mosquitoes
(V). Individuals in S become I at a rate that is
determined by the mosquito density (m), the 
human feeding rate per mosquito (a), the 
infectiousness of the mosquito population
(V/M), and the susceptibility of an individual
after being bitten by an infectious mosquito
(b). In absence of treatment, infected
individuals (I) recover completely without 
conferring long-lasting immunity at a rate (γ) 
that is determined by the reciprocal of the
average time for the spontaneous clearance of
parasites from blood. Regarding the mosquito
population (M), S become V at a rate
determined by: the human feeding rate per
mosquito (a), the proportion of infectious
individuals in the human population (I/N), and
the mosquito susceptibility to infection after
biting an infectious individual (c). Mosquitoes
do not recover from infection due to their short
life span. Both infected humans and
mosquitoes are infectious since the time they
acquired the infection. 
Unlike Ross model, Macdonald model
divides the mosquito population (M) into three
compartments (U, L, V). Mosquitoes are not
infectious immediately after infection; they
remain in a latent state (L) for a specific time
period before developing sporozoites and
becoming infectious (V). The estimation of 
surviving mosquitoes by the end of the latent
period requires an adjustment by the factor e-
μ2*n which incorporates a constant mosquito
mortality rate (μ2) and the average mosquito
latent period (n). 
Anderson and May model added the latent
period in humans. Then, the model allows the
human population (N) to move between three
different states (S, E, I). After being bitten by
an infectious mosquito, individuals progress to
the latent state (E), from which they develop
gametocytes in the blood and become 
infectious after a latent period (l). The 
estimation of individuals who move from E to
I at the end of latent period requires an
adjustment by the factor e-(μ1+γ)*l which 
incorporates a constant human mortality rate
(μ1) and the average human latent period (l). 
Schematic representation of models and
formulas for basic reproductive ratio (R0) are 
presented in the right side of the box.  
                                           Ross model 
 
                                           
 
MacDonald model 
 
  
 
Anderson and May model 
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Figure 2.5. Effect of the incorporation of latency periods in the prevalence of infection in 
humans and mosquitoes. Graph generated using R considering the following parameters: N=500, 
M=15000, I=1, m=30, a=0.2 day-1, b=0.2, c=0.5, γ=1/210 day-1, μ2=0.2 day-1, n=10 days (used in 
MacDonald and Anderson &May model), μ1=0.00005 day-1, l=21 days (used only in Anderson 
&May model).   Continuous lines represent prevalence of infected individuals (I), while dotted lines 
prevalence of infected mosquitoes (V).  
 
The basic reproductive number (R0) can also be used to describe and compare these basic 
models. Ro is the number of infections that one infection generates on average over the 
course of its infectious period in a population with no previous exposure to malaria and 
no malaria control [67,68]. Regarding compartmental models, R0 is defined as the number 
of secondary infections arising from a single infection in an otherwise uninfected 
population [34] and can be used to determine whether or not an infectious disease can 
spread through a population: malaria spreads in a population only if R0>1 (epidemic), 
remains in an endemic stable state if R0=1, or disappears if R0<1. The incorporation of 
latency periods of mosquitoes and human involves the adjustment of the Ross R0 formula 
by negative exponential functions, resulting therefore in further reductions of R0 values 
(see Box 2.3).  
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Despite their relative simplicity, basic models can be used in describing how the control 
and elimination interventions can influence the transmission of the disease [25].  
Parameters that regulate the fraction of human population that will enter into the exposed 
(E) and infectious compartments (I) (m, a, b, μ2) may be modified by specific 
interventions resulted in changes in the intensity of the disease transmission, which can 
be measured though the Ro. Similarly, changes in the duration of the infection (γ) will 
also affect Ro estimates.  
 
      
Figure 2.6. Effect of modifying the parameters values used in figure 2.5 for Macdonald 
model on the Ro predictions. Baseline values: N=500, M=15000, I=1, m=30, a=0.2 day-1, b=0.2, 
c=0.5, γ=1/210 (0.0047) day-1, μ2=0.2 day-1, n=10 days (used in MacDonald and Anderson 
&May model), μ1=0.00005 day-1, l=21 days (used only in Anderson &May model).   Continuous 
lines represent prevalence of infected individuals, while dotted lines prevalence of infected 
mosquitoes. 
 
Figure 2.6 shows the effect of modifying the parameters values used in Figure 2.5 for the 
Macdonald model on the R0 predictions. It is not surprising that the square dependence 
of the human feeding rate (a) implies that halving the biting rate is more effective than 
halving the mosquito density (m). However according to the model, interventions that 
reduce the survival of mosquitoes (i.e., increasing the mortality, μ2) would be the most 
effective in reducing malaria transmission.  As mentioned before, this approach provided 
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the rationale for GMEP campaigns focused on the use of DDT. This strategy not only 
increased the mosquito mortality rate (μ2), but also decreased the mosquito density (m) 
and the human feeding rate (a). 
Several models have been developed that expand the basic models by considering factors, 
such as age-related differential susceptibility to malaria in human populations, acquired 
immunity [69], and spatial and genetic heterogeneity of the host and parasite [70,71].  
Basic and complex models have been widely used to evaluate effects of different 
strategies such as vector control [72], the use of future vaccines [73], the use of 
artemisinin-based combination therapies, as well as different levels of anti-malarial 
resistance [74]. 
Modelling to support malaria control and elimination 
Despite providing the rationale for the eradication, the overall role of mathematical 
modelling in the GMEP was limited. Modelling informed the design of the attack phase 
of malaria eradication [34,35], but not the design or implementation of other phases, and 
there were no provisions made to evaluate or update the design of the GMEP despite its 
obvious limitations. Modelling as part of M&E could have helped to anticipate, analyse, 
and adjust for some problems that developed during the eradication efforts [14], such as 
the reduced impact of GMEP campaigns due to the spread of mosquito resistance to DDT.  
Since the GMEP, substantial advances have been made in the theory of simulation 
modelling of malaria transmission, but NMCPs are still not able to integrate these models 
with M&E activities and with the revision of national plans.  As countries scale up malaria 
control efforts and reach high intervention coverage targets, they are faced with the 
question of what to do next. The strategy for maintaining and enhancing the achieved 
reductions in transmission is not obvious. It is often not clear whether current coverage 
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levels of interventions would continue to reduce transmission, or whether new 
interventions are necessary to keep the reduction trend and even to accelerate progress 
toward the elimination of the disease. Mathematical modelling can build on available 
data, test multiple scenarios and combinations of intervention strategies, and make 
verifiable predictions on what can be expected from these strategies. 
Modelling can help inform decision-making around malaria control because of the 
disease's complex biological systems, the considerable infrastructural and cost 
requirements of prevention and elimination strategies, and the rapid pace of change in 
global planning and national programming to halt malaria. Findings from modelling can 
provide valuable data to help inform a range of decision-making on issues such as 
identifying potential effective combinations of interventions, setting feasible coverage 
targets, devising target product profiles for new interventions, anticipating the 
implications of introducing new interventions, understanding the potential for malaria 
resurgence; and establishing how malaria surveillance and M&E systems can best 
enhance the country progress [75]. 
Like with all mathematical models of biology, limitations of malaria models are 
associated with the trade-off between parsimony and the fitting of details to what is 
known about the dynamics being modeled.  Although a model is only useful if it 
represents a simplification, indicating which elements of the processes being analyzed are 
important, the better the fit to reality, the more likely are the predictions to be accurate.  
Model predictions should be interpreted taking into account their underlying assumptions, 
some of which are intended to simplify the complex malaria transmission dynamics, 
while others attempted to fill the knowledge gap in the transmission of the disease.  
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Mathematical modelling should involve partnership and good communication between 
technical experts in mathematical modelling, experts in malaria field and laboratory 
science, and health policy decision-makers. Models produce the most useful information 
when they are formulated with important biological, economic, and practical realities in 
mind and when their results are interpreted with care considering the model’s limitations 
and underlying assumptions. 
2.5. Peru – country profile  
Peru, located along the South America’s central Pacific coast, is home to about 30 million 
inhabitants living in 1,838 municipalities in 25 regional governments (24 departments 
and the constitutional province of Callao) [76]. With a total surface area of 1,285,220 
km2, Peru has the third greatest biodiversity in the world, hosting 84 of the 117 recognized 
ecosystems [77]. Three very different natural regions are identified with contrasted 
climates: the semi-desert Coast, the rugged Andean Mountains, and the tropical Amazon 
Basin.  
Despite the recent world financial crisis, Peru has logged fifteen consecutive years of 
positive economic growth. Under successive three presidential transitions (2001, 2006 
and 2011), the Peruvian economy has proven resilient, driven by free markets and 
grounded in clear macroeconomic policies. Peru’s gross national income (GNI) per capita 
was 3,990 US dollars (USD) in 2008 and its economy has been classified as upper-
middle-income country since 2009 [78]. However, while poverty significantly declined 
nationwide from 54% in 2001 to 25.8% in 2012, a large part of the population is still 
unable to benefit from such economic growth, with poverty rates exceeding 50% in rural 
areas, mainly in the Andean Mountains and the Amazon Region [79].  
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Income levels in the country remain highly unevenly distributed with an estimated Gini 
coefficient of about 0.5 [80]. Furthermore, socio-economic inequalities between groups 
have increased over the recent years, thereby reinforcing traditional ethnic and 
geographical divisions [81]. The differences are most pronounced between the coast, 
which covers only 16% of the territory but holds 60% of the population and 70% of the 
wealth, and the Amazon Basin, which covers 50% of the territory, yet contains only 12% 
of the population and 7% of the wealth. Such disparities have resulted in substantial 
variations in life expectancy. While a newborn in one of the poorest districts in the 
Amazon Basin, can expect to live to around 60 years, in the more affluent areas of the 
Coast, such as Lima, newborns are anticipated to live almost 15-20 years longer [76]. 
The good economic performance achieved in recent years, together with targeted social 
spending and social programs has made significant progress possible in the fulfilment of 
some MDGs, such as: reduction in the extreme poverty from 23% to 7.6% (1991-2010); 
reduction of infant mortality from 53 per 100 live births to 17 per 100 live births (1993-
2012); and reduction in chronic child malnutrition from 26.5% to 15.2% NCHS (1999 – 
2011) [82]. Despite these achievements, the health sector still faces important big 
challenges: a) the total health expenditure continues to be among the lowest in Latin 
America (4.8% of National Gross Domestic Product-GDP) [80]; b) the health and health 
care inequity remains mainly in preventive services [83]; c) the decentralization process 
and sub-national capacity building for management of social production of healthcare are 
still incomplete [84]; d) the increased risk of non-communicable chronic diseases and 
external causes (e.g., road crashes); and e) the persistence of communicable diseases, such 
as: tuberculosis, dengue and malaria. 
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2.6. Malaria control in Peru 
Malaria remains one of the most important public health problems in Peru. As shown in 
Figure 2.7, the incidence of cases has fluctuated dramatically over the last 75 years, 
however the history of malaria control suggested on two different occasions that malaria 
elimination in the country could be feasible. Indeed, this was observed during the 
dramatic drop of malaria burden during the eradication efforts in the 1960s, and more 
recently, the early success in decreasing the malaria incidence following the 
implementation of comprehensive control strategies during the PAMAFRO project in the 
2000s.           
After peaking with over 95,000 cases in 1944 [1], malaria dropped drastically in the 
following years, and  between 1960 and 1970 annual incidence rates remained below 1 
case per 1,000 inhabitants with the minimum levels registered in 1965, when only  about 
1,500 cases were reported [85]. This achievement can be attributed to the use of DDT for 
vector control campaigns since 1946, and to the shift of malaria control to eradication 
since 1957 [1].  Malaria eradication efforts were implemented by the Peruvian NMES 
and supported by the National Health Fund and Social Welfare, the Interamerican Public 
Health Service (IPHS) and UNICEF. It was initially planned that five years of aggressive 
antimalarial and insecticide application would eradicate malaria [86]. The major vector 
in the Amazon (i.e., An. darlingi) was eliminated, and almost the entire coast, the inter-
Andean valleys, and the Southern Amazon were malaria free by 1970 [86,87]. However, 
the development of DDT resistance, the decrease of funds to maintain the interventions, 
and the transfer of malaria control responsibilities to the health services did not allow for 
keeping the malaria control progress [86].  
During the 1980s, the Peruvian malaria control program was unstructured [86].  DDT use 
was first halted in the Amazon in 1988, and then stopped across the country. The 
reintroduction and later spread of An. darlingi in the Amazon [85], as well as the 
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occurrence of drug-resistant Plasmodium falciparum strains to CQ in the northern coast 
[88] and to CQ and sulphadoxine-pyrimethamine (SP) in the Amazon [89,90],  likely 
enhanced the huge malaria epidemic associated with El Niño Southern Oscillation 
(ENSO) climatologic phenomenon  in the late 1990s [2].  After heavy rains and flooding, 
malaria increased dramatically reaching a peak of more than 200,000 cases in 1998, of 
which almost half were due to P. falciparum. The Amazon and the northern coast were 
the most affected regions, accounting respectively for approximately 45% and 40% of the 
total malaria cases, and for 45% and 50% of the total P. falciparum cases in the country 
during the 1997-1998 epidemic period [91].  
 Figure 2.7. Historical trends of reported malaria incidence in Peru: 1939-2014.  
Source: Peruvian Ministry of Health.
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Figure 2.8. Malaria risk map of Peru based on annual incidence rates (annual parasitological index, API).  
Source:  Peruvian Ministry of Health  
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After the epidemic, annual incidence dropped markedly, and between 2000 and 2005 it 
remained between 70,000 and 80,000 cases (20%-25% due to P. falciparum), followed 
again by a steady decrease until 2010 and 2011, when only 29,355 and 23,075 cases were 
reported, respectively. The significant reduction in malaria incidence (around 90%) from 
1998 to 2011 changed completely the malaria risk map in the country, with each year a 
larger predominance of low transmission areas over high and moderate transmission areas 
(Figure 2.8). After almost 40 years and for the second time in the history of malaria in 
Peru, the malaria incidence rate was below 1 case per 1,000 inhabitants in those two 
consecutive years (2010 and 2011) (Figure 2.7).  This achievement can be attributed to 
the strengthening of the NMCP, the changes in the malaria treatment policy, and the 
implementation of comprehensive malaria control interventions in the most endemic 
areas with strong support of international donors (e.g., US Agency for International 
Development (USAID), and the GFATM.  
Indeed, following drug efficacy studies in the late 1990s and early 2000s and showing 
increasing level of P. falciparum resistance to CQ or SP in the Amazon, and the northern 
coast), the NMCP decided to introduce two different ACTs as the first line treatments for 
P. falciparum, i.e. mefloquine (MQ)-artesunate (AS) in the Amazon Region, and SP-AS 
in the Pacific northern coast [89].  With these changes, Peru became the first country in 
the Americas to use ACTs for P. falciparum malaria and the first country in the world to 
use two different ACTs in different regions [91]. Regarding P. vivax malaria, treatment 
guidelines were also adjusted following adherence problems to the radical regimen based 
on 14 days Primaquine (PQ) together with CQ (3 days). Thus the PQ regimen was 
shortened to 7 days at increased daily dose (0.5- instead of 0.25mg/kg/day). In addition, 
guidelines encouraged health facilities to offer directly observed therapy (DOT) for 
malaria, and started a 28-day follow up for all patients diagnosed with malaria. Despite 
their inclusion in the previous treatment guidelines of 1994 [89], both DOT and the 28-
day follow up of confirmed malaria cases had been only partially accomplished.    
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The new malaria treatment policy was implemented faster in the northern coast than in 
the Amazon, mainly due to the better accessibility to the malaria endemic areas (i.e., peri-
urban communities) in the northern coast that facilitated the training and supervision of 
the local health facilities and staff. PCD and treatment of confirmed malaria infections 
with ACT, together with the implementation of community-based environmental 
management strategies to control the predominant vector An. albimanus (such as the shift 
of rice cultivation patterns), have probably contributed to the steady decline in malaria 
incidence observed in the northern coast since the early 2000s.  
In the Amazon Region, the new treatment policy took more time to be efficiently 
implemented. Since 2005, the implementation process was powered by the Global Fund's 
Malaria Project “PAMAFRO” [4] by increasing the accessibility and quality of 
microscopy-based diagnosis, ensuring the availability of the antimalarial drugs, and the 
periodical training and supervision of local health workers, even in the most remote 
endemic areas. PAMAFRO was simultaneously applied at the border areas of Venezuela, 
Colombia, Ecuador, and Peru between October 2005 and September 2010, with common 
control strategies, including early diagnosis and treatment, ACD interventions in 
communities of high malaria risk, mass distribution of LLINs, community participation, 
and intensified health education and promotion campaigns.  During this period, similarly 
to the majority of intervention areas of the project, malaria declined drastically in Loreto, 
from 54,291 reported cases in 2005 to 11,446 in 2010 [3].  
Alarmingly since 2010, the number of malaria cases is rising again in Loreto, with the 
total number of reported P. falciparum and P. vivax malaria cases increasing from 2,238 
to 10,243 and from 9,208 to 52,323 cases, respectively, from 2010 to 2014.  Currently, 
Loreto reports the vast majority of malaria cases (94%) in the country.  The resurgence 
of malaria in the Peruvian Amazon after 2010 is thought to be associated with the limited 
capacity of NMCP to keep up with the intense control interventions implemented during 
the PAMAFRO project ended. The reallocation of funds to more pressing public health 
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issues in the region (particularly dengue) after assuming that malaria was “under control”, 
and the unusual heavy rains since 2011, causing damage and flooding to many rural 
communities located along the Amazon river and all its tributaries, further worsened the 
situation. Currently, five strategies are prioritized for malaria control in the country: a) 
surveillance, case identification and effective, free, and timely treatment of confirmed 
infections; b) distribution of LLINs when available; c) behaviour change communication 
(BCC) activities; d) community participation in environmental management; and e) 
entomological surveillance and integrated and selective vector control.   
Malaria surveillance relies mainly on PCD with microscopy. Patients presenting with 
fever or any other symptoms compatible with malaria are systematically tested by 
microscopy at health facilities and treated with CQ for 3 days (10mg/g on days 1 and 2, 
and 5mg/kg on day 3), plus PQ for 7 days (0.5 mg/kg/day) if P. vivax malaria is 
confirmed, or with MQ (12.5 mg/kg/day for 2 days) plus AS (4 mg/kg/day for 3 days) if 
P. falciparum malaria is confirmed. According to treatment guidelines all health facilities 
should perform DOT with these treatment combinations [92].   
According to the current guidelines [92], any unusual recent increase of malaria cases 
detected by PCD at local level (local outbreak) should trigger reactive case detection 
(RACD) which consists of systematic screening for malaria by microscopy of all 
individuals living in close proximity to passively detected cases, and the treatment of 
confirmed infections irrespectively of symptoms. However, due to the lack of evidence-
based guidelines, the criteria and procedures to implement RACD interventions have 
often been arbitrarily decided and are subject to annual variations in logistical and 
financial resources.  In addition, the NMCP has recently introduced focal screening and 
treatment (FSAT) to further decrease the malaria burden in the Amazon Region. FSAT 
interventions are implemented based on prior information about monthly malaria 
incidence and specific high-risk groups in geographical areas where transmission is 
known to be highest (i.e., hotspots).  
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2.7. Peruvian malaria endemic regions 
About half the total population is exposed to malaria or live in areas with ecological 
factors favourable to transmission which are represented by the Amazon region and the 
Pacific northern coast (Table 2.2)  
Table 2.2.  Characteristics of malaria transmission in the Amazon region and northern coast 
Characteristics Amazon region Northern coast 
Period of transmission Perennial transmission with 
marked seasonality.  
Seasonal transmission
Environmental 
conditions 
Tropical rainforest, heavy rains 
(November-April) 
Dry desert area, rainfall (December-
March) influenced by ENSO.  
Other ecological 
conditions 
Deforestation Rice farming
Vector An. darlingi, An. benarrochi. An. albimanus
Parasite P. vivax (80%), P. falciparum
(20%) 
P. vivax (98%), P. falciparum (2%) 
Risk areas Rural, peri-urban Urban, peri-urban.
House characteristics Open houses without or 
rudimentary walls 
Closed houses with completed walls 
Economical activities Subsistence-scale agriculture, 
logging, fishing, hunting. 
Commerce, fishing, agriculture. 
Accessibility to health 
services 
Limited Accessible
 
The Loreto department, the largest department of the country (28.7% of the Peruvian 
territory), covers most of the Amazon Region in the northeast part of Peru, and borders 
with   Brazil, Colombia and Ecuador. According to national statistics, the Loreto 
population totalled about one million inhabitants (including more than one third (38.6%) 
below the age of 15 years), and about one third (34.6%) living in rural areas [76]. The 
local economy varies according to the different areas with indigenous and rural villages 
mainly depending on natural resources exploitation such as agriculture, wood logging and 
fishing [93], and bigger localities focusing on commercial activities [94]. The region is 
situated between 61 to 220 metres above sea level, and is covered by tropical rainforest 
and an extensive fluvial network connecting to the Amazon River.  
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The climate in Loreto is warm and humid with a heavy rainy season from November to 
May and a mild rainy season from June to October [85]. The annual average temperature 
is around 27°C, the relative humidity above 80%, and an average annual rainfall of 4 
meters [95]. Malaria transmission in the region is perennial, with a peak between February 
and July [96]. P. vivax and P. falciparum infections occur at a ratio 5:1, and mostly affect 
rural and remote villages along the main Amazon River and its tributaries.  Most people 
in these villages live in open or semi-closed wood houses. All age groups are at risk of 
infection, though adults more than children. An. darlingi is the main malaria vector and 
is highly anthropophilic [97].  
Despite the fact that Loreto is considered as low endemic area [94], routine surveillance 
data and epidemiological studies suggest that malaria transmission in the region is highly 
heterogeneous. More than 80% of the total malaria clinical cases detected by PCD in 
Loreto are concentrated in only 10-20% of the total communities of the department [7]. 
Moreover, cross-sectional studies using LM for malaria diagnosis have also showed that 
malaria parasite prevalence varied considerably  across communities around Iquitos 
(capital of Loreto) [94,96], and those differences remained or even increased when using 
more sensitive diagnostic tests [94,98]. Indeed, the recent use of PCR in epidemiological 
studies have shown that an important proportion of the total infections are asymptomatic 
and with low and sub-microscopic parasite densities [94,96,98].  Similarly, entomological 
studies have also evidenced heterogeneity in the transmission by finding a wide variation 
of EIR estimations at micro-geographical level in riverine campsites about 50 km of 
Iquitos and along the unique highway of Loreto  (i.e., Iquitos-Nauta road) [97,99,100]. 
Ecological factors that provided optimal conditions for mosquito breeding and resting 
sites associated with deforestation, natural and man-made water bodies (e.g. fish ponds), 
and surrounding secondary vegetation are among the potential explanations for the spatial 
malaria heterogeneity. Besides ecological factors, human socio-economic differences 
such as poorer housing conditions (open or semi-closed houses) and outdoor economic 
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activities (such as farming, logging or fishing) may also play an important role in 
increasing exposure to mosquito bites [93,101]. 
The northern coast, which includes Tumbes, Piura, Lambayeque and La Libertad 
departments, has historically been the second most important region for malaria 
transmission after the Amazon rainforest [1].  It is characterized by the presence of coastal 
valleys receptive to the vector and by human migration for labour-intense agricultural 
activities [102].  The region has winter seasons from April to November with cool and 
dry days, and hot and humid summers with moderate rains from December to March.  
However, this seasonal climate pattern has been altered in the past by the ENSO 
phenomenon [2] with torrential rains and strong winds causing flooding and landslides 
which have been associated with malaria outbreaks (e.g. malaria epidemic in 1997-1998). 
The significant decline in malaria incidence over the past decade has modified the 
epidemiological profile of the disease in the region [7]. Currently, reported malaria cases 
are only due to P. vivax and concentrated in a few localities of Piura and Tumbes. 
Transmission occurs in epidemic and sporadic patterns between February and June, the 
months of highest density of the main vector, An. Albimanus [103].  The most affected 
people live in peri-urban localities in close proximity to irrigated fields and irrigation 
canals which provide the favourable environment for the development of anopheline 
mosquitoes [103,104].  Though houses in those localities have complete walls (closed 
houses), they are mainly made of precarious materials leaving many small openings for 
mosquitoes to enter. 
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3.1. Abstract 
 
 
Background: Where malaria endemicity is low, control programmes need increasingly 
sensitive tools for monitoring malaria transmission intensity (MTI) and to better define 
health priorities. A cross-sectional survey was conducted in a low endemicity area of the 
Peruvian north-western coast to assess the MTI using both molecular and serological 
tools. 
Methods: Epidemiological, parasitological and serological data were collected from 
2,667 individuals in three settlements of Bellavista district, in May 2010. Parasite 
infection was detected using microscopy and polymerase chain reaction (PCR). 
Antibodies to Plasmodium vivax merozoite surface protein-119 (PvMSP119) and to 
Plasmodium falciparum glutamate-rich protein (PfGLURP) were detected by ELISA. 
Risk factors for exposure to malaria (seropositivity) were assessed by multivariate survey 
logistic regression models. Age-specific antibody prevalence of both P. falciparum and 
P. vivax were analysed using a previously published catalytic conversion model based on 
maximum likelihood for generating seroconversion rates (SCR). 
Results: The overall parasite prevalence by microscopy and PCR were extremely low: 
0.3 and 0.9%, respectively for P. vivax, and 0 and 0.04%, respectively for P. falciparum, 
while seroprevalence was much higher, 13.6% for P. vivax and 9.8% for P. falciparum. 
Settlement, age and occupation as moto-taxi driver during previous year were 
significantly associated with P. falciparum exposure, while age and distance to the water 
drain were associated with P. vivax exposure. Likelihood ratio tests supported age 
seroprevalence curves with two SCR rather for both P. vivax and P. falciparum indicating 
significant changes in the MTI over time. The SCR for PfGLURP was 19-fold lower after 
2002 as compared to before (λ1 = 0.022 versus λ2 = 0.431), and the SCR for PvMSP119 
was four-fold higher after 2006 as compared to before (λ1 = 0.024 versus λ2 = 0.006). 
Conclusion: Combining molecular and serological tools considerably enhanced the 
capacity of detecting current and past exposure to malaria infections and related risks 
factors in this very low endemicity area. This allowed for an improved characterization 
of the current human reservoir of infections, largely hidden and heterogeneous, as well as 
providing insights into recent changes in species specific MTIs. This approach will be of 
key importance for evaluating and monitoring future malaria elimination strategies. 
Keywords: Malaria transmission intensity, low endemicity, elimination, polymerase 
chain reaction, serology, Peru. 
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3.2. Background 
Despite recent reduction in its estimated incidence, malaria remains the most important 
human arthropod-borne disease, worldwide and in the Americas [105]. In Peru, malaria 
incidence has fluctuated dramatically over the last 50 years. Between 1954 and 1967, 
malaria was well under control by coordinated eradication efforts (resulting in only 1,500 
cases in 1965) [106], but returned to high levels when eradication campaigns ceased. 
Following the occurrence of drug-resistant Plasmodium falciparum strains to chloroquine 
(CQ) and sulphadoxine-pyrimethamine (SP) [88,107] and the spread of Anopheles 
darlingi in the Amazon Region [85], malaria re-emerged in the 1990s, reaching a peak of 
more than 200,000 cases in 1998 after the El Niño Southern Oscillation (ENSO) 
climatologic phenomenon [2]. Between 2000 and 2005, the annual incidence fluctuated 
between 70,000 and 80,000 cases followed by a steady decrease until 2011, when 22,877 
cases were reported [7]. This achievement can be attributed to the strengthening of the 
National Malaria Control Programme (NMCP) and to the implementation of 
comprehensive interventions such as the use of artemisinin-based combination therapy 
(ACT), the distribution of long-lasting insecticidal mosquito nets (LLINs), and health 
education campaigns with the strong support of international donors, e g, US Agency for 
International Development (USAID), and the Global Fund for Aids, Tuberculosis and 
Malaria (GFATM) [6,89,108]. 
In Peru, the significant decline in malaria incidence over the past decade has modified its 
epidemiological profile and consequently calls for adapted control strategies. Currently, 
there is the need for targeting interventions and surveillance to foci of residual 
transmission in the north-west coast as well as in the Peruvian Amazon region. A key 
element for this re-orientation will be the availability of accurate measurement of malaria 
transmission intensity (MTI) and its evolution in space and time [11,12]. However, it is 
not clear how best to monitor changes in transmission and disease burden in low 
endemicity areas [109]. 
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Traditional methods to measure MTI include the collection of entomological and 
parasitological parameters. However, in areas of low endemicity, these measures are often 
subject to fluctuations for reasons other than true changes in transmission. For example, 
the improvement of case detection methods usually leads to an artificial increase in 
malaria incidence, which makes difficult the comparison between pre- and post-
intervention data. Furthermore, entomological (entomological inoculation rate (EIR)) and 
parasitological measures (infections detected by microscopy) estimated through 
community surveys require very large sample sizes and are therefore extremely time and 
money consuming, while not able to catch seasonal variations [18,44]. Moreover, 
parasitological surveys using microscopy cannot detect subpatent infections which are 
commonly reported in areas of low transmission [110,111]. Molecular tests such as 
polymerase chain reaction (PCR) are much more sensitive for the detection of low 
parasite-density infections, and will become increasingly important for malaria 
elimination programmes [112,113]. 
Serological markers have recently been used in several endemic areas across the world to 
estimate MTI [20,21,59,114,115] and monitor its changes over time following 
interventions [22]. Serological techniques are particularly suited to low endemic areas as 
antibodies remain in the blood longer than malaria parasites and are thus easier to detect 
and less subject to seasonal variations. This paper reports on population-based estimates 
of P. falciparum and Plasmodium vivax prevalence and seroprevalence in an area of low 
endemicity in the north-west coast of Peru. The combination of molecular and serological 
tools is aimed at improving the detection of current malaria infections as well as recent 
exposure, in order to get insights into the residual transmission dynamics. 
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3.3. Methods 
Study area 
The study was conducted in Bellavista, a small district of Sullana province located in 
Piura department, north-western coast of Peru (Figure 3.1). Piura is historically 
considered an important focus of malaria transmission in Peru [3]. Bellavista district is a 
peri-urban settlement (37,000 inhabitants in 2010) directly connected to Sullana city, at 
30 km from Piura, the fifth largest city in Peru. Three contiguous squatter settlements 
were selected for the study: Pavletich (PAV, nine blocks of houses), Jose Carlos 
Mariátegui (JCM, 12 blocks) and Nuevo Porvenir (NP, 13 blocks) based on their malaria 
endemicity (between 2008 and 2010 most of the district malaria cases occurred in these 
settlements) and their proximity to the largest water drain called Boqueron (=big hole). 
Situated at the eastern edge of the settlements, this artificially created drain flows south 
to north for about 2 km (maximum width 100 m, depth 30 m) to end into the Chira River. 
 
Figure 3.1. Study area in Bellavista district (Piura department, northwestern coast of 
Peru) including three settlements. Pavletich (PAV), Jose Carlos Mariátegui (JCM) and 
Nuevo Porvenir (NP) 
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The winter season is from May to November and the hot and rainy summer from 
December to April. This seasonal pattern is periodically altered by the ENSO 
phenomenon [2] with torrential rain and strong winds that can cause flooding and 
landslides. In 2010, annual rainfall, average relative humidity and average temperature 
were 103 mm, 76% and 24.2°C, respectively [95]. The main vector is Anopheles 
albimanus and the vast majority of malaria cases are due to P. vivax [116]. The main 
occupations in the area are informal trade, agriculture and small animal farming. 
Data collection 
A full census of the study population was carried out in April 2010, collecting individual 
data on sociodemographic (age, gender, education, economic activities, income) as well 
as on malaria prevention characteristics. Each house was identified with a unique code 
number and georeferenced using a handheld global positioning system (GPS) device 
(Garmin’s GPSMAP 60CSx) that also calculated the closest distance to the water drain. 
Each individual was given a seven-digit unique code number combining the village, 
household and individual code. 
The cross-sectional survey was carried out in May 2010 and included all residents in the 
study area. Each household was visited, and a written informed consent was sought from 
each participant. If part of, or the whole household, was absent at the time of survey, the 
study team would return within the next two days to maximize subject participation. Each 
participant was examined for fever and malaria symptoms, and a finger-prick blood 
sample was taken for immediate microscopy (thick and thin blood smears) and later 
serological and molecular tests at Institute of Tropical Medicine Alexander von 
Humboltd, Lima (ITM-AvH). Filter paper (Whatman grade 3, Whatman, Springfield 
Mill, USA) dried blood samples were individually stored at 4°C with desiccant until 
processed at the ITM-AvH. Infected individuals (presence of Plasmodium trophozoites) 
were treated according to the national guidelines. 
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Additionally, retrospective data on annual malaria incidence by species from 1990 to 
2010, registered by the Office of Epidemiology at Regional Health Direction of Piura, 
were obtained from the National Institute of Statistics and Informatics [7]. In Peru, weekly 
notification of confirmed malaria cases (by standard microscopy) at health facilities and 
data aggregation at district and at departmental level are mandatory. Patients presenting 
with symptoms compatible with malaria at health facilities are systematically tested by 
microscopy and treated following national guidelines. 
Laboratory procedures 
Microscopy 
Thick and thin smears were stained for 10 min with a 10% Giemsa solution, and parasite 
density was expressed as the number of parasites/μl, after counting a total of 200 white 
blood cells (WBC) (or 500 WBCs if less than ten parasites/field), and assuming an 
average of 6,000 WBCs/μl according to the national guidelines [117]. Microscopy 
examination was performed immediately after sample collection at the Reference 
Laboratory in Sullana, and later quality control was done blindly on all positive slides and 
10% of randomly chosen negative slides by a senior technician at ITM-AvH. Any 
discordant results were reread by a second senior technician until agreement. 
Species-specific polymerase chain reaction (ss-PCR) 
Parasite DNA was extracted using the saponin Chelex 100 method [118]. Briefly, filter-
paper blood spots containing approximately 20 μl of blood were cut into pieces of 
approximately 5 sq mm, and incubated with 20 μl of 0.05% saponin at room temperature 
for four hours. Then, 10 μl of 20% Chelex 100 solution was added, and the sample was 
incubated for 10 min at 95°C, followed by a centrifugation at 11,000 g. The supernatant 
(DNA) was transferred into a new tube and stored at −20°C until PCR was performed. 
The DNA was amplified by a semi-nested multiplex PCR method targeting the 18S rDNA 
region, as described by Rubio et al [119]. PCR products were analysed in a 2% agarose 
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gel with a standard 100 bp DNA lader, using ethidium bromide staining (0.5 μg/ml) and 
a data image Analyzer with UV trans-illuminator. 
Serology 
Plasmodium falciparum glutamate-rich protein (PfGLURP) and P. vivax merozoite 
surface protein119 (PvMSP119) antibodies were detected using an ELISA protocol 
published elsewhere [120]. Briefly, dried blood filter-paper samples (5 mm diameter 
disc/sample) were eluted overnight at 4°C in 2 ml of PBS-Blotto-Tween. Two hundred 
μl of the eluate were added in duplicate to blocked ELISA plates (Plate Chamaleon, 
Hydex) coated separately with P. falciparum GLURP R2 [121] and P. vivax MSP1-19 
[122]. Pooled sera from five P. falciparum- or P. vivax-infected patients, and from five 
non-infected control group were diluted at 1:400 in PBS-Blotto, as positive and negative 
control, respectively. Goat anti-human IgG (H + L) peroxidase (Sigma, affinity purified) 
diluted to 1: 20,000 in PBS-Tween was used as conjugate and incubated for one hour 
before development of the ELISA using 200 μl ABTS substrate-chromogen solution. 
Optical densities (ODs) were read at 405 nm, and corrected OD values were computed 
by subtracting the mean OD of the antigen negative control wells from the mean OD of 
the corresponding antigen containing wells. To ensure a standardization of the sample 
results across ELISA plates, the percent positivity (PP) of each specimen was calculated 
using the OD of the positive control serum as 100%. Quality control was done blindly at 
ITM-AvH on 5% of randomly chosen samples. The cut-off for positivity was generated 
using a mixture model as previously described by Corran et al [58]. 
Data management and statistical analysis 
Data were double entered, validated and cleaned in Excel (Microsoft Corp, USA), and 
data analysis was performed with Stata v.11 (Stata Corp, College Station, USA) and R 
v.2.15 software (R Development Core Team, R Foundation for Statistical Computing, 
Austria). 
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Malaria infection by PCR was defined as an individual with a positive PCR result, 
regardless of symptoms. Clinical malaria was defined as a patient with fever (body 
temperature >37.5°C), and/or history of fever in the previous two days, and positive for 
malaria by microscopy and/or PCR. As maternally derived antibodies can be found in 
young infants [123], malaria exposure was defined as an individual older than six months 
with a positive ELISA test for either or both P. falciparum and P. vivax. Descriptive 
statistics were used to calculate malariometric indices (parasite and antibody prevalence). 
Uni- and multivariate adjusted analyses were performed using survey logistic regression 
to determine risk factors for malaria infection (PCR positive) or malaria exposure 
(serology positive) adjusting for all potential confounders such as: settlement, gender, 
age, income, education, occupation during previous year, bed net use, distance to the 
water drain, and movements outside the settlement during previous year. A p-value <0.05 
was considered significant for risk factors to be included in the multivariate adjusted 
model. Interactions were systematically checked for up to order two. All analyses took 
into account the survey design characteristics, using settlement as strata and household as 
primary sampling unit. 
A simple reversible catalytic conversion model was used to fit the dichotomized 
serological results, using maximum likelihood methods as published by Drakeley et al 
[20]. Briefly, this model generates age-seroprevalence curves, allowing for the estimation 
of the force of infection, or seroconversion rate (SCR, λ), and a seroreversion rate (ρ). 
Upon visual examination, if age-seroprevalence data suggest an obvious step at a certain 
age (time point), a model allowing for two forces of infection (λ1 and λ2) and related 
profile likelihood plots are run to determine the most likely time point for change in SCR, 
as previously described by Stewart et al [21]. The identified time point is subsequently 
incorporated into the catalytic model to fit a seroprevalence curve with two forces of 
infection (before and after time cut-off)[57], which is then compared -using the likelihood 
ratio (LR) test (p < 0.05)- with a sero-prevalence curve with only one force of infection. 
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Ethical issues 
Permission was received from health and local authorities after explaining the purpose 
and procedures of the survey. Signed, informed consent was obtained prior to 
participation by all adults and the parents of all participating children <18 years. In 
addition to their parent’s consent, children ≥ seven years old provided signed informed 
assent prior to participating. Ethical clearance was obtained from the Ethics Review 
Board of the Universidad Peruana Cayetano Heredia, Lima, Peru (SIDISI code: 056736). 
 
3.4. Results 
A total of 996 households and 4,650 individuals were identified during the census, and 
were distributed over the three study settlements as follows: PAV (433 houses; 2,163 
individuals), JCM (312; 1,358) and NP (251; 1,129). The overall sex ratio was 0.94, and 
the age distribution showed that half of the population was <20 years old. A total 2,733 
individuals (58.8%) living in 871 households (87.4%) were available at the time of the 
survey and 97.6% (2,667/2,733) of them accepted to participate. Females (61%) slightly 
outnumbered males, but the age distribution was very similar to the one in the total 
population. Among adults aged ≥18 years old, 60% had completed secondary education 
level. Only about 20% of the respondents had a regular income, almost all below the 
minimum national vital wage. The most commonly reported occupations were housewife 
(27.1%), labourer (9.0%) and trader (6.4%), while preprofessionals (children, students) 
and retired represented half of the participants. Very few respondents reported having 
been working as farmer (2.4%) or moto-taxi driver (2.6%) in the past year. More than 
half (52.6%) of the participants stated they were regularly sleeping under an untreated 
net, and 11.5% had experienced at least one confirmed P. vivax episode during the 
previous year (Table 3.1). 
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Table 3.1. Baseline characteristics of the study population (N = 2,667) 
  n % 
Settlement  
 Pavletich (PV) 1,128 42.3 
José Carlos Mariategui (JCM) 797 29.9 
Nuevo Porvenir (NP) 742 27.8 
House distance to water drain (m)  
 <100 183 6.9 
100-250 1401 52.5 
>250 1,083 40.6 
Gender  
 Female 1,628 61.0 
Male 1,039 39.0 
Age groups (years)  
 0-5 447 16.8 
6-10 404 15.1 
11-19 491 18.4 
20-39 889 33.3 
> = 40 436 16.4 
Education (> = 18 years, n = 1,421)  
 None 44 3.1 
Primary 517 36.4 
Secondary 689 48.5 
Superior 171 12.0 
Income amount*  
 None 2,081 78.0 
< 650 PEN 458 17.2 
> = 650 PEN 83 3.1 
Missing 45 1.7 
Current economic activity  
 None (children, students, retired) 1,319 49.5 
Farmer 41 1.5 
Moto-taxi driver 74 2.8 
Housewife 723 27.1 
Trader 172 6.4 
Laborer (indoor, manual worker) 240 9.0 
Others 98 3.7 
Occupation as farmer (previous 12 months)  
 No 2,604 97.6 
Yes 63 2.4 
Occupation as moto-taxi driver (previous 12 months)  
 No 2,598 97.4 
Yes 69 2.6 
Bed net use  
 Never/Sometimes 1,250 46.9 
Always 1,402 52.6 
Missing 15 0.5 
Confirmed P. vivax malaria (previous 12 months)  
 No 2,360 88.5 
Yes (1 episode) 273 10.2 
Yes (> = 2 episodes) 34 1.3 
*Income expressed in Peruvian nuevos soles (PEN). The official vital minimum wage in Peru is 650 PEN 
(approx 230 USD). 
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Parasite prevalence determined by microscopy was 0.3% (total eight P. vivax infections) 
while by PCR it was estimated at 1% including one P. falciparum and 25 P. vivax 
infections (Table 3.2). Malaria seroprevalence for P. vivax and P. falciparum was 
estimated at 13.6 and 9.8%, respectively, with 9.0% of the total seropositive individuals 
having antibodies against both antigens. A very weak correlation between antibody 
responses (percent positivity = PP) to the two species were found in individuals older than 
ten years (r = 0.1, p < 0.001), but not in younger children (p > 0.1). Most of the P. vivax 
PCR-positive cases were submicroscopic (17/25 = 68.0%) and asymptomatic (22/25 = 
88.0%) at the time of the survey (Table 3.3).  PCR positivity to P. vivax was significantly 
associated with the presence of P. vivax parasites (by microscopy) (p < 0.001) or 
antibodies (p < 0.001), as well as with symptoms (p < 0.001). Association between PCR 
and sero-positivity to P. falciparum could not be explored since only one P. falciparum 
infection was detected by PCR. This infection was asymptomatic and submicroscopic, 
and was found in a 16-year-old girl who also had antibodies against P. falciparum. 
 
 
Table 3.2. Malaria prevalence (by microscopy and PCR) and seroprevalence 
 n N % 95% CI 
Prevalence by microscopy P. vivax 8 2,667 0.3 [0.2; 0.6] 
Parasite density/μl, median [range] 432 [112; 1,529]   
Prevalence by PCR P. vivax 25 2,667 0.9 [0.7; 1.4] 
 P. falciparum 1 2,667 0.04 [0.01; 0.3] 
 Any species 26 2,667 1 [0.6; 1.4] 
Seroprevalence PvMSP119 360 2,653 13.6 [12.2; 15.1] 
 PfGLURP 259 2,653 9.8 [8.6; 11.1] 
 Total 567 2,653 21.4 [19.7; 23.1] 
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Table 3.3.  Association between Plasmodium vivax PCR results and microscopy, serology 
and symptoms 
 P. vivax PCR Negative P.vivax PCR Positive 
p-
value 
(N = 2642) (N = 25)
n % n %
P. vivax microscopy      
 Negative 2,642 100 17 68.0 <0.001 
Positive 0 0 8 32.0  
P. vivax MSP1-19 serology      
 Negative 2,282 86.8 11 44.0 <0.001 
Positive 346 13.2 14 56.0  
P. falciparum GLURP serology      
 Negative 2,369 90.2 22 88.0 0.71 
Positive 256 9.8 3 12.0  
Fever and/or history of fever  
(previous 2 days) 
     
 No 2,592 98.1 22 88.0 <0.001 
Yes 50 1.9 3 12.0  
 
Given the small number of PCR-positive individuals, a multivariate adjusted risk factor 
analysis was not carried out, and the univariate analysis showed that distance to water 
drain was significantly associated with the risk of P. vivax infection (no association could 
be found with age, gender, income, education, bed net, or previous travelling outside the 
community ). Individuals living at <100 m from the water drain) had increased odds of 
P. vivax infection than those living farther (≥100 m) (OR=3.4, 95% CI [1.3–9.0]).     
Distance to water drain, age, education, income, occupation as farmer in the previous 
year, and history of P. vivax malaria in the previous year were significantly associated to 
P. vivax exposure in the univariate analysis (Table 3.4). The multivariate analysis 
(excluding history of malaria in the previous year) showed that only age and distance to 
water drain remained independently associated with P. vivax seropositivity. Individuals 
older than ten years had increasingly higher odds of P. vivax seropositivity compared to 
younger children (test for trend p<0.001), while those living at closer distance to the water 
drain had increasingly higher odds of exposure to P. vivax compared to those living 
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farther than 250 m. A significant interaction (OR=5.7; p=0.014) between age groups > 
ten years and distance <100 m was found, showing that the effect of age (>ten versus ≤ 
ten years) was significantly higher in those living closer (<100 m) to the drain (OR=11.7; 
95 CI [3.0; 45.1]; p<0.001) compared to those living farther (OR=2.0; 95 CI [1.5; 2.7], 
p<0.001). Conversely, the effect of distance to water (<100 m versus ≥100 m) was 
significant only in the older age group (OR=2.4, 95 CI [1.6; 3.7], p<0.001). 
Significant risk factors for P. falciparum exposure identified in the univariate analysis 
were the following: settlement, age, education, prior work as farmer or moto-taxi driver, 
and bed net use (Table 3.5). The multivariate-adjusted analysis showed that only 
settlement, age and previous work as moto-taxi driver remained independently associated 
with exposure to P. falciparum (no interaction was found). Individuals living in JCM 
(AOR: 1.5, 95% CI [1.02–2.1]) and in NP (AOR: 2.2, 95% CI [1.6–3.2]) were more likely 
to be exposed to P. falciparum compared to those living in PAV. In addition, individuals 
older than five years had increasingly higher odds (test for trend p < 0.001) of P. 
falciparum seropositivity compared to younger children, and those having worked as 
moto-taxi driver in the previous year were two times more exposed to P. falciparum 
(AOR: 2.1, 95% CI [1.1–3.8]) compared to those who did not. 
Note: Two tables (S3.1 and S3.2) were added as supplementary files in the Annex 
(Chapter 9). Table S3.1 show the distribution of P. vivax infections across age groups 
(p=0.87) and between adult sub-groups with and without outdoor occupations (i.e., 
farmers, moto-taxi drivers) (p=0.47, p=0.53). Table S3.2 shows the prevalence of P. 
falciparum exposure between adult sub-populations with and without occupation as 
moto-taxi drivers (p=0.008). 
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Table 3.4. Multivariate analysis for the risk of exposure to P. vivax using survey logistic 
regression 
Risk factors Positive PvMSP1-19 Unadjusted Adjusted ≈ 
 % 95% CI n N OR 95% CI OR 95% CI 
Settlement         
 PAV 12.7 [10.8; 14.9] 143 1,123 1.0  -  
JCM 15.6 [13.1; 18.5] 123 789 1.3 [0.95; 1.7] -  
NP 12.7 [10.0; 15.9] 94 741 1.0 [0.7; 1.4] -  
House distance to water drain (m)         
 >250 9.5 [7.8; 11.6] 103 1,080 1.0  1.0  
100-250 15.6 [13.6; 17.9] 217 1,391 1.8* [1.3; 2.3] 1.8* [1.4; 2.4] 
<100 22.0 [16.2; 29.2] 40 182 2.7* [1.7; 4.1] 2.8* [1.8; 4.4] 
Age groups (years)         
 0.5-5 6.7 [4.7; 9.4] 29 433 1.0  1.0°  
6-10 8.9 [6.5; 12.1] 36 404 1.4 [0.8; 2.2]   
11-19 13.9 [10.7; 16.7] 68 491 2.2* [1.4; 3.5] 2.1*∞ [1.6; 2.8] 
20-39 15.8 [13.4; 18.4] 140 889 2.6* [1.7; 3.9]   
> = 40 20.0 [16.5; 24.0] 87 436 3.5* [2.2; 5.4] 3.1* [2.2; 4.4] 
Education         
 None 8.1 [6; 10.8] 39 483 1.0  -  
Primary 13.3 [11.3; 15.7] 140 1,199 1.8* [1.2; 2.5] -  
Secondary 16.3 [14; 19] 153 829 2.2* [1.5; 3.2] -  
Superior 15.1 [10.7; 20.9] 27 141 2.0* [1.2; 3.4] -  
Income amount         
 None 12.6 [11.1; 14.3] 261 2,067 1.0  -  
< 650 PEN 17.9 [14.7; 21.7] 82 458 1.5* [1.2; 2] -  
> = 650 PEN 14.5 [8.4; 23.8] 12 83 1.3 [0.6; 2.2] -  
Occupation as farmer 
(previous 12 months) 
        
 No 13.3 [11.9; 14.8] 344 2,590 1.0  -  
Yes 25.4 [16.3; 37.3] 16 63 2.2* [1.3; 3.9] -  
Occupation as moto-taxi driver 
(previous 12 months) 
        
 Never/Sometimes 13.4 [12.1; 14.9] 347 2,584 1.0  -  
Always 18.8 [11.2; 30.0] 13 69 1.5 [0.8; 2.8] -  
Bed net use         
 No 13.0 [11.1; 15.2] 162 1,244 1.0  -  
Yes 14.1 [12.2; 16.2] 196 1,395 1.1 [0.9; 1.4] -  
Confirmed P. vivax malaria 
(previous 12 months)+ 
        
 No 10.5 [9.3; 12] 247 2,346 1.0  -  
Yes (1 episode) 33.3 [27.9; 39.3] 91 273 4.2* [3.2; 5.7] -  
Yes (> = 2episodes) 64.7 [46.7; 79.3] 22 34 15.6* [7.3; 33] -  
* p < 0.05. + Not considered in the multivariate analysis. 
° Baseline category = 0.5-10 years. ∞ Include ages between 11 and 39 years. 
≈ A significant interaction (OR=5.7; 95CI [1.4; 22.7], p=0.014) was found between age>10 y and distance <100 m. 
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Table 3.5. Multivariate analysis for the risk of exposure to P. falciparum using survey 
logistic regression 
Risk factors Positive Pf GLURP-19 Unadjusted Adjusted 
 % 95% CI n N OR 95% CI OR 95% CI 
Settlement  
 PAV 7.4 [5.9; 9.3] 83 1,123 1.0 1.0  
JCM 9.6 [7.6; 12.2] 76 789 1.3 [0.9; 1.9] 1.5* [1.02; 2.1] 
NP 13.6 [11; 16.5] 100 738 2.0* [1.4; 2.8] 2.2* [1.6; 3.2] 
House distance to water drain (m)  
 >250 10.6 [8.7; 12.8] 114 1,080 1.0 -  
100-250 8.7 [7.3; 10.4] 121 1,388 0.8 [0.6; 1.1] -  
<100 13.2 [8.7; 19.5] 24 182 1.3 [0.8; 2.2] -  
Age groups (years)  
 0.5-5 3.7 [2.9; 7.4] 16 432 1.0 1.0  
6-10 7.4 [3.4; 8.0] 30 404 2.1* [1.1; 3.9] 2.1* [1.1; 3.8] 
11-19 12.5 [9.7; 15.9] 61 490 3.7* [2.1; 6.5] 3.2*∞ [1.9; 5.3] 
20-39 10.3 [8.4; 12.5] 91 888 3.0* [1.8; 5.0]  
> = 40 14.0 [11.0; 17.6] 61 436 4.2* [2.4; 7.4] 4.7* [2.6; 8.3] 
Education  
 None 6.0 [4.2; 8.5] 29 483 1.0 -  
Primary 10.0 [8.3; 12] 105 1,051 1.7* [1.1; 2.7] -  
Secondary 11.1 [9.2; 13.4] 104 937 2.0* [1.3; 3] -  
Superior 11.8 [7.8; 17.6] 21 178 2.1* [1.2; 3.8] -  
Income amount  
 None 9.2 [8; 10.6] 190 2,064 1.0 -  
< 650 PEN 11.8 [9.1; 15.1] 54 458 1.3 [0.96; 1.8] -  
> = 650 PEN 14.5 [8.4; 23.8] 12 83 1.7 [0.9; 3.1] -  
Occupation as farmer (previous 12 
months) 
 
 No 9.6 [8.4; 10.9] 248 2,587 1.0 -  
Yes 17.5 [9.9; 29] 11 63 2.0* [1.03; 3.9] -  
Occupation as moto-taxi driver 
(previous 12 months) 
 
 No 9.5 [8.3; 10.8] 245 2,581 1.0 1.0  
Yes 20.3 [12.4; 31.4] 14 69 2.4* [1.3; 4.4] 2.1* [1.1; 3.8] 
Bed net use  
 Never/Sometimes 11.3 [9.5; 13.4] 141 1,244 1.0 -  
Always 8.5 [7.1; 10.2] 118 1,392 0.7* [0.6; 0.96] -  
* p < 0.05. 
∞ Included all ages between 11 and 39 years. 
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Age seroprevalence plots for PvMSP119 and PfGLURP are shown in Figure 3.2 (A and 
B), and confirm previous results: increasing P. vivax and P. falciparum seroprevalence 
with age. Likelihood ratio (LR) tests supported models with two SCR (forces of infection) 
rather than one SCR for both P. vivax (p = 0.028) and P. falciparum (p = 0.046), indicating 
significant changes over time in the MTI for both species. For PvMSP119, best estimates 
indicated a significant four-fold increase in the SCR approximately four years prior to the 
survey (year 2006): post-2006 λ1 = 0.024 (95% CI [0.018–0.032]) and pre-2006 λ2 = 0.006 
(95% CI [0.002–0.017]). For PfGLURP, best estimates indicated a 19–fold drop in the 
SCR approximately eight years prior to the survey (year 2002): post-2002 λ1 = 0.022 
(95% CI [0.014–0.033]), and pre-2002 λ2 = 0.431 (95% CI [0.041–4.54]). 
 Figure 3.2. Malaria seroprevalence curves. A: Seroprevalence curve for Plasmodium vivax. B: 
Seroprevalence curve for Plasmodium falciparum.  Points represent observed data points, whilst 
the blue lines represent the maximum likelihood model and 95% confidence intervals. Estimated 
force of infection (λ) is plotted on the graphs. Two forces infection are plotted by likelihood ratio 
tests indicating change at a certain point in calendar time. 
 
 
The retrospective analysis of 20-year annual malaria incidence and rainfall from 1990 to 
2010 in Piura department showed that after the El Niño-Southern Oscillation (ENSO) 
phenomenon in 1997–1998 (Figure 5.3), when nearly 50,000 P. falciparum cases were 
recorded (1998), P. falciparum incidence dropped and stabilized around 4,000-5,000 
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cases annually in 2000–2001. This was followed by a steady decrease, and since 2006, 
autochthonous P. falciparum reported cases have become scarce (six and three reported 
cases in 2006 and 2008, respectively; and no cases in 2007, 2009 and 2010). Similarly to 
P. falciparum, P. vivax incidence decreased gradually after the ENSO (around 23,000 
cases in 1998) reaching very low levels during the four-year period of intense droughts, 
with only 700, 315, 168, and 606 reported cases, respectively from 2004 to 2007. 
However, since then, P. vivax cases have increased with 4,185, 2,735 and 2,153 cases in 
2008, 2009 and 2010, respectively. During the same period, annual rainfall in Piura 
dramatically dropped from 1998 (1,687 mm) to minimum values (between 14.3 and 59.4 
mm) during the drought period, but subsequently increased since 2008 (193.5 mm in 
2008). 
 
 Figure 3.3. Evolution of the annual malaria incidence, and rainfall, in Piura department: 
1990–2010. Information on annual malaria cases, registered by Regional Health Direction of Piura, 
was obtained from the National Institute of Statistics and Informatics [27]. Numbers in the timeline 
point out important events that influenced malaria incidence: 1) moderate ENSO phenomenon 
(1991–1992), 2) first reports of chloroquine (CQ) failure for Plasmodium falciparum (since 1994), 
3) very strong ENSO phenomenon (1997–1998), 4) confirmed CQ resistance for Plasmodium 
falciparum (1999), 5) ACT implementation (2001–2003), 6) intense droughts (2004–2007). 
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3.5. Discussion 
The combination of molecular and serological tools, in addition to standard microscopy, 
allowed for an in-depth characterization of the current malaria transmission pattern as 
well as recent changes in species-specific MTI in this peri-urban area of the Peruvian 
northern coast. Most of the malaria infections were submicroscopic (70%), as well as 
asymptomatic (89%) despite the low level of transmission. Though P. vivax was 
predominant, species-specific seroprevalence showed that exposure to P. falciparum still 
occurs in the study area. Interestingly, over the past ten years, both species experienced 
significant but opposite changes in MTI: while P. falciparum MTI dropped after 2002, 
the one of P. vivax significantly increased after 2006. 
Despite having been conducted at the end of rainy season, when the health information 
system usually records the highest malaria incidence [7], few malaria-infected individuals 
were identified and most of them had not had malaria-related symptoms within the two 
days prior to the survey. These results are in line with findings from other areas in the 
northern coast [103] and the Peruvian Amazon region [96,124] and support the hypothesis 
that this asymptomatic and submicroscopic reservoir of infections contributes to malaria 
transmission [125]. 
In areas of low malaria transmission with seasonal patterns affected by climatic 
conditions, such as the Peruvian northern coast region, parasitological indicators 
determined by microscopy or PCR can be insensitive. In these areas, serological measures 
can be used as a proxy for malaria transmission intensity [22,58,59,115]. Indeed, 
seroprevalence reflects the cumulative exposure to malaria and, since antibodies persist 
longer in the blood than parasites, it is more sensitive and less affected by seasonality or 
unstable transmission [10,20,115]. Though it may be limited in detecting discrete 
seasonal variations in transmission, it is a good indicator of long-term transmission 
potential [20,21]. 
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Even though P. falciparum reported cases in Piura department have been extremely rare 
in the past five years, P. vivax and P. falciparum seroprevalence indicated ongoing 
exposure to both species. The low PfGLURP seropositivity in young children and the 
only one P. falciparum case detected by PCR suggest that a residual P. falciparum 
transmission is still present in the study area. This residual transmission may be due to 
asymptomatic P. falciparum infections that remain undetected, unless a population-wide 
survey (such as the present study) is carried out. However, the implementation of mass 
screening as a public health strategy in low transmission settings remains a matter of 
debate [96,112,124], as the cost-effectiveness of such an intervention remains difficult to 
establish. The role of asymptomatic infections in maintaining malaria transmission as 
well as the impact of mass screening and treatment should be further evaluated through 
modelling techniques [126]. 
One might argue that an alternative explanation for the observed P. falciparum 
seropositivity could be the presence of antibodies cross-reacting with P. vivax or other 
infectious agents’ antigens. Limited information is available about the cross-reactivity 
between P. falciparum and P. vivax antigens [122,127], and this has not been reported for 
PfGLURP. In addition, the lack of association between confirmed P. vivax infections by 
PCR and PfGLURP seropositivity, and the absence of correlation between antibody 
responses to the two species suggest that cross-reactivity is probably minimal. A few 
studies have suggested the cross-reactive potential of PfGLURP with Schistosoma 
haematobium [128], which is unlikely inthe study area since the latter has not been 
reported in Piura. 
Serologic markers can also be used to determine risk factors for malaria. This is 
particularly important in low endemicity areas as the one reported here, where the low 
malaria prevalence jeopardizes the risk factor analysis. In the study area, age was the only 
independent risk factor that was associated to both species. The age-dependent 
PvMSP119 and PfGLURP seropositivity indicates cumulative P. vivax and P. falciparum 
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exposure with increasing age. As antibody responses will persist for prolonged periods, 
the rate of acquisition in young age groups can be used to determine current malaria 
transmission intensity [20-22,115] as well as to identify recent changes in MTI. 
The higher seroprevalence in individuals with several P. vivax malaria episodes also 
confirmed that PvMSP119 antibody detection measures cumulative exposure. However, 
the history of P. vivax malaria in the past year was not included in the multivariate risk 
factor analysis for P. vivax exposure, since it is not a risk factor for P. vivax infections 
per se but rather a consequence of previous exposure to a given risk factor. Plasmodium 
vivax infections are on the pathway between risk factors and the presence of P. vivax 
antibodies. 
Differences in the risk factors for P. vivax and P. falciparum seropositivity reflect the 
heterogeneity of malaria transmission intensity between species. Age and distance to the 
water drain were the only two independent risk factors significantly associated with P. 
vivax exposure. As mentioned above, the effect of age on seroprevalence usually reflects 
the cumulative exposure to malaria infections occurring with age rather than a higher risk 
of exposure in adults as compared to children. However, the significant interaction found 
between age and house distance to the drain, beside the cumulative effect of age on 
seroprevalence, indicates a significant lower exposure in children aged < ten years. 
Indeed, the effect of distance (<100 m versus ≥100 m) on P. vivax seropositivity was only 
significant in adults, indicating that children living close to the drain were not exposed 
any more to infectious bites compared to children living farther. Water accumulation in 
the drain provides breeding habitats for Anopheles malaria vectors after rains [116,103], 
resulting in a higher risk of exposure to infectious vectors for people living close to the 
drain. This is also supported by the results of univariate analysis for the risk of P. vivax 
infection. However, since adults are more likely to have outdoor evening activities, this 
could explain why children below ten, were no more at risk of malaria while living close 
to the drain. 
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Besides age, settlement and prior work as moto-taxi driver in the previous year, there 
were two additional independent risk factors for P. falciparum seropositivity. 
Historically, the three study settlements were important foci of P. falciparum 
transmission during the epidemic of 1998 and the early 2000s [129]. Therefore, higher 
seroprevalence in JCM and NP, compared to PAV again suggest differential reduction 
rates in MTI between villages (heterogeneity). Occupational activities outside settlements 
(as moto-taxi driver) that were associated with increased P. falciparum exposure support 
the hypothesis that transmission occurs not only in the immediate house environment as 
previously described by Guthmann et al [116], but outside the community as well. Moto-
taxi drivers in the study area usually work in evening times, when exposure to An. 
albimanus bites increases. Occupational risk for malaria has also been found in the 
Peruvian Amazon Region, where malaria morbidity has been clearly associated with 
forest-related activities such as farming, land clearing and wood extraction [93,100]. 
The catalytic model used to generate PfGLURP seroprevalence curves suggested that a 
significant decline in P. falciparum transmission occurred in the study area approximately 
eight years before the current study (around 2002). This supports the idea that the wide 
scale implementation of ACT since 2001 has significantly contributed to the reduction of 
P. falciparum MTI. Indeed, following the 1998 epidemic and the subsequent intensified 
control interventions implemented [108], P. falciparum incidence returned to the pre-
epidemic levels (1997) by 2000–2001 (around 5,000 cases), and since 2002 it steadily 
decreased to reach almost undetected levels from 2007 onwards (Figure 3). In addition, 
the absence of P. falciparum surge after the drought period in 2007, as observed with P. 
vivax, advocates for the additional significant effect of the ACT deployment on P 
falciparum MTI in the northern coast region [89]. 
Since the end of the drought period and the resuming of the rains, P. vivax incidence 
substantially increased [7] (Figure 3) which is concordant with the fitted results from the 
model, i.e., significant increase in P. vivax MTI after 2006. Plasmodium vivax 
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transmission in this area seems to be more sensitive than P. falciparum to changes in 
climatological and environmental conditions, especially since the implementation of 
ACT. The recent changes in species specific MTIs are also in line with the results of the 
multivariate risk factor analysis. While children under-five were significantly at lower 
risk of P.falciparum exposure compared to older children age 6–10, this was not the case 
for the P. vivax exposure where the under five were at similar risk of exposure compared 
to the 6–10 years old. 
The number of antigens used in the two serological tests could be a limitation of the study. 
Due to the degree of sequence variability, it is recommended to use multiple antigens for 
each species in order to optimize the sensitivity of the antibody detection and to improve 
the identification of changes in malaria transmission over time in low transmission 
settings [57,59]. However, the observation that the antigens used in the study are 
relatively conserved [130] combined with results from recent studies performed in 
Cambodia, Vietnam and Peru suggests that PfGLURP and PvMSP119 are highly suitable 
for the detection of antibodies against P. falciparum and P. vivax, respectively [120,131]. 
Multiplexing the serological tests as well as standardizing the antigens used is of crucial 
importance for monitoring elimination efforts and comparing trends across countries and 
regions. 
 
3.6. Conclusions 
Monitoring MTI in areas of low endemicity and seasonal patterns, such as the north-
western coast of Peru, poses a major challenge to national malaria control programmes. 
In this setting, molecular tools confirmed the current malaria transmission pattern 
characterized by low parasite rates, mainly due to P. vivax with a majority of 
asymptomatic and sub-microscopic infections. Additionally, serological markers 
reflected exposure to malaria and allowed for species-specific risk factor analysis, as well 
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as showing recent changes in respective MTIs. In conclusion, the combination of both 
serological and molecular tools improved detection sensitivity, and provided new insights 
into recent changes in transmission intensity for both species. This invaluable information 
can help decision-makers to adjust malaria control strategies in order to maintain current 
achievements, avoid outbreaks, and possibly move towards the elimination of malaria. 
 
Authors’ contributions 
AR contributed to the study design, analysed the data and wrote the paper; ALL and VS 
contributed to the study design and paper review; NS and JC contributed to the data 
analysis and paper review; JCM contributed to the fieldwork supervision and processed 
the blood samples with ELISA and PCR; EP and OJP carried out and coordinated the 
fieldwork; DG contributed to the supervision of the sample processing and paper review; 
MOP, ISS and MT contributed antigen to the project and reviewed the article; UDA 
contributed to the study design and reviewed the manuscript; AE contributed to the study 
design, the data analysis and reviewed the paper. All authors read and approved the final 
manuscript. 
Acknowledgements 
We would like to thank Socrates Herrera and the Centro Latino Americano de 
Investigación en Malaria (CLAIM) for their contribution to the fieldwork, and all study 
participants and the local authorities for their enthusiastic support provided to our study.  
 
 
 
 
 
 
Assessing malaria transmission in the Peruvian northern coast 
60 
 
 
 
 
 
 
 
Hotspots of malaria transmission in the Peruvian Amazon 
 
61 
 
4. HOTSPOTS OF MALARIA TRANSMISSION IN THE 
PERUVIAN AMAZON: RAPID ASSESSMENT 
THROUGH A PARASITOLOGICAL AND 
SEROLOGICAL SURVEY.  
Authors: Angel Rosas-Aguirre, Niko Speybroeck, Alejandro Llanos-Cuentas, Anna 
Rosanas-Urgell, Gabriel Carrasco-Escobar, Hugo Rodriguez, Dionicia Gamboa, Juan 
Contreras-Mancilla, Freddy Alava, Irene Soares, Edmond Remarque, Umberto 
D´Alessandro, Annette Erhart. 
Journal: Published in Plos One 2015 Sep 12. 
 
4.1. Abstract 
 Background:  With low and markedly seasonal malaria transmission, increasingly 
sensitive tools for better stratifying the risk of infection and targeting control interventions 
are needed.  A cross-sectional survey to characterize the current malaria transmission 
patterns, identify hotspots, and detect recent changes using parasitological and serological 
measures was conducted in three sites of the Peruvian Amazon.  
Material and Methods: After full census of the study population, 651 participants were 
interviewed, clinically examined and had a blood sample taken for the detection of malaria 
parasites (microscopy and PCR) and antibodies against P. vivax (PvMSP119, PvAMA1) 
and P. falciparum (PfGLURP, PfAMA1) antigens by ELISA. Risk factors for malaria 
infection (positive PCR) and malaria exposure (seropositivity) were assessed by 
multivariate survey logistic regression models. Age-specific seroprevalence was analyzed 
using a reversible catalytic conversion model based on maximum likelihood for 
generating seroconversion rates (SCR, λ). SaTScan was used to detect spatial clusters of 
serology-positive individuals within each site.  
Results: The overall parasite prevalence by PCR was low, i.e. 3.9% for P. vivax and 6.7% 
for P. falciparum, while the seroprevalence was substantially higher, 33.6% for P. vivax 
and 22.0% for P. falciparum, with major differences between study sites. Age and location 
(site) were significantly associated with P. vivax exposure; while location, age and 
outdoor occupation were associated with P. falciparum exposure. P. falciparum 
seroprevalence curves showed a stable transmission throughout time, while for P. vivax 
transmission was better described by a model with two SCRs. The spatial analysis 
identified well-defined clusters of P. falciparum seropositive individuals in two sites, 
while it detected only a very small cluster of P. vivax exposure.  
Conclusion: The use of a single parasitological and serological malaria survey has proven 
to be an efficient and accurate method to characterize the species specific heterogeneity 
in malaria transmission at micro-geographical level as well as to identify recent changes 
in transmission.   
 
Keywords: Malaria; transmission; PCR; Serology; hot-spot; heterogeneity; Peruvian 
Amazon. 
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4.2. Background 
Despite several decades of intense control efforts, malaria remains an important public 
health problem in Peru [1], mainly in the department of Loreto in the Amazon region, 
which has historically accounted for most of the malaria burden within the country [7]. 
After malaria resurgence in the late 90s, with a peak of more than 120,000 slide confirmed 
cases in 1997 [1,2], the annual incidence in Loreto following intensified control activities 
decreased and stabilized at around 45,000-55,000 cases between 2002 and 2005 [7]. 
Between October 2005 and September 2010, increased support from international donors, 
e.g. the Global Fund-PAMAFRO Project [4], allowed the scale-up of comprehensive 
malaria control strategies in the Peruvian Amazon [5,6]. During this period, malaria 
declined drastically in Loreto from 54,291 reported clinical cases (25% due to P. 
falciparum) in 2005 to 11,604 cases (20% due to P. falciparum) in 2010, [7]. Since 
October 2010, malaria control activities are mainly supported by the Ministry of Health 
(MoH) budget, prioritizing passive and reactive case detection using standard light 
microscopy (LM) and treatment of confirmed infections. Unfortunately since 2012, 
malaria incidence in Loreto is rising again, with more than 25,000 cases reported [7]. 
Although Loreto is considered as a low endemic area [94], previous studies around Iquitos 
have reported high heterogeneity in malaria transmission at micro-geographical scale 
[96,132]. Even though this heterogeneity creates opportunities for targeted control 
interventions [9], the identification of hotspots of high malaria transmission intensity 
(MTI) is not straightforward. Choosing an appropriate method to measure MTI is key in 
assessing the risk of infection. Though the entomological inoculation rate (EIR) is usually 
considered as the gold standard for measuring MTI, in low transmission area this measure 
has proven to be insensitive and non cost-effective [16,17]. Incidence of confirmed 
clinical malaria has frequently been used for malaria risk stratification; however, its 
validity is affected by the differential acquisition of immunity inside and outside hotspots 
as well as contextual factors such as treatment seeking behaviors [9]. Although 
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determining malaria parasite carriage (both symptomatic and asymptomatic infections) 
through large community surveys seems to be a more accurate method, this is still unable 
to capture seasonal variations [16,18]. Additionally, low-parasite-density infections 
would only be detected by highly sensitive diagnosis tests such as polymerase chain 
reaction (PCR) [19]. 
Cross-sectional surveys using serological markers are increasingly proposed as useful 
alternatives for estimating MTI in low transmission settings, especially for the 
identification of malaria hotspots and related risk factors [10,59,115,120,133]. Age-
stratified seroprevalence data have been used to model seroconversion rates (SCR) which 
closely correlated with EIR, parasite prevalence rates [20,21] as well as related changes 
over time following specific interventions [22], seasonal or behavioral changes [23].  
Following the recent changes in malaria control activities in the Peruvian Amazon region, 
we conducted a cross-sectional survey combining molecular and serological markers with 
the aim of characterizing the current malaria transmission patterns, detecting hotspots, 
and identifying recent changes in species-specific MTI in three sites around Iquitos city.  
  
4.3. Methods 
Study area 
The study was conducted in three different sites in San Juan (south of Iquitos city) (Figure 
4.1), one of the most malaria endemic district in Loreto over the past five years. Study 
sites included communities which were established after the 1980s following the 
intensification of the deforestation and the extension of the road connecting Iquitos to 
Nauta district [134]. Site A included three contiguous peri-urban communities, i.e. 
Aguaje (AG), Agua Blanca (AB) and Pampachica (PA), located about 500 meters from 
the Nanay river, just on the administrative border between San Juan and Iquitos districts. 
The communities have well-constructed wooden houses (with 24 hour electric service) 
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built on stilts as the river floods the area during the rainy season. Site B included three 
rural communities, i.e. El Milagro (EM), Villa Buen Pastor (BP) and San Carlos (SC), 
situated at 21 kilometers (km) from Iquitos on the Iquitos-Nauta district road, and then at 
2, 4 and 9 km, respectively via a rural trail. The surrounding area is mainly composed by 
dense secondary growth vegetation with natural water bodies (swamps, ground pools, 
etc.) that enlarge during the rainy season. Among the three communities, only SC has 
direct access to the Itaya River.  Site C was the farthest, consisting of two rural 
communities, i.e. San Lucas (SL) and El Triunfo (ET), with houses located on both sides 
of the Iquitos-Nauta road between the 42nd and 48th km. Several fish ponds are found 
along this section of the road. Unlike site A, communities in sites B and C have an 
important proportion of semi-closed wooden houses and no electricity. The study 
population was predominantly mestizos - referring to all Peruvians that cannot be clearly 
identified as belonging to any ethnic minority population- living mainly from small-scale 
agriculture, fishing, and small commercial activities.  
 
Figure 4.1. Study area in San 
Juan district, Loreto department, 
Northern Peruvian Amazon.  
Eight communities in three sites 
were included: Site A: Aguaje 
(AG), Agua Blanca (AB) and 
Pampachica (PA); Site B: El 
Milagro (EM), Villa Buen Pastor 
(BP) and San Carlos (SC); and Site 
C: San Lucas (SL), El Triunfo (ET). 
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The climate is tropical, warm and humid with a rainy season from November to May and 
a dry season from June to October. The annual average temperature is around 27°C, the 
relative humidity above 80%, and an average annual rainfall of 4 meters [85]. Malaria 
transmission in the area is perennial, with a peak between February and July [96]. 
Anopheles darlingi is the main malaria vector and is highly anthropophilic. A recent 
entomological study carried out in some communities near the study area [135] showed 
that An. darlingi was now mainly biting outdoors while it was previously known to bite 
equally in- and outdoors. P. vivax and P. falciparum infections at district level occur at a 
ratio 5:1 and all age groups are at risk of infection, though adults more than children.  
Malaria surveillance relies on passive case detection (PCD) with microscopy. Patients 
presenting with fever or any other symptoms compatible with malaria are systematically 
tested by microscopy at health facilities and treated with chloroquine (CQ) for 3 days 
(10mg/g on days 1 and 2, and 5mg/kg on day 3), plus primaquine (PQ) for 7 days (0.5 
mg/kg/day) if P. vivax malaria is confirmed, or with mefloquine (MQ) (12.5 mg/kg/day 
for 2 days) plus artesunate (AS) (4 mg/kg/day for 3 days) if P. falciparum malaria is 
confirmed. These treatment guidelines are in place since 2001, and all health facilities 
should perform directly observed therapy (DOT) [92]. 
Data collection 
A complete census of the study population with collection of information on socio-
demographic variables (age, gender, education, occupation, socio-economic status) and 
malaria preventive measures (bed net use), was conducted two weeks prior to the survey. 
Each house was identified with a unique number and geo-referenced using a handheld 
Global Positioning System (GPS) device (Garmin’s GPSMAP 60CSx, Garmin 
International Inc., USA).  
The survey was done in November 2012. Each household was visited and all available 
children between six months and seven years old, plus one randomly selected individual 
above 7, were enrolled after providing written informed consent/assent. Whenever 
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selected individuals were absent, the household was revisited within the next two days to 
maximize subject participation. Each participant had the axillary temperature taken, 
malaria symptoms were recorded, and a finger-prick blood sample collected for 
immediate microscopy (thick and thin blood smears) and on filter paper (Whatman grade 
3, Whatman, Springfield Mill, USA) for later serological and molecular tests. Filter paper 
dried blood samples were individually stored at 4°C with desiccant until processed at 
Institute of Tropical Medicine Alexander von Humboldt, Lima (ITM-AvH). All 
individuals with a malaria infection detected by LM were treated according to the national 
guidelines.  
Laboratory procedures 
Microscopy 
Thick and thin smears were stained for 10 minutes with a 10% Giemsa solution, and 
parasite density was computed after counting the number of asexual parasites for 200 
white blood cells (WBC) in the thick smear and assuming a concentration of 8,000 
WBCs/μl. Slides were read during the survey and then a day later by an expert at 
microscopy at the reference laboratory in Iquitos. A slide was declared negative if no 
malaria parasite was found after examining 100 fields. Quality control was done blindly 
on all positive slides and 10% of randomly chosen negative slides by a senior technician 
at ITM-AvH. Any discordant results were reread by a second senior technician until 
agreement. 
Species-specific Polymerase Chain Reaction (ss-PCR) 
Parasite DNA was extracted using the Saponin lysis Chelex 100 method and stored at 4°C 
for immediate use in PCR reactions or at -20°C for later use. All samples were first 
analyzed by ssPCR following a protocol published elsewhere [119]. Briefly, this ssPCR 
consisted of a primary PCR with primers directed to specific Plasmodium sequences, and 
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obtained amplicons were used for a second PCR using P. falciparum and P. vivax specific 
primers. 
Serology 
Antibodies for specific IgG responses to P. vivax merozoite surface protein-1(19-kDa C-
terminal region, PvMSP-119) [122] and apical membrane antigen-1 (PvAMA-1) [136], 
and to P. falciparum glutamate-rich protein-fragment R2 (PfGLURP-R2) [121] and 
apical membrane antigen-1 (PfAMA-1) [137] were detected using ELISA.  Although data 
on the kinetics of antibody responses are limited, some studies using similar antigens 
(such as AMA-1 and MSP1-19) have reported that these antibodies are not short-lived 
(lasting from months to several years) and that the half-live of those responses can be 
influenced by differences in the background immunity of populations and in the level of 
malaria transmission [138].  According to the ELISA protocol [120], dried blood filter 
paper samples (5mm diameter disc/sample) were eluted overnight at 4°C in 2 ml of PBS-
Blotto-Tween. Two hundred microliters of the eluate were added in duplicate to blocked-
ELISA plates coated separately with each antigen. Pooled sera from five P. vivax and five 
P. falciparum infected patients, and from five control individuals without recent (negative 
PCR) and past history of malaria infection were diluted at 1:400 in PBS-Blotto, as positive 
and negative control respectively. Goat anti-human IgG (H+L) specific peroxidase 
(Merck Millipore, USA) diluted to 1:20,000 in PBS-Tween was used as conjugate and 
incubated for 1 h before development of the ELISA using 200μl ABTS substrate-
chromogen solution. Optical Density (OD) values at 405 nm (Lector Multi-Modal 
Synergy H1, BioTek, USA), were corrected by subtracting the mean OD of the antigen 
negative control wells from the mean OD of the corresponding antigen containing wells. 
Analyses with duplicate OD values that differed by more than 1.5-fold were rejected and 
rerun. To ensure a standardization of the sample results across ELISA plates, the percent 
positivity (PP) of each specimen was calculated using the OD of the positive control 
serum as 100%. Quality control was done blindly at ITM-AvH on 5% of randomly chosen 
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samples. The criterion for positivity was determined for each antigen of each species 
applying a mixture model to the PP data which assumed two inherent Gaussian 
distributions: a narrow distribution or seronegatives, and a broader distribution of 
seropositives. Cut-off value was calculated as the mean plus 3 standard deviations of the 
narrow distribution [21].  
Data analysis 
Survey data were double entered and cross-checked in Excel (Microsoft Corp, USA), and 
data analysis was performed with R v.2.15 software (R Development Core Team, R 
Foundation for Statistical Computing, Austria). Baseline characteristics between sites 
were compared using the Chi-squared test. Species-specific parasite prevalence (by LM 
and by PCR) as well as seroprevalence were estimated overall and by site.  
Uni- and multivariate adjusted analyses were performed using survey logistic regression 
to assess risk factors (i.e., site, age, gender, out-door occupation, predominant material in 
walls and roof, availability of electricity, and past history of malaria) for species-specific 
malaria outcomes (i.e. malaria infection, and malaria exposure), adjusting for potential 
confounders. Malaria infection was defined as an individual with a positive PCR result, 
regardless of symptoms; while malaria exposure to any of the two species was defined as 
an individual with a positive serology to any of the two antigens for each species. Factors 
with p-values <0.1 for the likelihood ratio test in the univariate analysis (intended to 
assess enough potential risk factors) were considered for inclusion in the multivariate 
adjusted model. Using the manual backward methods, final models retained all factors 
that were significantly associated with the malaria outcome (p <0.05). Interactions were 
systematically checked for up to order two. All analyses took into account the following 
survey design characteristics: community as strata, household as primary sampling unit, 
and corresponding sampling weights (w) for children <7 years (w=1) and for individuals 
≥7 years (w=1/n, where n=number of individuals ≥7 years at household).  
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The QGIS™ software QGIS v.2.6 (QGIS developer team, Open Source Geospatial 
Foundation) was used to map all surveyed individuals [139] and the SaTScanTM software 
v.9.3 (M Kulldorff and Information Management Services Inc, USA) [140] to detect 
spatial clusters of individuals with malaria infection as well as with malaria exposure in 
each site, using the following characteristics: purely spatial analysis, Bernoulli probability 
model [141], latitude/longitude coordinates, report of most likely clusters with no 
geographical overlap of secondary clusters, Gini optimizer cluster collection, and 
maximum spatial cluster size equal to 50% of total population.  The main analysis was 
done without adjustment for covariates, and a secondary analysis included age as 
covariate. SaTScan applies multiple circular windows with varying size (from zero to a 
maximum radius of 50% of total population) across the study area, each circle 
representing a possible cluster. Clusters were assessed based on 999 Monte Carlo 
simulations to determine the probability of observed frequency of infected/exposed 
individuals being due to chance relative to expected frequency under the null hypothesis 
of no clustering. The null hypothesis was rejected if any resulting p-value of assessed 
clusters was <0.05 and the window with the maximum log likelihood ratio (LLR) was 
identified as the most likely cluster. The relative risk (RR) reported for each identified 
cluster was the estimated risk within the cluster divided by the estimated risk outside the 
cluster [141]. Moreover, uni- and multivariate survey logistic regression analysis were 
performed in sites with detected spatial clusters to determine association between the 
residence of individuals (inside or outside the spatial cluster) and potential risk factors.  
Seroprevalence was stratified into yearly age-decile groups and then analyzed using a 
reverse catalytic conversion model [20] which allowed the estimation of two parameters: 
a) a seroconversion rate (SCR, λ) or force of infection (FOI) defined as the annual rate at 
which individuals change from seronegative to seropositive); and b) a seroreversion rate 
(SRR, ρ) defined as the annual rate at which seropositive individuals revert to a 
seronegative state. The main assumptions of the model are the following [142]: all 
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individuals spent their entire live in the community, migration is negligible, there are no 
individual differences in SCR between subjects of a same community, and the disease 
transmission in the community is at an endemic steady-state, i.e. SCR is assumed constant 
over time.  
Since study communities were established in the early 1980s, the first analysis excluded 
individuals older than 30 years old (21.2% of total population) in order to comply with 
the first assumption mentioned above. The dataset of all sites was first analyzed using a 
reversible catalytic model that assumed a stable transmission throughout time estimating 
SCR and SRR for the study population up to age 30 years.  Then, the specific data set 
from each site was analyzed using two reversible catalytic models, one that assumed a 
constant-SCR over time and another that assumed a change in SCR at a given time point. 
All these models included the population SRR as common parameter. Profile likelihood 
plots were applied to determine the most likely time point for change in the transmission 
prior to survey [21]. The latter was subsequently incorporated into the catalytic model to 
fit a seroprevalence curve with two SCRs (before and after time cut-off) [22], which was 
then compared with a single SCR seroprevalence curve using the likelihood ratio (LR) 
test (p<0.05). Bootstrapped 95% confidence intervals for SCR and SRR were estimated 
using the bias-corrected and accelerated (BCa) bootstrap resampling method [143].  
Later, a sensitivity analysis was done including individuals of all ages in order to assess 
the influence of the individuals older than 30 years old on the age-seroprevalence curves 
and on the identification of most likely time points for change in the transmission 
according to the model. 
Additionally, routine surveillance data, namely reported clinical malaria episodes through 
PCD provided by the Regional Direction of Health Loreto, were used to explore the 
association between malaria incidence trends in the department (between 1990 and 2013) 
[7] and the changes in malaria transmission obtained from catalytic models. Since routine 
malaria surveillance data since 2002 could be reliably disaggregated only to the district 
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level but not to the village level, an retrospective revision of all registered individuals 
detected by PCD between January and December 2012 was done in all health facilities 
near the study communities in order to estimate the annual parasite index for P. vivax 
(APIv) and P. falciparum (APIf) per site in the year of the survey.  
Ethical issues 
Ethical clearance was obtained from the Ethics Review Board of the Universidad Peruana 
Cayetano Heredia, Lima, Peru (SIDISI code: 059745). Permissions were received from 
health and local authorities after explaining the purpose and procedures of the study. 
Signed informed consent was obtained prior to participation and blood sampling by all 
adults and the parents of all participating children <18 years. Besides their parent's 
consent, children older than 7 years provided a signed informed assent.  
 
4.4. Results 
 
Figure 4.2. Flowchart of study participants   
A total of 348 houses and 1,649 individuals were identified during the census, with the 
following site specific distribution: Site A=129 houses (H) and 655 individuals (Ind); Site 
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B=80 H and 377 Ind; Site C=139 H and 617 Ind. The overall ratio of female to male was 
1.04; half of the population was less than 15 years old. The survey enrolled 651 
individuals: 304 (72.4%) of the total 420 censored children between 6 months and 7 years, 
and 347 (31.2%) individuals of the total individuals ≥ 7 years.  Figure 4.2 presents the 
flowchart of participants and Annex (Chapter 9)-Table S4.1 shows the survey coverage 
by site and age group.    
Table 4.1. Baseline characteristics of the study population 
  Site A  
(AG, AB, PC) 
Site B  
(SC, BP, 
EM) 
Site C  
(ET, SL) 
Total 
  n % n % n % N % 
Total surveyed 238 36.6 153 23.5 260 39.9 651 100.0 
Gender         
 Female 137 57.6 77 50.3 134 51.5 348 53.5 
Age groups (years)         
 < 7   109 45.8 74 48.4 121 46.5 304 46.7 
 7-14.9 42 17.6 19 12.4 40 15.4 101 15.5 
15-30 47 19.7 17 11.1 44 16.9 108 16.6 
> 30 40 16.8 43 28.1 55 21.2 138 21.2 
Education (>=18 years, n=218)*         
 None 0 0.0 2 3.6 3 3.5 5 2.3 
 Primary 23 29.5 28 50.9 55 64.7 106 48.6 
 Incomplete secondary 29 37.2 11 20.0 18 21.2 58 26.6 
 Complete secondary/+ 26 33.3 14 25.5 9 10.6 49 22.5 
Occupation (≥15 years, n=246)*         
 None (students, retired) 12 14.1 7 11.7 12 11.9 31 12.6 
Housewife 46 54.1 23 38.3 41 40.6 110 44.7 
Laborer/trader/mototaxi driver 22 25.8 3 5.0 2 2.0 27 11.0 
Farmer/guard/logger/fisher 5 5.9 27 45.0 46 45.5 78 31.7 
Predominant material in roof*         
 Palm leaf, straw 56 22.8 88 56.0 197 79.9 341 51.5 
 Tin roof 182 77.2 65 44.0 56 20.1 303 48.5 
Missing     7  7  
Electricity availability*         
 Yes 225 96.0 91 65.3 113 47.6 429 65.9 
Sleeping under bednet previous 
night  
        
 Yes 227 96.7 149 99.7 259 100.0 635 98.8 Missing 4  3  1  8  
Self-report of confirmed 
malaria* 
        
 Never 182 65.0 74 31.3 135 42.7 391 60.4 
In the past 12 months 7 3.8 25 19.1 66 29.5 98 15.1 
>12 months 48 31.1 54 49.6 56 27.8 158 24.4 
 Missing 1    3  4  
* p-value <0.05 for differences between sites 
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Of the total 651 individuals, 238 (36.6%) lived in Site A, 153 (23.5%) in Site B, and 260 
(39.9%) in Site C (Table 4.1). Children under 7 represented between 45% and 48% of the 
participants across sites, and females slightly outnumbered males in site A (ratio 
female/male =1.15; p=0.27). The majority of adult participants had only primary school 
education level, except in site A where 70.5% had secondary or higher education level 
(p<0.001).  Overall, the most commonly reported occupation among individuals aged ≥15 
years was housewife, followed by farmers and guards in sites B and C, while activities 
were more diversified including traders and indoor laborers in Site A (p<0.001). In all 
sites, most of houses had wooden walls, with roofs of predominantly palm leaf and straw 
in Sites B and C, and tin sheets in Site A (p<0.001).  Reported bed net use was very high 
(>95%) in all sites; nevertheless, most participants in site A stated of never have 
experienced malaria, while this was not the case in the other two sites (p<0.001). 
By LM, the overall prevalence was 3.3% (7 P.vivax and 10 P.falciparum infections), and 
by PCR 10.9% (18 P. vivax, 34 P.falciparum and one mixed infections) (Table 4.2), with 
the highest figures in the two rural sites B and C. Species-specific parasite prevalence 
varied widely across the sites by both LM and PCR (p<0.001). By PCR, both species had 
similar prevalence in site C (8.0%) and A (3.0 vs 1.1%), while in site B P.falciparum was 
predominant (11.2%) over P.vivax (2.1%). The species specific seroprevalence showed 
similar heterogeneity between sites. P.vivax seroprevalence was equally high in sites B 
(42.3%) and C (46.7%), and relatively low in site A (16.4%) (p<0.001). P.falciparum 
seroprevalence was 36.7% in site B, 16.7% in site A and 18.7% in site C (p<0.001).  
Interestingly for both species, sites with the highest seroprevalence were respectively the 
ones with the highest prevalence by PCR, and also the ones with the highest API 
estimated from PCD records in 2012.  Gametocytes were found in 4 (44.4%) of the total 
9 microscopically confirmed P.falciparum infections in site B, as well as in 4 (57.1%) of 
the total 7 microscopically confirmed P. vivax infections in site C. The unique 
microscopically confirmed P.falciparum infection in site C had also gametocytes.  
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Table 4.2. Malaria prevalence (by microscopy and PCR) and seroprevalence by study site 
 Site A  Site B Site C Total 
 n % 95% CI  n % 95% CI n % 95% CI n % 95% CI 
Microscopy                  
P.vivax* 0 0.0   0 0.0  7 4.9 [2.1,10.8] 7 1.8 [0.8,4.1] 
P.falciparum* 0 0.0   9 6.4 [3.0,13.1] 1 0.2 [0.0,1.2] 10 1.5 [0.7,3.1] 
Total* 0 0.0   9 6.4 [3.0,13.1] 8 5.0 [2.2,10.9] 17 3.3 [1.9,5.8] 
PCR              
P.vivax* 1 1.1 [0.1,7.3]  2 2.1 [0.5,8.1] 15 8.0 [4.4,14.0] 18 3.9 [2.3,6.5] 
P.falciparum* 6 3.0 [1.2,7.8]  14 11.2 [6.2,19.2] 14 8.0 [4.2,14.6] 34 6.7 [4.5,9.9] 
Mixed 0 0.0   1 1.1 [0.1,7.2] 0 0.0  1 0.2 [0.0,1.7] 
Total 7 4.1 [1.7,9.6]  17 14.4 [8.6,23.0] 29 15.9 [10.5,23.5] 53 10.9 [8.0,14.6] 
Seropositivity P.vivax            
MSP1-19* 13 8.1 [4.2,14.8]  26 24.2 [16.5,34.0] 88 38.5 [30.6,47.1] 127 23.1 [19.2,27.6] 
AMA-1* 18 11.9 [7.0,19.5]  35 33.5 [24.5,43.9] 67 34.5 [27.1,42.6] 120 25.2 [21.1,29.9] 
Total* 27 16.4 [10.7,24.4]  45 42.3 [32.6,52.6] 102 46.7 [38.5,55.1] 174 33.6 [29.0,38.5] 
 Seropositivity P. falciparum           
GLURP* 26 13.7 [8.8,20.8]  34 27.9 [19.9,37.7] 39 15.8 [10.8,22.5] 99 17.7 [14.2,21.8] 
AMA-1* 9 4.3 [1.9,9.2]  22 20.7 [14.0,29.7] 18 8.5 [4.9,14.6] 49 9.6 [7.1,12.8] 
Total* 33 16.7 [11.5,23.8]  46 36.7 [27.9,46.5] 47 18.7 [13.2,25.8] 126 22.0 [18.3,26.3] 
Incidence rate (2012)           
APIv (x1000)+  7.6    66.3   205.8     
APIf  (x1000)+ 4.6    148.5   14.6     
API total  (x1000)+ 12.2    214.8   220.4     
*p-value<0.05 for significant differences between sites.  
+ APIv= Annual parasite index for P. vivax, APIf= Annual parasite index for P. falciparum, APItotal= Annual parasite index 
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Most of PCR-positive infections were sub-microscopic (>70%) and asymptomatic 
(>75%) at the time of the survey, regardless of the Plasmodium species (Table 4.3). 
Species-specific PCR positivity was significantly associated with species-specific 
seropositivity both overall and for each specific antigen (p < 0.05).   
Table 4.3. Association between PCR results and microscopy, serology and symptoms 
  PCR results*  
  Negative P. vivax 
P. 
falciparum  
p-
value 
    n % n % n %     
          
Total analyzed  596  18  34    
Microscopy         
 Negative 594 99.7 13 72.2 24 70.6  <0.001 
P. vivax 2 0.3 5 27.8 0 0   
 P. falciparum 0 0 0 0 10 29.4   
P. vivax MSP-119 serology        
 Negative 485 81.4 10 55.6 26 76.5  0.043 
Positive 111 18.6 8 44.4 8 23.5   
P. vivax AMA-1 serology         
 Negative 493 82.7 9 50 26 76.5  0.004 
Positive 103 17.3 9 50 8 23.5   
Combined P. vivax serology         
 Negative 445 74.7 8 44.4 21 61.8  0.011 
Positive 151 25.3 10 55.6 13 38.2   
P. falciparum GLURP serology         
 Negative 513 86.1 15 83.3 21 61.8  0.003 
 Positive 83 13.9 3 16.7 13 38.2   
P. falciparum AMA-1 serology         
 Negative 554 93 18 100 27 79.4  <0.001 
 Positive 42 7 0 0 7 20.6   
Combined P. falciparum serology         
 Negative 489 82 15 83.3 18 52.9  <0.001 
 Positive 107 18 3 16.7 16 47.1   
Fever/history of fever  (previous 2 
days) 33 5.6 3 16.7 8 23.5 <0.001 
* One mixed infection not shown (asymptomatic individual seronegative both forP. falciparum and P. vivax  
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Given the small number of PCR-positive infections by species, multivariate adjusted risk 
factor analysis was carried out only for any parasite infection. Only site and age remained 
independently associated with malaria infection:  while individuals living in Site B (AOR: 
3.9, 95% CI [1.4–11.5]) and in Site C (AOR: 4.5, 95% CI [1.6–12.7]) were more likely 
to be infected than those living in Site A, individuals >30 years had higher odds of malaria 
infection than children < 7 years (AOR: 2.4, 95% CI [1.0–5.7]). Considering P. vivax 
exposure, the multivariate adjusted risk factor analysis showed that site and age remained 
independently associated with the P.vivax seropositivity: individuals living in Site B 
(AOR: 3.9, 95% CI [2.0–7.7]) and in Site C (AOR: 5.1, 95% CI [2.8–9.3]) had higher 
odds of P. vivax seropositivity than those in Site A, and  those older than seven years had 
increasingly higher odds (test for trend p < 0.001) of P. vivax seropositivity compared to 
younger children (Table 4.4).  
For P. falciparum exposure, site, age and outdoor occupation remained independent risk 
factors in the final model: individuals living in Site B (AOR: 2.3, 95% CI [1.2–4.4]) were 
more likely to be exposed to P. falciparum than those in Site A, adults >30 years (AOR: 
2.1, 95% CI [1.1–4.0]) were more exposed than children<7 years, and people working 
outdoor were three times more exposed to P. falciparum (AOR: 3.1, 95% CI [1.5–6.6]). 
Despite being significantly associated with both P. vivax (OR: 6.8, 95% CI [3.7–12.5]) 
and P. falciparum exposure (OR: 2.7, 95% CI [1.5–4.8]) in the univariate analysis, the 
history of malaria in the past year was not included in the multivariate analysis, since it 
is not a risk factor for malaria infections per se but rather a consequence of previous 
exposure to given risk factors.    
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Table 4.4. Univariate and multivariate risk factor analysis for species-specific malaria exposure  
  Univariate Multivariate 
  P. vivax P. falciparum P. vivax P. falciparum 
  % n/N OR  [95%  CI] % n/N OR  [95%  CI] AOR  [95%  CI] AOR  [95%  CI] 
                  
Site                 
 A 16.4 27/238 1   16.7 33/238 1   1   1   
 B 42.3 45/152 3.7 * [2;7.1] 36.7 46/152 2.9 * [1.6;5.2] 3.9 * [2;7.7] 2.3 * [1.2;4.4] 
C 45.0 102/259 4.4 * [2.4;8.1] 18.7 47/259 1.1  [0.6;2.1] 5.1 * [2.8;9.3] 0.8  [0.4;1.6] 
Age groups (years)                 
 < 7   13.1 40/303 1   13.7 39/303 1   1   1   
 7-14.9 27.0 27/101 2.5 * [1.5;4.2] 18.0 16/101 1.4  [0.7;2.6] 2.9 * [1.7;5] 1.5  [0.8;2.8] 
15-30 34.8 35/107 3.6 * [2.1;6.1] 18.3 20/107 1.4  [0.7;2.7] 4.3 * [2.4;7.7] 1.3  [0.7;2.6] 
> 30 52.6 72/138 7.4 * [4.5;12] 34.7 51/138 3.3 * [1.9;5.7] 8.8 * [5.2;14.8] 2.1 * [1.1;4] 
Gender                 
 Female 29.6 80/346 1   16.9 54/346 1         
Male 38.7 94/303 1.5 o [1;2.3] 28.6 72/303 2 * [1.2;3.2]       
Outdoor occupation (farmer, 
guard, logger, fisher) 
                
 No 29.0 127/571 1   18.1 91/571 1      1   
 Yes 63.3 47/78 4.2 * [2.4;7.6] 47.5 35/78 4.1 * [2.3;7.5]    3.1 * [1.5;6.6] 
Predominant material in roof                 
 Palm leaf, straw 25.1 52/302 1   19.0 43/302 1         
 Tin roof 41.5 120/340 2.1 * [1.3;3.4] 24.6 82/340 1.4  [0.8;2.3]       
Electricity availability                 
 Yes 29.3 95/428 1   20.9 76/428 1         
 No 44.1 79/221 1.9 * [1.2;3.0] 24.7 50/221 1.2  [0.7;2.1]       
Malaria episode in the past 12 
months 
                
 No 26.3 108/547 1   18.9 89/547 1         
Yes 70.8 66/98 6.8 * [3.7;12.5] 38.3 37/98 2.7 * [1.5;4.8]       
*p<0.05,  o p<0.1
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Figures 4.3 and 4.4 show the spatial distribution of infected (positive PCR) and exposed 
(positive serology) individuals by species and for each site. Despite some aggregation of 
cases within adjacent houses in sites B and C, no significant spatial clusters of infections 
were identified by SaTScan, mainly because of the low number of infections. However, 
the purely spatial analysis without adjustment for covariates confirmed that malaria 
exposure mainly to P. falciparum was not randomly distributed. In site A, the most likely 
spatial cluster of P. falciparum seropositive individuals (RR=6.3, p<0.001), located on 
the western part of the village close to Nanay river (Figure 4.3A), had  a 120m radius area 
which included 114 surveyed individuals (47.9% of total) in 59 households (45.7% of 
total). This cluster represented 85.3% (29/34) of all P. falciparum seropositive 
individuals, but only two of the six PCR-confirmed infections by species. In site B, the 
most likely P. falciparum-exposure cluster (RR=2.9, p=0.001) had a radius of 1.3 km 
including 50 individuals (32.7% of the total) in 30 households (37.5% of the total) (Figure 
4.3B).  This cluster represented 58.7% (27/46) of all 46 P. falciparum seropositive 
individuals in the site, and 9 (64.2%) of the 14 P. falciparum mono-infections detected 
by PCR. Site C had no significant spatial cluster of P. falciparum exposure but was the 
only site where a most likely cluster of P. vivax-exposure (RR=2.9, p=0.001) could be 
identified (Figure 4.4C). This was a small cluster of 68m radius that included 10 
households, all surveyed individuals were P. vivax seropositive but none of them was 
infected (PCR negative).  Adding age group as covariate in SaTScan analysis to locate 
species-specific exposure clusters had no effect on the results.  
The multivariate survey logistic regression analysis for risk factors independently 
associated with the most likely P. falciparum-exposure cluster in site B identified outdoor 
occupations and electricity availability.  Indeed people living inside the most likely cluster 
were more likely to have outdoor activities (AOR: 4.4, 95% CI [1.6–11.8]), and a house 
with electricity (AOR: 4.5, 95% CI [1.6–12.9]) compared to people not living in that 
cluster. No significant risk factors were found with the residence inside the detected 
clusters in sites A and C (see Annex, Chapter 9, Table S5.2).  
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Figure 4.3. Distribution of P. falciparum infected and exposed individuals by study site (A, B, C) with respective significant spatial clusters for 
P. falciparum seropositivity. 
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Figure 4.4. Distribution of P. vivax infected and exposed individuals by study site (A, B, C) with respective significant spatial clusters for P. 
vivax seropositivity 
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Age seroprevalence curves of individuals aged ≤ 30 years confirmed a significant increase 
of malaria seroprevalence with age, but with different species specific patterns (Figure 
4.5). The overall (all sites) P. falciparum age seroprevalence was better described by a 
model with only one SCR (λ=0.08) and one SRR (ρ=0.384), while the overall P. vivax 
age seroprevalence was best modeled with two SCR (pre-2010 λ1=0.046, post-2010 
λ2=0.122) and one SRR (ρ=0.096) indicating an increase in MTI in 2010 for this species 
(p=0.01). The reversible catalytic models for P. falciparum confirmed a stable 
transmission, with higher transmission intensity in Site B (λ=0.129) than in sites A 
(λ=0.061) and C (λ=0.075).  Conversely, best models for P. vivax differed by site. While 
site C had a change in P. vivax MTI in 2010 with a significant threefold increase (pre-
2010 λ1=0.09, post-2010 λ2=0.241, p=0.02), sites A and B experienced significant drops 
in SCR but at different times: 13-14 years before the survey in site A (pre-1998-1999 
λ1=0.023, post-1998-1999 λ2=0.007, p=0.04), and 7-8 years prior survey in site B (pre-
2005 λ1=0.028, post-2005 λ2=0.008, p=0.03).  Moreover for both species, sites with the 
highest SCRs (SCR after the time cut-off in models with two SCRs) were respectively 
the ones with the highest API. 
Although the inclusion of seroprevalence data of individuals >30 years did not change the 
assumption of a stable transmission over time for P. falciparum per site (site A, λ=0.024; 
site B, λ=0.063; site C, λ=0.033), it allowed identifying a decrease in SCR for P. 
falciparum 32 years before the survey when the analysis included all the sites (pre-1980 
λ1=0.05, post-1980 λ2=0.031, p=0.03) (Figure 4.6). For P. vivax, the incorporation of 
antibody responses of individuals >30 years had different effects. While in all sites and 
site C it was identified an increase in SCR for P. vivax two years before the survey (all 
sites: pre-2010 λ1=0.035, post-2010 λ2=0.117, p=0.002; site C: pre-2010 λ1=0.061, post-
2010 λ2=0.231, p=0.003), P. vivax seroprevalence curve in site A was best described by 
a model assuming a decrease in malaria transmission 37 years prior survey (pre-1975 
λ1=0.031, post-1980 λ2=0.009, p=0.008). Conversely, model results for site B indicated 
a constant P. vivax SCR over time (λ=0.04). 
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Figure 4.5. P. vivax and P. falciparum age-seroprevalence curves for individuals under 30 years old in each site. Black dots represent observed 
prevalence, whilst the blue lines represent the maximum likelihood model. Seroconversion rates (λ, (95%CI)) are plotted on the graphs. Two 
seroconversion rates (λ1 and λ2) are plotted in graphs if likelihood ratio tests indicate change at a certain point in calendar time. 
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Figure 4.6. P. vivax and P. falciparum age-seroprevalence curves for individuals of all ages in each site. Black dots represent observed prevalence, 
whilst the blue lines represent the maximum likelihood model. Seroconversion rates (λ, (95%CI)) are plotted on the graphs. Two seroconversion rates (λ1 
and λ2) are plotted in graphs if likelihood ratio tests indicate change at a certain point in calendar time. 
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The retrospective analysis (1990-2013) of annual malaria incidence in Loreto department 
(Figure 4.7) showed a peak during the malaria epidemic (1996-1998) associated with the 
ENSO phenomenon when more than 65,000 P. vivax and 50,000 P. falciparum cases were 
recorded.  After the epidemic, incidence dropped drastically and stabilized between 2000 
and 2001 at around 30,000 total annual cases, and at 45,000 and 55,000 cases between 
2002 and 2005.  During this post-epidemic period, a new antimalarial treatment policy 
(2001-2004) was progressively implemented as previously described. During the Global 
Fund-PAMAFRO Project (2005-2010), intense control efforts resulted in a marked 
decline of malaria morbidity from 54,291 reported clinical cases in 2005 to 11,604 cases 
in 2010.  However, since 2011 (11,703 cases), malaria incidence is doubling each year. 
Noteworthy, P. falciparum infections usually followed similar trends than P. vivax, 
accounting for 20-25% of the total malaria cases, with exception of 1996-1998 when they 
represented almost 45% of the cases in Loreto. Between 2002 and 2013, though San Juan 
and Iquitos districts followed similar trends of malaria incidence than Loreto department 
(See Annex, Chapter 9, Figure S4.1), P. falciparum cases started to increase two years 
earlier (2009) in these two districts.  
 Figure 4.7. Evolution of the annual malaria incidence in Loreto department: 1990–2013. 
Information on annual malaria cases was obtained from the Regional Health Direction of Loreto. 
Numbers in the timeline point out important events that influenced malaria incidence: 1) First report P. 
falciparum in Loreto (1990), 2) first reports of chloroquine resistance (CQR) in P. falciparum (since 
1994), 3) very strong ENSO phenomenon (1996–1998), 4) Implementation of new antimalarial treatment 
policy for P. falciparum and P. vivax (2001–2004), 5) Global fund-PAMAFRO project (2005–2010). 
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4.5. Discussion 
The combined analysis of parasitological and serological measures collected during a 
single cross-sectional survey allowed for an in-depth characterization of the malaria 
transmission patterns in three different sites in an endemic district of the Peruvian 
Amazon. Most malaria infections detected by PCR were sub-microscopic and 
asymptomatic. The site specific analysis of both prevalence and seroprevalence data 
showed a high degree of heterogeneity at micro-geographic level and in time for both P. 
falciparum and P. vivax. However, species-specific parasitological and serological 
metrics (i.e., seroprevalence, SCRs) were in good agreement with IPA estimates by 
species.    
Although the survey was conducted in November, before the usual peak of clinical 
malaria cases, an important number of malaria-infected individuals were identified, 
mainly by P. falciparum, and most of them were undetectable by microscopy and free of 
malaria-related symptoms. As reported by other countries in the region, asymptomatic 
malaria infections (including submicroscopic infections) are common in low endemic 
settings, representing a “hidden” human reservoir likely to contribute to maintain 
transmission [54,111,124,125]. Previous cross-sectional studies using PCR in rural peri-
Iquitos communities have also reported high prevalence of asymptomatic parasite carriers 
(5%-14%) [94,96,98]; however, the surveys were conducted at the time of high seasonal 
transmission and P. vivax was always the predominant species.  
Although routine surveillance data at district and department level showed a 
predominance of P. vivax over P. falciparum reported cases, parasitological and 
serological measures indicated that species-specific malaria transmission may vary 
widely across sites.  Indeed, site C had similar prevalence of both species by PCR, but 
the higher seroprevalence and SCR estimates for P. vivax compared to those of P. 
falciparum suggested a very recent increase in P. falciparum infections. Moreover, in site 
Hotspots of malaria transmission in the Peruvian Amazon 
 
86 
 
B the higher P. falciparum seroprevalence and SCR compared to those of P. vivax 
suggested that the predominance of P. falciparum infections detected by PCR was not 
new. Additionally, the identification of P. falciparum gametocyte carriers by microscopy 
suggested ongoing transmission of this species in the site. These hypothesis were further 
supported by the newly generated site incidence data on P. falciparum (IPAf) and P. vivax 
(IPAv) in 2012. These results highlight the added value of combining parasitological and 
serological metrics in accurately understanding the local epidemiology since data from 
the health information system are often missing or not very reliable. 
The differences in species-specific seroprevalence across sites were in line with findings 
from previous entomological studies, all reporting a high heterogeneity in malaria 
transmission in the peri-Iquitos region [99,100]. During the late 90s malaria epidemic, 
EIRs for P. falciparum were significantly higher in rural communities along the Iquitos-
Nauta road than in periurban areas, with large monthly variations ranging from 0 to 12 
infective bites per person per month [99]. More recent studies have shown a positive 
association between EIR and level of deforestation [45] as well as significant 
heterogeneity between collection sites and over time, reaching sometimes comparable 
EIR estimates to holoendemic African areas. Deforestation in areas of site B and C 
following road construction and subsequent population settlements may have resulted in 
favorable ecological conditions for mosquito breeding and resting sites near households. 
Though entomological evaluations (mosquito larval habitat mapping, mosquito density 
and biting patterns) were not included in the study, previous reports showed that natural 
water bodies and fish ponds (such those located in sites B and C) constituted ideal 
breeding sites for An. darlingi, and were significantly associated with malaria infection 
[100,144]; while surrounding secondary vegetation in previously deforested zones would 
provide resting place for adult mosquito populations [100]. Besides ecological factors, 
human socio-economic differences such as poorer housing conditions (mostly semi-
closed houses) and higher proportion of individuals with outdoor economic activities in 
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rural sites B and C compared to site A, may play an important role in increasing exposure 
to mosquito bites [93,101].  
Genetic factors may play a role in human susceptibility to malaria infection and human 
infectiousness to mosquitoes [145,146]. However, there is insufficient data to establish 
their role in determining heterogeneity of malaria transmission in the Peruvian Amazon. 
The later could be partly due to the biological differences between P. falciparum and P. 
vivax [147,148]. Even though in theory P. vivax relapse patterns may influence 
serological profiles, the quantification of their effect on the production of malaria 
antibodies remains unclear due to the difficulty to classify a recurrent parasitaemia as 
relapse, new infection or recrudescence [147,148].   
Species specific heterogeneity was not only observed at small-scale geographical level 
but also over time as illustrated by the respective SCR estimates calculated by models 
including and excluding individuals older than 30 years old. A strong advantage of SCRs 
is the ability to reconstruct the history of malaria exposure in a population [16], but one 
important assumption of the model is that all individuals in a specific community have 
experienced the same disease transmission intensity over time. Thus, reductions in 
malaria transmission identified more than 30 years ago, as identified by catalytic models 
using seroprevalence data of all ages, may be explained by higher exposure to malaria of 
this age group prior to the settlement in 1980s of the study communities.  
On the other hand, SCR estimates generated using seroprevalence data of individuals aged 
≤ 30 years would be more accurate to identify more recent changes in malaria 
transmission.  Indeed, reversible catalytic models used to generate P. vivax 
seroprevalence curves showed that the significant decline in malaria transmission in sites 
A and B occurred at different points in time. While in site A, this time point coincided 
with the drastic reduction in P. vivax incidence after the late 90s epidemic; in site B, the 
change was concordant with the start in 2005 of the Global Fund-PAMAFRO project 
which prioritized comprehensive malaria control interventions in rural communities 
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[5,6,149].  Since the end of this project in 2011, malaria incidence has steadily increased 
and already reached pre-PAMAFRO levels in 2013 and 2014, highlighting the potential 
risk of rapid malaria resurgence in the Amazon Region [7]. This was captured by the age-
seroprevalence model for P. vivax in site C, i.e. increase in MTI two years before the 
survey. The fact that the catalytic model did not detect similar changes in SCRs for P. 
falciparum transmission as for P. vivax, could be due to the lack of power due to the lower 
levels seropositivity for P. falciparum and therefore insufficient sample size. Moreover, 
the independent association of outdoor economic activities with P. falciparum exposure 
would influence the model fit to age-seroprevalence data, since the assumption of the 
catalytic model that P. falciparum transmission is homogeneous in the community would 
not be fulfilled [142].  
Effective methods for quantifying micro-geographical variations in malaria exposure 
should be able to identify stable hotspots of transmission over time [9]. The spatial 
analysis of clinical malaria incidence over several seasons should be a good method for 
detecting hotspots; provided most malaria infections are symptomatic, detected by health 
facilities, and accurately traced for place of infection and/or residence. However, this is 
rarely the case in most endemic settings, especially in low endemic area such as the one 
in our study, where most infections remain asymptomatic. Therefore the spatial 
identification of hotspots using serological measures may produce more robust results 
[10,150]. Serological markers can also be used to identify high risk sub-groups (or “hot-
pops”)[151] within communities that could be targeted by additional interventions such 
as focal screening and treatment (FSAT) or mass drug administration (MDA)[152], which 
are financially and logistically unattractive at when implemented at large scale.  
Our spatial analysis using serological data allowed the identification of clusters with the 
highest P. falciparum exposure:  while in site A, the cluster covered the area closest to 
the river which floods every year during the rainy season; in site B, the cluster location 
was associated  with  outdoor occupations (i.e. farmer, guards), as well as with electricity 
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availability which has been reported to influence evening outdoor activities (e.g., 
watching television, chating, resting, etc.) of the household members [153]. These 
findings correlate well with the recent entomological findings from communities near the 
study area that showed that An. darlingi mosquitoes bite mainly outdoors [135]. On the 
other hand, the quasi absence of clustering in site C may be explained by the local 
mosquito and human mobility patterns. Indeed the presence of several permanent 
breeding sites (i.e. fish ponds) along the Iquitos-Nauta road could result into a wider 
dispersal of An. darlingi and numerous movements of infected individuals through the 
unique and highly accessible road could further increase the dispersal of parasites.  
Although a similar explanation could be advanced for the absence of P. vivax clusters in 
site A and B, it is difficult to know how the relapse patterns can affect the spatial analysis 
using serological data. 
Our study has some limitations. First, despite the use of two antigens of proven sensitivity 
for each Plasmodium species [57,133], regional variability in immunogenicity cannot be 
excluded and could be overcome by combining more antigens [22,59]. Though further 
research is still needed to identify the best antigens for measuring MTI [138] in Peruvian 
malaria endemic areas, we believe that sets used in our study were adequate and 
complementary since the antibody response produced was a good proxy for malaria 
exposure in other south-American endemic areas [133,154,155].  Ongoing cohort studies 
in the Peruvian Amazon will contribute to provide insights into the kinetics of antibody 
responses in the region.  Second, the assumption by the mixture model of a bi-modal 
distribution of seropositives and seronegatives for the determination of the cut-off for 
seropositivity may not be true. However, in the absence of a good “gold standard”, this 
approach is widely accepted for determining an event status such as “malaria exposure” 
[156]. Third, due to the lack of information about SRR in the Amazon region, we included 
a common species-specific SRR (the study population SRR) into each corresponding site 
model as previously reported in other serological studies [154].  Although this approach 
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allows comparing SCR estimates across sites, it is important to note that marked 
differences in SRR across sites could influence significantly the SCR estimates. Finally, 
despite the characteristics of the survey sampling, an enough proportion of individuals of 
each age group were included in each study site reducing the potential for selection bias.  
However, detecting the time point for change in malaria transmission as well as 
estimating corresponding SCRs may be slightly less accurate before than after 7 years 
prior the survey.   
4.6. Conclusions 
The use of a single parasitological and serological malaria survey has proven to be an 
efficient and accurate method to characterize the species specific heterogeneity in malaria 
transmission at micro-geographical level as well as to identify recent changes in 
transmission. This approach, once optimized by a validated set of best antigens by 
geographical area, represents a reliable and effective tool to accurately identify and 
characterize hotspots of transmission and consequently help decision-makers to better 
design and deliver targeted interventions. This is particularly important in low 
transmission settings moving towards malaria elimination such as the Peruvian Amazon.   
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5.1. Abstract 
 
Background: Focal screening and treatment (FSAT) of malaria infections has recently 
been introduced in Peru to overcome the inherent limitations of passive case detection 
(PCD) and further decrease the malaria burden. Here, we used a relatively straightforward 
mathematical model to assess the potential of FSAT as elimination strategy for 
Plasmodium falciparum malaria in the Peruvian Amazon Region.  
Methods: A baseline model was developed to simulate a scenario with seasonal malaria 
transmission and the effect of PCD and treatment of symptomatic infections on the P. 
falciparum malaria transmission in a low endemic area of the Peruvian Amazon. The 
model was then adjusted to simulate intervention scenarios for predicting the long term 
additional impact of FSAT on P. falciparum malaria prevalence and incidence. Model 
parameterization was done using data from a cohort study in a rural Amazonian 
community as well as published transmission parameters from previous studies in similar 
areas. The effect of FSAT timing and frequency, using either microscopy or a supposed 
field polymerase chain reaction (PCR) test, was assessed on both predicted incidence and 
prevalence rates. 
Results: The intervention model indicated that the addition of FSAT to PCD significantly 
reduced the predicted P. falciparum incidence and prevalence. The strongest reduction 
was observed when three consecutive FSAT were implemented at the beginning of the 
low transmission season, and if malaria diagnosis was done with PCR. Repeated 
interventions for consecutive years (10 years with microscopy or 5 years with PCR), 
would allow reaching near to zero incidence and prevalence rates.  
Conclusions: The addition of FSAT interventions to PCD may enable to reach P. 
falciparum elimination levels in low endemic areas of the Amazon Region, yet the 
progression rates to those levels may vary substantially according to the operational 
criteria used for the intervention. 
 
Keywords: Malaria, Plasmodium falciparum, Focal Screening and Treatment (FSAT), 
Modelling, Elimination, Peru. 
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5.2. Background 
Despite several decades of intense control efforts, malaria remains an important public 
health problem in Peru, especially in the Amazon region where most (85%) of the malaria 
cases occur, mainly due to P. vivax [7]. Increased financial support from international 
donors, e.g., the Global Fund-PAMAFRO Project (2005–2010), allowed for the scaling-
up of comprehensive malaria control strategies such as the use of artemisinin-based 
combination therapy (ACT) and the distribution of long-lasting insecticidal mosquito nets 
(LLINs) [6]. During this period, malaria declined drastically in Peru from 87,805 reported 
clinical cases in 2005 to 29,355 and 23,075 cases in 2010 and 2011, respectively. Since 
2011, following the reduction of financial support allocated to malaria control activities, 
malaria incidence started to increase again with a doubling of clinical cases in 2013, 
highlighting the potential risk of rapid malaria resurgence in the Amazon Region [7]. 
In contrast to the classical statement that the development of acquired malaria immunity 
requires long-term exposure and intense transmission, recent studies in endemic countries 
of South America have reported a large proportion of asymptomatic malaria infections 
[54,94,96,98,111,157-161] suggesting that clinical immunity may develop as well in low-
transmission settings of the subcontinent. The wider use of molecular diagnostics in 
epidemiological studies allows for a better knowledge on the extent of these 
asymptomatic infections, thus uncovering a “hidden” human infectious reservoir likely to 
contribute in maintaining transmission in endemic areas [111,124]. Indeed, cross-
sectional surveys conducted in rural communities surrounding Iquitos city in Peru 
reported prevalence of asymptomatic parasite carriers ranging from 5 to 14%, mostly 
detectable only by polymerase chain reaction (PCR) [94,96,98]. 
National malaria surveillance in the Amazon Region relies on passive case detection 
(PCD) with microscopy [92]. Patients presenting with fever or any other symptoms 
compatible with malaria are systematically tested by microscopy at peripheral health 
facilities and treated following national guidelines. However, the major limitation of PCD 
Modelling the potential impact of FSAT for P. falciparum in the Amazon 
 
93 
 
is that asymptomatic individuals do not seek medical care and therefore remain 
undetected and untreated [96,125], extending the period of parasite carriage [162]. Other 
described limitations of PCD include the quality of microscopy-based diagnosis [47], the 
access to health services with available microscopy [163], and social and cultural factors 
that influence treatment seeking behaviour at community level [48]. 
Active case detection (ACD) has recently been recommended in low transmission and 
malaria-elimination settings to overcome the inherent limitations of PCD and target the 
asymptomatic parasite reservoir [164]. According to the World Health Organization 
(WHO), ACD is defined as the detection of malaria infections through household visits 
in population groups that are considered to be at risk. In the Peruvian Amazon, focal 
screening and treatment (FSAT), has recently been introduced by the National Malaria 
Control Program (NMCP) to target malaria hotspots and further decrease the malaria 
burden. Malaria hotspots are well-delimited villages in rural areas or neighborhoods in 
periurban areas in which the cumulative malaria incidence over the past 3–5 years is the 
highest. These hotspots represent ~10-20% of the total malaria reporting-localities and 
account for more than 80% of the total cases in the Region. The intervention consists of 
systematic finger prick blood sampling of the whole population (100–1000 inhabitants) 
during the period of highest incidence (usually between February and May) and the 
treatment of all microscopically positive infections, irrespective of the presence of 
symptoms [92]. Following the national treatment guidelines, P. falciparum infections are 
treated with an ACT -mefloquine and artesunate (MQ-AS)-, and P. vivax infections with 
chloroquine (CQ) and primaquine (PQ) [92]. However, due to the lack of evidence-based 
guidelines [46,151], the criteria and procedures to implement FSAT interventions in the 
Amazon Region have often been arbitrarily decided and are subject to annual variations 
in logistical and financial resources. 
Mathematical models of various levels of complexity have been used for understanding 
malaria transmission dynamics and informing decision-making in malaria control and 
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elimination efforts [25,165-167]. Here, we used a model to assess the long term impact 
of FSAT on the P. falciparum malaria transmission intensity (MTI) in a low endemic area 
of the Peruvian Amazon Region. Retrospective data from a cohort study in a rural 
community of the Peruvian Amazon were used to estimate infection rates and a time-
variant seasonal vector parameter, and then to evaluate the model. Other malaria-
transmission parameters were obtained from previously published studies in the Amazon 
region. Eventually, the model was used to predict the potential reduction in malaria 
transmission following the addition of FSAT to the ongoing PCD, allowing for a 
simulation of the effect size according to the diagnostic tools used, as well as the timing 
and frequency of FSAT interventions. 
5.3. Methods 
Baseline model 
An extension of the Anderson-and-May’s malaria transmission model [67] and the 
corresponding differential equations was used to simulate a scenario where seasonal 
malaria transmission remains at similar levels each year within a restricted human 
population with ongoing PCD and treatment of symptomatic P. falciparum infections 
(Figure 5.1 and Annex-Chapter 9: Figure S5.1). The deterministic model allows the 
human population (N) to move between four different states (compartments), and the 
mosquito population (M) between three states. Individuals initially start in a susceptible 
state (S) and become infected at a rate that is determined by the mosquito density (m), the 
human feeding rate per mosquito (a), the infectiousness of the mosquito population 
(V/M), and the susceptibility of an individual after being bitten by an infectious mosquito 
(b). Individuals progress to the latent state (E), from which they develop gametocytes in 
the blood and become infectious after a latent period (l). Two consecutive sub-states are 
distinguished in infected latent individuals (E1 and E2) thus dividing the latent period into 
two time intervals: between sporozoite inoculation and development of detectable asexual 
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stage parasites in blood (l1), and between asexual parasite infection and development of 
gametocytes (l2). Then, the number of individuals who move from E1 to E2 at time t is 
equal to the number of individuals who entered E1 at time t-l1 adjusted by the factor e-l1*h, 
which incorporates the human mortality rate (h) and the average time interval for 
developing asexual blood parasites (l1). On the other hand, infected individuals leave sub-
state E2 at a rate (1/l2) which is the reciprocal of average duration of the 
gametocytogenesis process. 
 
Figure 5. 1.  Schematic diagram of the human and vector model states. The human population 
(N) is divided into 4 compartments: susceptible (S), infected latent (E), infectious treated (T) and infectious 
untreated (Ι) individuals. The latent period has 2 sub-states: latent which have not yet developed asexual blood-
stage parasites (E1) and latent with asexual blood-stage parasites (E2). Before becoming recovered, individuals 
in I compartment need to pass through 2 sub-states: those who have not yet (Ι1) and those who have 
spontaneously cleared the asexual blood stage parasites (Ι2). The mosquito population (M) is divided into 3 
compartments: uninfected (U), infected latent (L) and infectious (V) mosquitoes. The addition of FSAT to 
PCD allows for the detection and treatment of individuals in E2, I1 and I2 compartments.
 
While a constant fraction (y) of symptomatic infections of all newly infected individuals 
is routinely detected by PCD and treated with an ACT of known effectiveness (ε) within 
the treated state (T), the remaining fraction (1-y*ε), including asymptomatic individuals 
and previously treated individuals with parasitological treatment failure, remains 
infectious in an untreated state (I) until the “spontaneous cure” of the disease (i.e. 
clearance of all parasite forms) unless they are actively detected and treated. Once 
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recovering from compartments T and I, individuals return to the susceptible state (S). 
While recovery rate for treated individuals (1/r1) is the reciprocal of average human 
infectious period (i.e. length of time gametocytes remain in the bloodstream) with 
effective treatment, recovery for untreated individuals requires they pass through two sub-
states before becoming recovered: those who have not yet (I1) and those who have 
spontaneously cleared the asexual blood stage parasites (I2). Then, the rate of movement 
of individuals from I1 to I2 (1/r2a), and from I2 to S (1/r2b) are the reciprocal of the average 
time for the spontaneous clearance of asexual parasites from blood (r2a), and the 
remaining average infectious period after the clearance of blood asexual parasites (r2b), 
respectively in untreated individuals. 
Regarding the mosquito population (M), the model includes an initial susceptible state 
(U) for all mosquitoes, becoming infected at a rate determined by the following three 
parameters: human feeding rate per mosquito (a), fraction of infectious individuals in the 
human population ((T + I)/N), and the mosquito susceptibility to infection after biting an 
infectious individual (c). Infected mosquitoes remain in a latent state (L) for a specific 
time period before developing sporozoites and becoming infectious (V). The estimation 
of surviving mosquitoes by the end of the latent period requires an adjustment by the 
factor e-g*n which incorporates a constant mosquito mortality rate (g) and the average 
mosquito latent period (n). The model assumes that mosquitoes remain infectious until 
they die. 
The main assumptions of this model are the following: i) human and mosquito 
populations remain constant (number of births and deaths are equal at any time); ii) 
malaria-attributable deaths are not explicitly incorporated (malaria mortality rate is 
similar to general mortality rate); iii) no individual differences in transmission parameters 
between subjects; iv) super-infections do not occur [168]; v) all infected individuals 
develop mature gametocytes immediately after they leave the latent sub-state E2; vi) any 
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gametocytemia represents potential for transmission; and vii) there is no prophylactic 
effect of the drugs post recovery. 
Retrospective data on malaria cohort study 
The model was fine-tuned by using retrospective data from a cohort study carried out 
between 2003 and 2008 in four rural communities of San Juan district, south of Iquitos 
city in the Peruvian Amazon [96,168,169]. Malaria transmission in this area typically 
starts in January and finishes in July with a peak of clinical malaria cases between 
February and March; P. vivax and P. falciparum infections occurring at a ratio 4:1. 
Previous reports from this area indicated that more than two thirds of P. falciparum 
infections were asymptomatic with low parasite density [94,96]. Anopheles darlingi is 
the major malaria vector with a strong anthropophilic behavior [97,170]. The initial cross-
sectional survey conducted in April 2003 among cohort participants showed that most of 
them reported sleeping under bed nets, although none of them mentioned the use of 
insecticide treated nets or repellents in their homes [96]. From 2004 to 2008, biannual 
community screening campaigns were carried out (beginning-end of each malaria 
season), and in between, weekly ACD for P. falciparum infections was conducted, 
sampling each month a new group of individuals living within a 100-m radius of houses 
where at least one P. falciparum infection was detected during the previous month (index 
houses), either through the surveys, ACD or the routine PCD at health facilities [96]. 
Since high coverage during screening campaigns was achieved only in Ninarumi 
community, local model parameters were estimated from this community only, and taking 
into account malariometric indices from the year 2004 only, which was the first full year 
of ACD in the cohort study. The prevalence of P. falciparum infections by microscopy in 
Ninarumi was measured at 6.5% and 1.1%, respectively in January and August 2004 
(Annex, Chapter 9: Table S5.1); and during that year a total of 139 new P. falciparum 
infections were detected (0.28 infections/person/year), 91 (65.4%) of them being 
symptomatic either at the time of sampling or during the following week. Of the 
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additional 48 infections which remained asymptomatic during the follow-up, 19 were 
confirmed only by retrospective PCR analysis on blood samples collected on filter paper 
from individuals during weekly ACDs. The detailed procedures for the PCR analysis are 
described elsewhere [169]. All individuals enrolled in the cohort study gave signed 
informed consent or assent. Ethical clearance was received from New York University 
(NYU Institutional Review Board [IRB] approval no. 08–982), the University of 
Alabama at Birmingham, and the Peruvian Ministry of Health and National Institutes of 
Health Internal Ethical Review Boards [169]. 
Transmission parameter values 
Considering days as the time unit, the model parameterization was done in several steps, 
i.e. using first the available cohort data for the estimation of important local parameters, 
and in a second step, using published data to improve the first step estimates or to set 
values for the remaining transmission parameters. A systematic literature search was 
undertaken in different databases (i.e. PubMed, EMBASE and SciELO) prioritizing 
published studies on malaria in the Amazon Region in English and Spanish language, 
especially those from the Iquitos area when available. Additional searches were 
conducted in Google and through reference tracking. Third, when parameters could not 
be identified in previous steps, they were estimated by fitting the model to the observed 
clinical malaria incidence in Ninarumi. Table 5.1 summarizes key parameter values used 
in the baseline model (see Annex, Chapter 9: Text S5.1 for a detailed description). 
FSAT model and assessment of interventions 
In the scenario with FSAT interventions, the baseline model was improved by allowing 
movements from sub-states E2, I1 and I2 to the treated state (T) (red dotted lines in Figure 
5.1), at specific rates that are determined by the coverage (∆), the reciprocal of duration 
of the intervention (1/v), the sensitivity of the diagnostic test used for malaria screening 
(s), and the effectiveness of treatment in confirmed infections (ε). 
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Table 5.1 Model parameters 
Parameters                                                                                   
Symbol                                                                                         
   Value Source
Baseline model parameters 
 Mosquito density (ratio female mosquitoes/humans) m 75 Estimation from fitting cohort data; 
values within published range. 
 Human feeding rate, bites per mosquito per day a 0.035 - 0.32
Mean: 0.088 
Monthly estimations from fitting 
cohort data; values within 
published range 
 Susceptibility of an individual to infection after being 
bitten by an infectious mosquito 
b 0.05 Estimation using cohort and 
published data 
 Mosquito susceptibility to infection after biting an 
infectious individual 
c 0.41 Published data
 Duration of human latent period for Pf* in days (Ɩ = Ɩ1+ 
Ɩ2) 
Ɩ 21 Published data
 Duration from sporozoite inoculation to development of 
blood asexual parasites in days 
Ɩ1 11 Published data
 Duration from asexual blood stage infection to 
development of gametocytes in days 
Ɩ2 10 Published data
 Duration of mosquito latent period in days n 11 Published data
 Daily human mortality rate h 0.00005 Published data
 Daily mosquito mortality rate g 0.16 Published data
 Fraction of symptomatic infections y 0.65 Cohort data
 Treatment effectiveness ε 0.98 Published data
 Duration of infectious period in treated humans with 
ACT (in days) 
r1 14 Published data
 Duration of infectious period in untreated humans in 
days  
(r2 = r2a + r2b) 
r2 200 Published data
 Duration of presence of blood asexual parasites in 
untreated humans in days 
r2a 80 Published data
 Duration of infectious period in untreated humans after 
clearance of blood asexual parasites in days 
r2b 120 Published data
FSAT parameters 
 Coverage of FSAT Δ 1 Assumption
 Duration of FSAT in days v 1 Assumption
 Sensitivity of microscopy for detecting Pf* asexual 
stages 
s1a 0.5 Published data
 Sensitivity of microscopy for detecting Pf*gametocytes s1g 0.1 Published data
 Sensitivity of highly sensitive diagnostic tests for 
detecting asexual stages 
s2a 0.95 Assumption
 Sensitivity of highly sensitive diagnostic tests for 
detecting gametocytes 
s2g 0.8 Assumption
       *Pf = P. falciparum 
After setting initial conditions for human and mosquito compartments based on the 
average observed prevalence in the 2004 Ninarumi surveys and the reported A. darlingi 
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sporozoite rates in the area [97], the baseline model was run until reaching steady levels 
(baseline scenario), indicated by the stable cumulative number of P. falciparum infections 
recorded for 20 more simulated years. Then, the model was run for an additional year 
(year 0) after which interventions based on FSAT (intervention scenario) were added to 
the routine PCD (baseline scenario). A first intervention scenario was modeled with the 
following assumptions: one FSAT during the peak of the high transmission season (only 
in February of year 1); FSAT covers 100% of population (∆ = 1) in one day (v = 1); 
microscopy used in FSAT allows for the detection of 50% of asexual blood-stage 
infections by P. falciparum (sub-states E2 and I1), and 10% of infections with only sexual 
stages (gametocytes) in blood (sub-state I2) [52]; and all detected P. falciparum infections 
are treated with a 98% effectiveness (ε = 0.98). 
Additional intervention scenarios were modeled to assess the impact of different 
operational criteria for FSAT implemented during only one year (i.e. timing, number and 
time intervals between consecutive interventions) on the predicted cumulative incidence 
and prevalence of P. falciparum infections. Besides microscopy, a field PCR was also 
considered as diagnostic test during malaria screening, assuming sensitivities of 95%, 
95% and 80% for detecting infections in sub-states E2, I1, and I2, respectively. The 
predicted cumulative incidence (i.e. cumulative number of new symptomatic and 
asymptomatic infections) was recorded over one-year and five-year periods from the start 
of the first FSAT in each intervention scenario, and was compared with the cumulative 
incidence found with the baseline PCD scenario. The predicted impact of each 
intervention was determined as the percentage difference between the cumulative number 
of new P. falciparum infections with baseline and with the respective intervention 
scenarios (cumulative number of infections averted). In addition, minimum and 
maximum predicted prevalence were determined during both the first and the fifth year 
after the onset of FSAT interventions. Finally, operational criteria for implementing 
FSAT interventions during only one year which had the strongest impact were used again 
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to assess the effect of the same interventions if implemented during several consecutive 
years. 
Malaria transmission scenarios were simulated in R software version 2.15.3 (function 
“dede” in deSolve package) allowing to solve delay differential equations to take into 
account latent periods for infected individuals and mosquitoes before being infectious 
(see R code for baseline model in Annex, Chapter 9: Text S5.2) [171]. Baseline model 
performance was examined by comparing predicted and observed P. falciparum 
incidence and prevalence from the cohort study. A Wilcoxon matched-pairs signed-ranks 
test was used to test differences between observed and predicted monthly incidence, with 
p < 0.05 indicating statistical significance. Different initial values for the A. darlingi 
sporozoite rate (V/M) were tested and did not affect the results. Moreover, a one-at-a-
time sensitivity analysis was conducted to determine the effect of the following 
parameters on the baseline model predictions [172]: the mosquito density (m), the human 
feeding rate (a), the fraction of symptomatic infections (y), and the treatment 
effectiveness (ε). Changes (increase and decrease) of 20% in parameter values were 
considered in the analysis. Finally, only human parameters (y, ε) were used later to assess 
their impact on the predictions of the intervention scenarios with FSAT. 
5.4. Results 
Baseline model predictions largely reflected P. falciparum incidence in Ninarumi in 2004 
(Figure 5.2A), with no statistically significant difference between observed and predicted 
monthly incidence of symptomatic P. falciparum infections. While Ninarumi reported 91 
symptomatic and 38 asymptomatic P. falciparum infections (total = 139 infections) in 
2004, the baseline model predicted 99 symptomatic and 43 asymptomatic infections (total 
= 152 infections). Furthermore, predicted prevalence curves accurately reflected the 
seasonal dynamics of malaria infections (figure 5.2B), with high transmission season 
(HTS) between January and July, and low transmission season (LTS) between August 
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and December. According to the baseline model predictions, the maximum overall and 
microscopically determined prevalence during HTS were 12.3% and 6.2%, respectively; 
while the corresponding minimum values during LTS were 3.4% and 0.7%, respectively. 
Therefore, predicted and observed prevalence by microscopy also correlated well in 
Ninarumi in 2004. Furthermore, the proportion of detected infections by microscopy 
among the total predicted infections was significantly higher in the peak of HTS (~50%) 
than in LTS (~10-20%). Similarly, the proportion of asymptomatic infections among the 
total predicted infections varied according to the season, from a minimum of 58% during 
the peak of HTS to a maximum of 96% in the middle of LTS. 
 Figure 5.2. Comparison between observed and baseline model-predicted P. falciparum 
malariometric measures in Ninarumi village. Curves with data from Ninarumi in 2004 were 
repeated for three consecutive years: A) observed and predicted P. falciparum monthly new P. 
falciparum infections (monthly incidence); B) observed and predicted P. falciparum prevalence. 
 
The sensitivity analysis for the baseline model (Figure 5.3) showed that with values above 
0.7 for the fraction of symptomatic infections (y), malaria transmission decreased 
progressively until almost undetectable levels. In addition, seasonal malaria transmission 
persisted only when mosquito density (m) and mean expected number of bites on humans 
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per mosquito (a) are higher than 67 and 0.080, respectively. Increasing monthly values 
of human feeding rate (a) by 20% had by far the strongest effect on the annual incidence, 
with more than three times the baseline number of P. falciparum infections (~225% more 
infections) (Figure 5.3A). On the other hand, a decrease from 0.65 to 0.5 in the fraction 
of symptomatic infections (y) had the highest impact on the predicted incidence of 
asymptomatic infections (increase of baseline incidence by ~250%) (Figure 5.3B). 
Moreover, the same changes in both parameters (i.e. human feeding rate and fraction of 
symptomatic infections) had similar effects on the predicted prevalence, almost 
triplicating the maximum and minimum prevalence in HTS and LTS, respectively 
(Figures 5.3C and 5.3D). Furthermore, a reduction of the treatment effectiveness from 
0.98 (baseline value) to 0.80 would increase the incidence and prevalence by more than 
100% and 150%, respectively. 
 
Figure 5.3. Sensitivity analysis for the baseline model. Changes in: A) annual overall incidence 
(baseline model prediction: 152 infections); B) annual asymptomatic incidence (baseline: 53 
infections); C) maximum prevalence during the year (baseline: 12.3%); D) minimum prevalence 
during the year (baseline: 3.5%). Results are expressed in percentage of change (%) in comparison 
with baseline model predictions. 
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Table 5.2. One and five-year predicted cumulative number of P. falciparum infections averted 
after the addition of FSAT interventions to PCD at different timing, using either microscopy 
or assumed PCR 
   Microscopy PCR 
   One year 5 years One year 5 years 
   n % n % n % n % 
One FSAT    
 Month of 
implementation 
January 11 6.9 41 5.4 36 23.8 145 19.0 
 February 6 3.8 34 4.5 15 10.0 84 11.0 
 March 23 15.1 98 12.8 45 29.7 200 26.3 
 April 26 16.9 104 13.6 53 34.7 224 29.4 
 May 23 15.3 95 12.4 50 32.6 213 28.0 
 June 26 16.9 101 13.2 56 36.5 232 30.5 
 July 29 18.7 108 14.2 64 41.8 260 34.1 
 August 31 20.4 113 14.9 74 48.3 292 38.4 
 September 28 18.7 102 13.5 73 48.2 290 38.2 
 October 26 17.0 93 12.2 73 47.9 287 37.7 
 November 23 15.4 84 11.0 72 47.1 281 37.0 
 December 20 13.2 72 9.5 66 43.4 257 33.8 
Two consecutive FSAT   
 Time interval 
between FSAT 
7 days 53 34.8 202 26.5 110 72.3 487 63.9 
 15 days 53 34.5 201 26.3 110 72.6 489 64.3 
 30 days 52 34.0 198 26.0 111 73.0 494 64.9 
 60 days 50 33.0 192 25.2 111 73.0 497 65.3 
 90 days 48 31.8 186 24.4 110 72.4 493 64.8 
 120 days 46 30.2 176 23.1 107 70.3 477 62.6 
 150 days 39 25.3 148 19.5 91 60.0 396 52.0 
 180 days 35 22.7 145 19.1 80 52.4 356 46.7 
Three consecutive FSAT   
 Time interval 
between FSAT 
7 days 68 45.0 271 35.7 127 83.7 598 78.5 
 15 days 68 44.5 269 35.3 129 84.5 608 79.8 
 30 days 66 43.5 263 34.6 130 85.1 617 81.1 
 60 days 62 40.6 246 32.3 128 83.9 609 80.0 
 90 days 51 33.8 217 28.5 113 74.5 535 70.3 
 
Table 5.2 shows the predicted impact on the P. falciparum incidence after the addition of 
different FSAT interventions according to timing and number of interventions. 
Conducting one FSAT intervention with microscopy alone between July and September 
during only one year would have a larger impact on the P. falciparum incidence than 
conducting it during any other month, with a reduction of about 20% and 15%, 
respectively at 1- and 5 years post intervention. However, the magnitude of this effect 
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would be twice as high if PCR is used instead of microscopy, reaching reductions of more 
than 40% and 30% respectively at 1- and 5 years after intervention. Similarly, the impact 
on P. falciparum prevalence was the highest when FSAT was added in LTS (August), 
instead of in HTS (February) during only one year (Figure 5.4A), with a significant 
reduction in the maximum prevalence reached during the next HTS (p<0.05), i.e. from 
12.3% (baseline prevalence) to 9.6% (using microscopy) or to 6.0% (if PCR is used). 
The strongest decrease in P. falciparum malaria incidence for interventions implemented 
during only one year was observed with three consecutive FSAT starting at the beginning 
of LTS and separated by time intervals of 7 to 60 days (Table 5.2), resulting in reductions 
of more than 40% and 30%, respectively after 1 and 5 years when using microscopy, and 
of more than 80% and 75%, respectively when using PCR. The impact of the number of 
consecutive FSAT at the start of LTS (one to three FSAT during only one year, separated 
by intervals of 30 days) on the predicted P. falciparum prevalence is shown in the Figure 
5.4B. While three consecutive FSATs using PCR would have the largest effect on the 
predicted prevalence, one FSAT alone using PCR would result in a similar reduction 
compared to three consecutive FSATs using microscopy. In all simulations including 
PCR, annual P. falciparum incidence and prevalence would return slowly to the initial 
levels after 10 years, if FSAT interventions are implemented only during one year. 
Figure 5.4C shows a progressive reduction of the predicted prevalence with annually 
repeated FSAT interventions starting at the beginning of LTS every year. All repeated 
interventions would reach the near-zero prevalence, however the rate of decrease largely 
depends on the number of monthly FSAT per year and the diagnosis test used for malaria 
detection. Indeed, while three-monthly FSATs using microscopy would require 
approximately 10 years to reach the zero level prevalence; this could be reached with 
three monthly FSATs using PCR for four consecutive years.  
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Figure 5.4. Model-predicted P. falciparum prevalence curves after the addition of different FSAT interventions to the baseline PCD. A) one 
FSAT at beginning of LTS only in year 0 (Y0) and in HTS only in year 1 (Y1), using microscopy or PCR; B) one to three successive FSAT starting at 
beginning of LTS only in Y0, with microscopy or PCR; C) one to three successive FSAT starting at beginning of LTS for consecutive ten years (from 
Y0 to Y10), with microscopy or PCR. 
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However, a decrease in the fraction of symptomatic infections from 0.65 to 0.5, or a 
decrease in the treatment effectiveness from 0.98 to 0.8, would substantially reduce the 
rate of progression to the elimination levels with FSATs using microscopy (Figure 5.5A), 
and consequently increase the time required to reach the elimination levels to more than 
20 years. Furthermore, if a reduction of FSAT coverage from 100% to 80% is added to 
those scenarios, P. falciparum prevalence would start to increase again despite of the 
FSAT interventions. Conversely, if annually repeated FSAT interventions are 
implemented using PCR, the effects of similar changes (i.e. decrease in the fraction of 
symptomatic infections, in the treatment effectiveness, or in the FSAT coverage) on the 
P. falciparum prevalence would be smaller, hence delaying the time to reach zero 
prevalence levels only by one or two years (6 or 7 years after onset of interventions) 
(Figure 5.5B). 
 
 
Figure 5.5 Long-term impact of changes in the fraction of symptomatic infections and the 
treatment effectiveness on the maximum predicted P. falciparum prevalence after the onset of 
annual FSAT interventions (three successive FSAT at beginning of LTS): A) FSAT interventions 
using microscopy for malaria screening; B) FSAT interventions using PCR for malaria screening. 
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5.5. Discussion 
Using a relatively straightforward mathematical model, our analysis showed that 
targeting the asymptomatic parasite reservoir with FSAT interventions, in addition to 
routine PCD, would significantly reduce P. falciparum malaria in low transmission areas 
of the Peruvian Amazon. The strongest reduction was observed if three consecutive FSAT 
were implemented annually at the beginning of low transmission season, and if malaria 
diagnosis was done with a highly sensitive field PCR. 
Modelling the effects of interventions that target the asymptomatic malaria reservoir 
requires a good knowledge of the burden of asymptomatic infections and their 
transmission dynamics. Cross-sectional surveys in the Peruvian Amazon reported that 
more than two thirds of malaria infections were asymptomatic [94,96]; however these 
studies did not take into account the incubation period for some of them, hence the 
potential development of symptoms at a later stage [111]. Therefore data from the cohort 
study conducting in peri-Iquitos communities including weekly monitoring of symptoms 
for one month of all infected individuals, enabled to overcome the limitations of previous 
survey results. Indeed, an important proportion of P. falciparum infections which were 
asymptomatic at the time of detection (either by microscopy or by retrospective PCR) 
developed malaria symptoms (reported and/or measured fever) after one week of follow-
up [96], resulting in only 35% of asymptomatic infections among all confirmed cases in 
the Ninarumi community in 2004. Another study conducted in the Brazilian Amazon in 
2004–2005 found similar results after combining PCD and ACD over a 14-month period, 
i.e. a total of 326 malaria infections were identified of which 96 (29.4%) were 
asymptomatic– a much lower proportion than reported in any of the cross-sectional 
surveys carried out during the same period [173]. 
The cohort study also allowed for an accurate measurement of seasonal variations in the 
incidence of symptomatic and asymptomatic P. falciparum infections in the area, and 
these seasonal dynamics were well reproduced by the baseline model. In addition, the 
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model predicted not only a 2–3 times higher prevalence of infections during the peak of 
HTS than during the LTS, but also temporal differences in the proportion of 
asymptomatic infections, which accounted for about 60% of all prevalent infections 
during the peak of HTS while they represented almost all infections in the middle of LTS. 
Moreover, the proportion of prevalent infections detectable by microscopy (“patent 
infections”) varied also with season, i.e. from almost 50% (6.2% of a total prevalence of 
12.3%) in the HTS to 20% (0.7% of a total prevalence of 3.4%) in the LTS. Those 
predictions suggest that in areas of low and seasonal transmission such as the Peruvian 
Amazon, non-detectable asymptomatic P. falciparum infections are able to persist during 
the LTS being potentially infectious to mosquitoes emerging after the start of the rains, 
as previously described in other areas with markedly seasonal transmission [174,175]. 
Since symptomatic P. falciparum infections are more likely to be identified and treated 
during PCD, and the duration of treated infections is considerably shorter than untreated 
infections; it is anticipated that potential changes in the fraction of symptomatic infections 
as well as in the effectiveness of case management, may significantly impact the malaria 
prevalence as shown by the sensitivity analysis. Indeed, simulations showed that a 
decrease in the fraction of symptomatic infections from 0.65 to 0.5 or a decrease in the 
treatment effectiveness from 0.98 to 0.8 resulted in similar effects as changes in 
entomological parameters (ratio female mosquitoes to humans from 75 to 90, human 
feeding rate by 20%) which are known as being important determinants for the vectorial 
capacity and the malaria transmission [176]. Asymptomatic infections are becoming 
increasingly common at low transmission levels [54,94,96,98,111,151,157-161], 
enlarging the human infectious reservoir which will enable onward transmission. On the 
other hand, treatment effectiveness can decrease due to the spread of drug-resistant strains 
of P. falciparum parasites and the lack of systems that assure the quality of both the 
antimalarial drugs and the case management procedures (e.g. poor prescribing practices 
by health workers, low patient adherence rates to treatment regimens) [46,177].  
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In contrast to the current strategy of the National Malaria Control Program consisting of 
adding FSAT with microscopy to PCD during HTS in prioritized localities of the Peruvian 
Amazon [92], our simulations showed that conducting a single FSAT at the beginning of 
LTS would not only result in a greater reduction in P. falciparum incidence and 
prevalence in the short term, but also decrease the progression rates of these indicators to 
the initial levels. Furthermore, the effect of FSAT would be maximal if three successive 
FSAT at time intervals of 7–60 days, would be implemented at the start of the LTS. Kern 
et al. found a similar impact on the P. falciparum transmission with a single FSAT with 
microscopy during the dry season using a seasonally-forced malaria model which 
incorporated periodically mosquito birth rates through a sinusoidal function and different 
levels of infectiousness for gametocyte carriers; however, while in areas of simulated low 
disease burden (entomological inoculation rates (EIR) < 10 infective bites/person/year) 
such as the Peruvian Amazon, the effect was sustained for over three years after the 
intervention, in areas of high endemicity (EIR > 200) the incidence rates of infection 
returned to their initial level in the subsequent year [178]. Moreover, the study also 
indicated that three FSAT scheduled at monthly intervals starting in the dry season had 
the greatest positive impact on transmission. Successive FSATs would not only allow for 
identifying infected individuals who were in a latent state at the time of the previous 
FSAT, but also would increase the coverage of the intervention in real-life situations by 
including individuals who were absent or not eligible (illness, pregnancy) during the 
previous FSAT. The relatively wide time interval (i.e. 7–60 days) for a subsequent 
intervention suggested by our model would facilitate the planning and logistics of mobile 
teams in charge of FSAT in the targeted communities. 
Beside timing and frequency of a given intervention, the other important determinant of 
impact is the duration (number of years) the intervention needs to be applied to reach 
sustainable elimination levels. Our model suggested that three successive FSAT with 
microscopy for ten consecutive years, would result in a sustained declining P. falciparum 
prevalence and incidence and eventually reach elimination levels. Long-term effects of 
Modelling the potential impact of FSAT for P. falciparum in the Amazon 
 
111 
 
FSAT has been previously described by Griffin et al. using a complex modelling 
approach (including immunity, super-infections, and heterogeneity in transmission 
intensity) fed with published transmission parameters and local epidemiological data of 
different endemic areas of Africa [179]. The results showed that in low-to-moderate 
transmission settings, 80% coverage of annual single round of FSAT using rapid 
diagnostic tests (RDTs) over 15 years, together with 80% coverage of insecticide treated 
nets (ITNs), would reduce the absolute parasite prevalence by 5–12%. On the other hand, 
in high transmission areas, the simulated impact of FSAT alone was marginal, the 
ultimate outcomes strongly depending on the initial transmission level, the frequency and 
duration of the intervention and the coverage of vector control (i.e. either ITN or indoor 
residual spraying) [179]. 
As a consequence of increased use of molecular tests for detecting submicroscopic 
malaria infections in both low and high-malaria transmission settings, as well as of recent 
studies reporting failures of FSAT to reduce transmission when using microscopy or 
RDTs [180], it has been suggested that PCR based strategies need to be deployed if such 
interventions are to be successful [181,182]. Our model simulations assessed the impact 
of FSAT interventions using an assumed field PCR with high sensitivity, under the 
assumption that any level of gametocyte density was potentially infectious [183]. 
Repeated FSAT interventions with PCR for several consecutive years would not only 
have a stronger impact on P. falciparum malaria transmission (halving time to reach 
elimination levels), but would also enable to sustain the impact despite eventual 
reductions in the proportion of symptomatic infections, treatment effectiveness and/or 
coverage of FSAT. Although these results support the importance of detecting and 
treating sub-microscopic infections at point of care for successful elimination strategies 
[46,184], implementing FSAT using PCR as routine strategy in prioritized localities of 
the Peruvian Amazon may not be feasible since current PCR tests are resource-intensive, 
time-consuming and expensive [113]. Recently, some studies have shown high sensitivity 
of non-conventional molecular tests based on loop-mediated isothermal amplification 
Modelling the potential impact of FSAT for P. falciparum in the Amazon 
 
112 
 
(LAMP) with no requirement for specialist staff and expensive equipment [185]; these 
molecular tests need to be optimized quickly to be used in the field for species-specific 
identification of Plasmodium parasites. 
Like with other mathematical models for malaria transmission, our predictions should be 
interpreted taking into account the underlying assumptions. Some assumptions were 
intended to simplify the complex malaria dynamics (e.g. constant mosquito and human 
populations, no individual differences in transmission parameters between subjects, 
similar levels of infectiousness for gametocyte carriers), while others attempted to fill the 
knowledge gap in the P. falciparum malaria transmission cycle (e.g. the development of 
mature gametocytes in all infected individuals, potential for transmission of any 
infectious individual independently of its gametocyte density in blood). Further research 
is still needed to define to what extend asymptomatic and submicroscopic malaria 
infections contribute to the infectious reservoir [186]; this information would 
considerably improve our model. Moreover, since model predictions may vary widely 
under the influence of uncertainties in many transmission parameters, a global sensitivity 
analysis may be required to accurately identify the parameters that have the biggest 
impact on the expected P. falciparum prevalence and incidence. In addition, after the 
development of a more complex model for P. vivax transmission using data of a recent 
cohort carried in the Peruvian Amazon [161], it will help to further fine-tune the model 
and define operational criteria for FSAT interventions to maximize the impact of the 
intervention on both species. 
5.6. Conclusions 
Our model suggested that FSAT combined to PCD enables to reach elimination levels in 
an area of low transmission of the Amazon Region, but the progression rates to those 
levels vary substantially according to the operational criteria used for the intervention 
(i.e., timing, number, coverage, and duration of FSAT) and the sensitivity of the 
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diagnostic test used for malaria screening. Despite its limitations, the modelling approach 
can contribute to design new field studies in the Peruvian Amazon to assess the 
effectiveness of FSAT and other strategies to further decrease malaria transmission. Even 
before easy-to-use molecular tests will be available at the point of care, as well as reliable 
evidence of the effectiveness of FSAT, the current strategy applied by the NMCP in Peru 
should be revised in the light of our results in order to be more cost effective. 
Programmatic FSAT interventions with microscopy (minimum of two successive FSAT) 
can be conducted at the beginning of the LTS in areas with known high risk of P. 
falciparum malaria transmission, trying to reach the maximum population coverage 
(avoiding areas with highly mobile populations). Alternatively to reach the areas of 
mobile populations, resources could be invested to implement a “smart surveillance 
system” based on reactive case detection guided by information from the PCD. 
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6.1. Abstract 
 Background: As transmission becomes increasingly focal in low transmission settings, 
an accurate identification of malaria hotspots is crucial to better design and deliver targeted 
interventions. The study evaluated if malaria hotspots detected using reported malaria 
incidence and survey serological data were associated with the P. vivax malaria incidence 
in the subsequent year in a low endemic area of the Peruvian northern coast.  
Methods:  After a full census and geo-referencing of all reported P. vivax episodes 
between June 2009 and May 2010 (year 1), a parasitological and serological survey was 
conducted (June 2010). Antibodies for specific IgG responses to P. vivax merozoite 
surface protein-1-19 (PvMSP-119) and apical membrane antigen-1 (PvAMA-1) were 
detected by ELISA. After the survey, an enhanced passive case detection (PCD) between 
June 2010 and May 2011 (year 2) allowed the detection of new P. vivax episodes in the 
study area. Spatial analysis of P. vivax incidence rates in year 1 as well as of P. vivax 
seropositivity at the moment of the survey allowed the retrospective identification of 
hotspots. Logistic regression was used to evaluate the association between hotspots and 
malaria incidence in the subsequent year.  
Results:  P. vivax malaria incidence decreased markedly from year 1 (416 episodes) to 
year 2 (32 episodes). Despite this reduction, logistic regression found that household (HH) 
location in hotspots (identified using either incidence rates in year 1 or seropositivity) were 
significantly associated with the occurrence of P. vivax episodes at HH in year 2 
(p<0.001), and this association remained after the multivariate analysis adjusted for mean 
HH age, male HH proportion and HH distance to the drain.   
Conclusions: Study findings confirmed that the spatial analysis using serological markers 
allowed for the accurate prediction of hotspots P. vivax malaria confirmed with subsequent 
PCD. These tools may support the risk stratification and prioritization of targeted 
interventions to better reduce transmission and move towards malaria elimination.    
 
Keywords:  Malaria, transmission, hot-spot, serology, low transmission 
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6.2. Background 
Over the past century, the Americas have experienced a significant reduction in malaria 
cases and deaths, and countries such as Argentina, Belize, Costa Rica, Ecuador, El 
Salvador, Mexico, and Paraguay are close to eliminating malaria from their territories 
[28]. In Peru, the decline in malaria incidence over the past decade has modified the 
epidemiological profile of the country, mainly in the northwestern coast near the border 
with Ecuador where transmission is seasonal, only due to P. vivax and concentrated in a 
few localities [1,3,7].  
Implementing control measures in low endemic areas with seasonal malaria transmission 
and increasing focal distribution poses a major challenge to national malaria control 
programmes [9]. Single communities or groups of households within communities that 
are at a substantially increased risk of malaria transmission, called hotspots, need to be 
accurately identified to better target the remaining parasite reservoirs [9,10].  
The spatial analysis of cumulative symptomatic malaria infections detected by passive 
case detection is theoretically a good method for detecting hotspots [187,188] in areas 
where most malaria infections are symptomatic, detected by health facilities, and 
accurately traced for place of infection and/or residence. However, this is rarely the case 
in many low endemic areas of South America, where most infections remain 
asymptomatic [54,96,133,160]. Asexual parasite carriage detected using highly sensitive 
diagnosis tests as polymerase chain reaction (PCR) in cross-sectional surveys seems to 
be a more accurate indicator of transmission intensity [16,189], however its inability to 
catch seasonal variations and the low parasite carriage rates can make less clear the 
geographical stratification of the malaria risk.  
The spatial identification of hotspots using serological measures is increasingly proposed 
for quantifying micro-geographical variations in malaria transmission based on 
epidemiological studies mostly conducted in P. falciparum endemic areas. Antibody 
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responses to malaria specific antigens are acquired in response to cumulative exposure 
and can be used to define small-scale variations in malaria exposure [10,20]. Because 
antibody responses are relatively long-lived, serological markers of malaria exposure are 
likely to be most suitable for detecting stable hotspots of malaria transmission [9,10], and 
most sensitive in areas of low endemicity with and without seasonal transmission patterns 
[57,59,115].   
The present study aimed to evaluate the association between households (HHs) located 
in malaria hotspots - identified in June 2010 through spatial analysis using two different 
malariometric indicators (malaria incidence and seropositive rates)- and the reported P. 
vivax malaria incidence (between June 2010 and May 2011) in a low endemic area of the 
Peruvian northern coast.   
6.3. Methods 
Study area 
Located in Piura department on the northwestern Peruvian coast, Bellavista (lat 
4°53′24″S, 80°40′51″W) is one of the districts with the highest population density in the 
country with ~37,000 inhabitants living in an area of 3.09 km2. The main occupations are 
informal labourer, trader, moto-taxi driver and farmer [133]. In the district, warm and dry 
winters range from May to October, while hot and humid summers with moderate rains 
occur from December to April. The annual average temperature is around 24°C and the 
relative humidity above 70% [95].  
Malaria transmission is currently exclusively by P. vivax [133]; the peak of cases occurs 
between February and May, the months in which the density of the main vector, 
Anopheles albimanus, increases [103,104]. After the intense droughts between 2004 and 
2006 in the northern coast, Bellavista experienced a significant increase in the P. vivax 
malaria incidence reaching more than 1,500 annually reported cases in 2008 and 2009 
(more than 50% of total cases of the Piura) (Figure 6.1). However, since then, P. vivax 
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incidence have decreased with only 659 and 160 reported cases in 2010 and 2011, 
respectively.   
Two neighbourhoods were selected for the study based on their malaria endemicity and 
their proximity to an artificially created water drain situated at the eastern edge of the 
district, where water frequently accumulates after the rains thus providing favourable 
breeding habitats for Anopheles mosquitoes [103].   
 
Figure 6.1. Annual P. vivax malaria incidence in Piura department and Bellavista district 
 
Study design 
A three-phase study was conducted. The first phase included a full census of the study 
population and the geo-referencing of the HHs of all reported P. vivax episodes in the 
study area between June 2009 and May 2010.  The second phase involved a 
parasitological and serological survey intended to include all residents in the study area 
in June 2010.  And, the third phase consisted of the passive case detection (PCD) of new 
P. vivax episodes at health facilities between June 2010 and May 2011, and the geo-
referencing of the HHs of those episodes occurred in the study area.  
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Data collection 
A full census of the study population was conducted two weeks prior to the survey, 
collecting data on socio-demographics and malaria history data. Each HH was identified 
with a unique code number and geo-referenced using a handheld global positioning 
system (GPS) device (Garmin’s GPSMAP 60CSx, Garmin International Inc., USA). 
Presence/absence of malaria episodes in the 12 months prior the survey was confirmed in 
all censored individuals through the systematic revision of PCD records at the two nearby 
health facilities: Bellavista health post and Sullana Hospital. Moreover, a cross-checking 
of the census database (using names, age, gender and address) against the malaria 
surveillance database of the Sub-Regional Health Direction of Sullana (SRHDS) was 
performed to identify additional episodes registered in other health facilities. 
The cross-sectional survey was done in June 2010. Each HH was visited and all available 
individuals were enrolled after providing written informed consent/assent. Whenever 
selected individuals were absent, the household was revisited within the next two days to 
maximize subject participation. Each participant had the axillary temperature taken, 
malaria symptoms were recorded, and a finger-prick blood sample collected for 
immediate microscopy (thick and thin blood smears) and on filter paper (Whatman grade 
3, Whatman, Springfield Mill, USA) for later serological and molecular tests. Filter paper 
dried blood samples were individually stored at 4°C with desiccant until processed at 
Institute of Tropical Medicine Alexander von Humboldt, Lima (ITM-AvH). All 
individuals with a malaria infection detected by LM were treated according to the national 
guidelines. 
After the survey, PCD activities at Bellavista health post and at Sullana Hospital were 
enhanced by the training of microscopists and other local malaria program staff as well 
as by the availability of new equipment (microscopes) and an expert microscopist at 
reference laboratory of SRHDS for the quality control of microscopic diagnosis. New 
detected individuals with P. vivax episodes between June 2010 and May 2011 were 
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carefully investigated and traced for place residence. A weekly cross-checking of the 
census database against the malaria surveillance database of SRHDS was performed to 
identify additional episodes registered in other health facilities. All identified individuals 
with P. vivax episodes living in the study area were visited and geo-referenced.  
According to national guidelines, a malaria episode detected by PCD occurs in an 
individual with fever (body temperature >37.5°C) and/or history of fever in the previous 
two weeks in a malaria risk area and a thick blood smear positive for Plasmodium [92]. 
Immediately after P. vivax malaria is confirmed, individuals receive directly observed 
therapy with chloroquine (25 mg/kg over 3 days) and primaquine (3.5 mg/kg over 7 days). 
The easy access to malaria diagnostic testing in health facilities as well as the high 
awareness of malaria and appropriate treatment-seeking behaviour in the study population 
facilitate the detection of most of malaria episodes in the study area. 
Laboratory procedures 
Microscopy 
Thick and thin smears were stained for 10 min with a 10% Giemsa solution, and parasite 
density was computed after counting the number of asexual parasites for 200 white blood 
cells (WBC) in the thick smear and assuming a concentration of 6,000 WBCs/μl 
according to national guidelines [117]. Slides were read during the survey and then a day 
later by an expert microscopist at the reference laboratory in Iquitos. A slide was declared 
negative if no malaria parasite was found after examining 100 fields. Quality control was 
done blindly on all positive slides and 10% of randomly chosen negative slides by a senior 
technician at ITM-AvH. Any discordant results were reread by a second senior technician 
until agreement. 
Species-specific polymerase chain reaction (ss-PCR) 
Parasite DNA was extracted using the saponin lysis Chelex 100 method [118] and stored 
at 4°C for immediate use in PCR reactions or at -20°C for later use. All samples were first 
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analyzed by ssPCR following a protocol published elsewhere [119]. Briefly, this ssPCR 
consisted of a primary PCR with primers directed to specific Plasmodium sequences, and 
obtained amplicons were used for a second PCR using P. falciparum and P. vivax specific 
primers. 
Serology 
Antibodies for specific IgG responses to P. vivax merozoite surface protein-1(19-kDa C-
terminal region, PvMSP-119) [122] and apical membrane antigen-1 (PvAMA-1) [190] 
were detected using an ELISA protocol published elsewhere [120]. Briefly, dried blood 
filter paper samples (5mm diameter disc/sample) were eluted overnight at 4°C in 2 ml of 
PBS-Blotto-Tween. Two hundred microliters of the eluate were added in duplicate to 
blocked-ELISA plates coated separately with each antigen. Pooled sera from five P. vivax 
infected patients, and from five control individuals without recent (negative PCR) and 
past history of malaria infection were diluted at 1:400 in PBS-Blotto, as positive and 
negative control respectively. Goat anti-human IgG (H+L) specific peroxidase (Merck 
Millipore, USA) diluted to 1:20,000 in PBS-Tween was used as conjugate and incubated 
for 1 h before development of the ELISA using 200μl ABTS substrate-chromogen 
solution. Optical density (OD) values at 405 nm (Lector Multi-Modal Synergy H1, 
BioTek, USA), were corrected by subtracting the mean OD of the antigen negative control 
wells from the mean OD of the corresponding antigen containing wells. Analyses with 
duplicate OD values that differed by more than 1.5-fold were rejected and rerun. To 
ensure a standardization of the sample results across ELISA plates, the percent positivity 
(PP) of each specimen was calculated using the OD of the positive control serum as 100%. 
Quality control was done blindly at ITM-AvH on 5% of randomly chosen samples. The 
criterion for positivity for each antigen was determined applying a mixture model to the 
PP data which assumed two inherent Gaussian distributions: a narrow distribution or sero-
negatives, and a broader distribution of seropositives. Cut-off value was calculated as the 
mean plus 3 standard deviations of the narrow distribution [21]. Sero-positivity to P. vivax 
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was defined as an individual with a positive serology to any of the two antigens for P. 
vivax. 
Data analysis 
Spatial clusters analysis  
Data were double entered, validated and cleaned in Excel (Microsoft Corp, USA). 
QGIS™ software v.2.0 [139] was used to map all census HHs and to classify them 
according to their P. vivax incidence rate in the 12 months prior the survey and to their 
proportion of P. vivax seropositivity in the survey. The annual parasite incidence (API) 
rate at the household level was calculated by dividing the annual number of reported P. 
vivax episodes in a HH during in the 12 months prior the survey by the total number of 
HH individuals. Using the API, HHs were classified into four categories: 0 
episodes/individual, <0.25, 0.25-0.50, and >0.50. The proportion of seropositivity at the 
household level was calculated by dividing the number of individuals with seropositive 
to P. vivax by the total number of surveyed individuals in the household. Using the 
proportion of seropositivity, HHs were classified into four categories: 0 
seropositives/individual, <0.25, 0.25-0.50, and >0.50.  
SaTScan TM software v.9.3 (M Kulldorff and Information Management Services Inc, 
USA)[140] was used to detect clusters of significant high (hotspot) and low (coldspot) 
risk of P. vivax transmission in the study area using incidence (i.e. IPA) and serological 
(i.e. proportion of seropositivity) data at HH level.   The main analyses were done without 
adjustment for covariates. A secondary analysis was only performed for the serological 
data including the proportion of individuals>10 years at household as covariate 
considering the reported significant higher seroprevalence of this age group compared to 
younger children in a previous study in the area [133]. The following settings were used 
in the analysis: purely spatial analysis [141]; Poisson probability model; 
latitude/longitude coordinates; report of most likely clusters with no geographical overlap 
of secondary clusters; and maximum spatial cluster size equal to 50% of total population.  
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SaTScan applies multiple circular windows, which are plastic in both position and size, 
across the study area. Each circle represents a possible cluster of high or low P. vivax 
transmission. Clusters were assessed based on 999 Monte Carlo simulations to determine 
the probability of the observed number of episodes/seropositives being due to chance 
relative to the expected number of episodes/seropositives. The null hypothesis of no 
clustering was rejected if any resulting p-value of assessed clusters was <0.05. The 
relative risk (RR) reported for each identified cluster was the estimated risk within the 
cluster divided by the estimated risk outside the cluster [140]. 
Risk factor analysis 
The variable outcome was the presence/absence of P. vivax episodes at HH level between 
June 2010 and May 2011 (i.e. HH with/without episodes), while the independent variable 
was the location of the HH in clusters detected by SaTScan using P. vivax incidence or 
seropositivity (i.e. hotspots, coldspots, or none of them).  Only results of age-covariate 
spatial analysis were considered for clusters of seropositivity.  Uni- and multivariate 
(adjusted for mean HH age, male HH proportion, and HH distance to water drain) 
analyses were performed to determine the association between the independent variable 
and the variable outcome. All reported p-values are two-sided and were considered 
statistically significant if <0.05.  
Ethical issues 
Permission was received from health and local authorities after explaining the purpose 
and procedures of the study. Signed IC was obtained prior to participation and blood 
sampling by all adults and the parents of all participating children <18 years of age. In 
addition to their parent’s consent, children more than seven years old provided signed 
informed assent prior to participation. Ethical clearance was obtained from the Ethics 
Review Board of the Universidad Peruana Cayetano Heredia, Lima, Peru (SIDISI code: 
056736). 
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6.4. Results 
A total of 745 HHs and 3,521 individuals were identified during the census (~10% of the 
total population of Bellavista district) (Table 6.1). The overall sex ratio was 0.94, and the 
age distribution showed that half of the population was <20 years old. A total 1,925 
individuals (54.7%) living in 613 households (82.3%) were available and accepted to 
participate in the survey in June 2010. Despite very few P. vivax infections were 
confirmed by LM (4 individuals, 0.2%) and by PCR (16 individuals, 0.8%), one-fifth (418 
individuals, 21.7%) of surveyed population were seropositive to at least one of the 
selected P. vivax antigens and this P. vivax seropositivity was significantly associated 
with past history of malaria. Indeed, individuals who presented confirmed (registered) P. 
vivax malaria episodes in the previous year were more likely to have positive serology 
than those who did not (OR: 4.7, 95% CI [3.5–6.2], p<0.001).  Furthermore, 
individuals>10 years had higher odds of P. vivax seropositivity compared to children ≤10 
years (OR: 3.2, 95% CI [2.4–4.3], p<0.001).  
Table 6.1. Census and survey population 
  Census Survey n % n % 
 
Total households (HH) 745 100.0 613 82.3 
Total individuals 3521 100.0 1925 54.7 
Individuals with positive microscopy ▁ ▁ 4 0.2 
Individuals with positive PCR ▁ ▁ 16 0.8 
Seropositive individuals  ▁ ▁ 418 21.7 
 
Analysis of PCD records and surveillance databases for the period June 2009 - May 2010 
identified 416 registered P. vivax malaria episodes (37.1% of the total registered cases in 
Bellavista), which occurred in 370 individuals living in 272 HHs (36.5% of total censored 
HHs): 331 (89.5%) with unique episodes, 33 (8.9%) with two episodes, 5 (1.4%) with 
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three episodes, and one with four episodes. Between June 2010 and May 2011, the malaria 
incidence decreased markedly in all the district and PCD only detected 32 individuals 
with unique episodes of P. vivax malaria in the study area (28.1% of the total registered 
cases in Bellavista), which occurred in 29 HHs. Only 8 (25%) of these 32 individuals had 
also presented P. vivax episodes in the period June 2009 - May 2010. 
No significant spatial clusters of infections were identified by SaTScan, given the small 
number of PCR-positive individuals in the survey. However, the analysis confirmed that 
one-year P. vivax malaria incidence rates before the survey as well as P. vivax 
seropositivity measured at the time of the survey were not randomly spatial distributed, 
detecting hotspots and coldspots respectively in the southeast and the northwest of the 
study area (Figures 6.2 and 6.3).  The hotspot of malaria incidence was a 220 m radius 
cluster composed of 921 censored individuals in 214 HHs (RR=2.3, p<0.001), while the 
coldspot was a 180 m radius including 1305 individuals in 258 HHs (RR=0.3, p<0.001) 
(Table 6.2).    
Table 6.2. Characteristics of identified spatial clusters  
    Center  
coord   
(S,W) 
Radius 
(meters) 
Households 
(N=745) 
Population 
(N=3521) 
RR° p-
value 
  n % n % 
Clusters usingprevious 
year’s incidence rate  
        
 Coldspot 4.8827S, 
80.6727W 
180 258 34.6 1305 37.1 0.27 <0.001 
 Hotspot 4.8892S, 
80.6683W 
220 214 28.7 921 26.2 2.26 <0.001 
Clusters using 
seropositivity (survey) 
        
 Coldspot 4.8836S, 
80.6732W 
250 258 34.6 1331 37.8 0.53 <0.001 
 Hotspot 4.8893S, 
80.6683W 
65 56 7.5 235 6.7 2.13 0.017 
Clusters using 
seropositivity  adjusted 
for age* (survey) 
        
 Coldspot 4.8842S, 
80.6722W 
210 255 34.2 1356 38.5 0.57 0.001 
 Hotspot 4.8900S, 
80.6676W 
190 171 23.0 721 20.5 1.73 0.003 
* Analysis included the proportion of individuals aged>10 years as covariate; °RR=relative risk.
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Figure 6.2. Significant spatial clusters of P. vivax incidence reported 
between June 2009 and May 2010 in the study area. 
Figure 6.3. Significant spatial clusters of P. vivax seropositivity reported 
by the survey in June 2010 in the study area.
Ongoing work 
 
127 
     
On the other hand, the hotspot of malaria seropositivity was a small cluster of a 65 m 
radius composed of 235 censored individuals in 56 HHs (RR=2.1, p=0.017), and the 
coldspot was a 250 m radius including 1331 individuals in 258 HHs (RR=0.5, p<0.001). 
The addition of the proportion of individuals >10 years at HH as covariate in the analysis 
increased three times the hotspot radius (190 m) including 721 individuals in 171 HHs 
(RR = 1.7, p=0.003), while the coldspot slightly changed its radius (210 m) and its 
included sub-population: 1356 individuals in 255 HHs (RR=0.6, p=0.001) (Table 6.2). 
HH location in hotspots was significantly associated with the occurrence of P. vivax 
episodes at HH in the subsequent year (p<0.001), and this association remained after the 
multivariate analysis adjusted for mean HH age, male HH proportion and HH distance to 
the drain (Table 6.3). HHs included in the hotspot of malaria incidence were more likely 
to present P. vivax episodes in the subsequent year (AOR=4.3, 95% CI [1.1–17.2]) than 
HH included in coldspots.  Similarly, HHs located in the hotspot of seropositivity had 
higher odds of P. vivax incidence in the following year compared to those located in the 
coldspot (AOR: 5.6, 95% CI [1.3–24.7]). 
Table 6.3. Association between households (HHs) being identified in hotspots (using previous 
year’s incidence rates or seropositivity) and malaria incidence in the subsequent year.  
 
    
HHs with 1-year 
reported incidence 
(after the survey) 
Unadjusted 
  
Adjusted 
  
    n N % OR 95% CI AOR 95% CI 
                      
Model 1         
Clusters using 
previous year’s 
incidence rates  
Coldspot 5 258 1.9 1  1  
Other 9 273 3.3 1.7 [0.6, 5.2] 2.1 [0.6, 7.4] 
Hotspot 15 214 7 3.8* [1.4, 10.7] 4.3* [1.1, 17.2] 
Model 2         
Clusters using 
seropositivy  
adjusted for age 
(survey) 
Coldspot 5 255 2 1  1  
Other 10 319 3.1 1.6 [0.5, 4.8] 1.8 [0.6, 5.7] 
Hotspot 14 171 8.2 4.5* [1.6, 12.6] 5.6* [1.3, 24.7] 
                  
† Multivariate analysis adjusted by mean HH age, male HH proportion, and HH distance to the drain;  
* p<0.05. 
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6.5. Conclusions 
In the study area of the northern coast, the spatial cluster of highest P. vivax seropositivity 
(adjusted for age) at the time of the survey not only coincided roughly with the spatial 
cluster of P. vivax incidencerate in the past year, but also it was able to predict accurately 
areas (hotspots) with the highest clinical malaria incidence detected by PCD in the 
subsequent year. This serological approach, once optimized and tested by geographical 
area, would represent a reliable and effective surveillance tool in low transmission areas 
to detect hotspots of high malaria risk (i.e., areas with high risk of having symptomatic, 
asymptomatic patent, and symptomatic sub-patent infections) in malaria endemic areas 
of Peru. The stability of malaria hotspots over time should also be monitored and 
considered by decision-makers to better design and deliver appropriate targeted 
interventions (e.g. focal screening and treatment (FSAT) or mass drug administration 
(MDA)).  
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7. GENERAL DISCUSION 
 
The first part of this thesis included two cross-sectional surveys that combined 
parasitological (i.e., parasite rates by light microscopy –LM– and by PCR) and 
serological (seroprevalence and seroconversion rates –SCR) metrics to characterize 
malaria transmission dynamics in low endemic areas of the Pacific northern coast 
(Chapter 3) and the Amazon region (Chapter 4) in Peru. Besides the serological 
evidence for high heterogeneity in malaria exposure, both to Plasmodium falciparum and 
Plasmodium vivax, at micro-geographical level and over time, PCR results confirmed that 
most of malaria infections in the study areas were asymptomatic and sub-microscopic, 
and therefore unlikely to be detected by the routine surveillance based on passive case 
detection (PCD). Considering those findings, a mathematical model was developed 
(chapter 5) in order to understand and predict the potential effect of adding focal 
screening and treatment (FSAT) interventions to the ongoing PCD on the incidence and 
prevalence of P. falciparum infections in an area of low transmission of the Amazon 
region. Although the model results suggested that combined interventions enabled to 
reach elimination levels, the progression rates to those levels varied substantially 
according to different operational criteria (timing, duration, diagnostic tool, etc.) used for 
the intervention.  
As previously described in other malaria endemic areas in South America 
[54,94,96,98,111,160], cross-sectional surveys in both of our study sites consistently 
showed that a large proportion (>75%) of malaria infections were asymptomatic, despite 
differences in malaria prevalence and ecological characteristics. Though cross-sectional 
surveys might overestimate the proportion of asymptomatic carriers due to the potential 
later development of symptoms [96,173], previous longitudinal studies in Peru and Brazil 
have also confirmed, the high burden of asymptomatic carriers among all malaria 
infections, though at lower levels compared to survey data [173]. Indeed, a 6-month 
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cohort study in peri-Iquitos communities combining PCD, active case detection (ACD), 
and weekly monitoring of symptoms for one month of all malaria infected individuals, 
reported that asymptomatic infections accounted for about 40% of all microscopically 
confirmed cases during the study period [96]. Another study conducted in the Brazilian 
Amazon in 2004–2005 [173], including cross-sectional surveys, PCD and ACD over a 
14-month period, found that among 93 asymptomatic infections confirmed by PCR 
during surveys, only 10 (10.7%) developed malaria symptoms over the subsequent two 
months of follow-up. 
As transmission decreases, malaria surveillance becomes challenging due to the 
increasing proportion of asymptomatic cases that limit the performance of the routine 
PCD, and also because a significant proportion of these asymptomatic infections carry 
parasites at densities below the LM detection threshold [52,191,192]. The increasing use 
of molecular diagnostics in epidemiological studies allowed for a more accurate 
determination of the prevalence of infections [52,191,192], especially in low transmission 
settings where the asymptomatic reservoir is mainly composed of sub-microscopic 
infections [52,110,191,193,194].  This is exactly the case in our study areas, where the 
overall ratio LM/PCR prevalence of about 0.3 in both the northern coast and the Amazon 
region indicated that 70% of the total infections were not detected by LM.  
The presence of known malaria mosquito vectors, i.e. An. albimanus in the northern coast 
and An. darlingi in the Amazon, together with the identification by LM of P. falciparum 
(only in the Amazon) and P. vivax (in both study areas) gametocyte carriers confirms 
potential for onward malaria transmission within our study areas.  Considering that LM 
has a very low sensitivity for detecting sexual parasite stages, it is likely that a substantial 
proportion of individuals with asymptomatic and sub-patent infections would also carry 
gametocytes, thus contributing to a “hidden” human infectious reservoir that would 
maintain transmission as it remains largely undetected and therefore untreated 
[54,111,124,125]. Although further research is still needed to define to what extend sub-
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patent infections contribute to malaria transmission, mosquito feeding experiments have 
shown an overall positive non-linear association between P. falciparum gametocyte 
density and mosquito infection rates with very low densities still able to infect mosquitoes 
[183,195,196].  Moreover, despite first assays using direct skin feeding suggesting that 
P. vivax transmission may be more efficient than that of P. falciparum [197], recent 
studies using membrane assays also found a weak positive association between P. vivax 
gametocyte density and infectiousness to mosquitoes [198,199]. Although the success 
rate of mosquito infections has been shown to be lower with sub-patent gametocytemia 
[196,200], it can be hypothesized that this low efficiency is somehow compensated by 
the number and duration of sub-patent infections.   
Since serology provides information on cumulative exposure over time rather than a 
single current infection, it can usefully complement LM and PCR prevalence data 
allowing for a more accurate picture of the malaria transmission dynamics at community 
level [16,58].  This was illustrated in the northern coast (Chapter 3) where the low P. 
falciparum seropositivity in young children and the single PCR detected P. falciparum 
infection during the 2010 survey, while correlating with the extremely low incidence of 
reported P. falciparum cases during the past five years, also suggested a residual 
transmission of P. falciparum infections in the study area. This may be due to 
asymptomatic and sub-patent P. falciparum infections that remain undetected unless 
actively screened with highly sensitive diagnostic tools such as PCR. Moreover, in the 
Amazon region (Chapter 4), while available surveillance data suggested a predominance 
of P.vivax cases at district level, the cross sectional survey using PCR identified an 
unexpected higher prevalence of P. falciparum than P. vivax infection, and it also showed 
how the combination of serology, PCR, LM, together with contextual data allowed for a 
better understanding of the local malaria epidemiology. Indeed, in the community where 
the highest P. falciparum prevalence by PCR was found, the higher seropositivity levels 
and sero-conversion rates, for P. falciparum compared to those for P. vivax indicated that 
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exposure to P. falciparum was as high if not higher than that to P. vivax malaria. These 
serological findings and the identification of asymptomatic gametocyte carriers by LM 
suggested that P. falciparum transmission in the study site was more intense than 
previously thought.  
In addition to the asymptomatic P. falciparum reservoir, other operational or social 
factors limiting the effectiveness of routine PCD to detect and treat symptomatic malaria 
infections (i.e., low treatment seeking behavior at community, poor quality of 
microscopy-based diagnosis, poor prescribing practices, low patient adherence to 
treatment regimens, etc.) can also contribute in maintaining P. falciparum malaria 
transmission [46]. Moreover, it should be mentioned that the Peruvian national malaria 
control program (NMCP) is currently not recommending the addition of a single dose 
primaquine treatment for uncomplicated P. falciparum malaria, thus losing one 
opportunity to further reduce malaria transmission [92].  
Serological metrics are particularly suited to low endemic areas with seasonal 
transmission patterns [16] such as the Peruvian study areas, where the extremely low 
parasite rates at the time of the surveys did not allow for the identification of risk factors 
nor of malaria hotspots at micro-geographical level.  Therefore, using serological markers 
(Chapter 4) we were able to show that exposure to P. falciparum in the Amazon region 
was independently associated with outdoor economical activities (e.g., farming, logging, 
and fishing) as well as with the place of residence confirming previously published studies 
from this area [93]. Although the place of residence as risk factor may be related with 
favorable ecological conditions for mosquito breeding or resting sites resulting in 
increased  vector densities and  human-vector contact rates [93,100,144], at smaller 
geographical scale (i.e. within the sites), the spatial heterogeneity in P. falciparum malaria 
exposure can also be explained by different human behaviour [132].  Indeed, in site A for 
example (Chapter 4), the hotspot of P. falciparum exposure was the closest area to the 
river which floods seasonally after heavy rains, while in site B, this hotspot included a 
General discussion 
 
133 
 
majority  individuals with outdoor occupations and with electricity in their houses 
therefore more likely to have evening outdoor activities.  
Determining spatial heterogeneity in P. vivax malaria transmission was less clear in the 
Amazonian study sites (Chapter 4).  As expected, the site with the highest P. vivax 
prevalence was also the one with the highest P. vivax seroprevalence.  Although the site 
of residence was the only independent risk factor for P. vivax exposure, the spatial 
analysis using serological data was not able to identify significant clusters of P. vivax 
exposure suggesting that for P. vivax transmission ecological factors would be less 
important than for P. falciparum.  This could be due partly due to the chronic and 
relapsing nature of P.vivax infections which may hide the existing link between exposure 
to new infections and place of residence. Although high P. vivax recurrence rates 
(including relapses, recrudescence, and reinfections) have been reported in the Amazon 
region [161], it remains unclear how they influence antibody responses and consequently 
the identification of clusters of P. vivax exposure.   
Conversely in the northern coast, a strong association between mosquito breeding sites 
(i.e., proximity to water drain) and P. vivax exposure [103,201] may explain why the 
spatial analysis using serological markers was more sensitive for identification of P. vivax 
malaria hotspots (Chapter 6). Indeed, the spatial cluster of highest P. vivax seropositivity 
at the time of the survey was able to predict accurately hotspots with the highest clinical 
malaria incidence detected by PCD in the subsequent year. This serological approach, 
once optimized and tested by geographical area, would represent a reliable and effective 
surveillance tool in low transmission areas to detect hotspots of malaria (i.e., areas with 
high risk of having symptomatic, asymptomatic patent, and symptomatic sub-patent 
infections) in the remaining endemic areas of Peru. The stability of malaria hotspots over 
time should be closely monitored and also considered by decision-makers to better design 
and timely deliver appropriate targeted interventions (e.g. focal screening and treatment 
(FSAT) or mass drug administration (MDA)).   
General discussion 
 
134 
 
As previously reported in low transmission settings [21,22,57,202], SCRs calculated from 
age-adjusted seroprevelance data in single surveys allowed to detect historical changes in 
malaria transmission in our study areas (Chapters 3 and 4). Most of those changes 
coincided with major changes in the malaria control strategies (or in the environmental 
conditions) and with changes in malaria incidence trends at district or departmental level. 
Although regional and local differences in the intensity of control efforts and transmission 
dynamics should be considered to understand differences in the history of exposure 
determined by age-seroprevalence models (Chapter 4), our results showed the high 
potential of this approach for assessing the impact of previous control efforts in Peru. As 
reported before, a strong advantage of SCRs is the ability to reconstruct the history of 
malaria exposure [16,59] which will be especially useful in countries such as Peru where 
malaria surveillance is still based mainly on PCD by LM. In addition, SCRs could be 
efficiently used in the common situation of unreliable or missing data from the health 
information system [59].        
The uncovered asymptomatic and sub-patent reservoir is currently challenging malaria 
surveillance in Peru which is mainly based on PCD by LM [26]. Since the NMCP has 
recently introduced FSAT to overcome the inherent limitations of PCD to identify 
asymptomatic carriers [8], a modelling approach was developed to assess the potential 
impact of this strategy on the P. falciparum transmission in the Amazon region and to 
provide insights for the best criteria for its implementation (Chapter 5).  Our analysis 
suggested that targeting the asymptomatic P. falciparum reservoir with FSAT 
interventions using LM, in addition to routine PCD, had the potential to significantly 
reduce P. falciparum malaria transmission as long as 2-3 successive interventions at 
periodical intervals (i.e. 7-60 days) in low transmission season for consecutive years 
would be implemented. However, this positive impact would be reduced and even 
reversed if one or more of the following conditions are presented: poor coverage of FSAT 
interventions, PCD not efficiently detecting symptomatic infections, efficacy of the 
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antimalarial treatment reduced, poor prescription practices, patient adherence to the 
treatment reduced, and the burden of asymptomatic and sub-microscopic infections 
increasing. On the other hand, implementing FSAT interventions using a supposed field 
PCR under the same operational criteria used for FSAT with LM would not only have a 
stronger impact on P. falciparum transmission enabling to reach elimination levels, but 
would also be less affected by the conditions mentioned above.  
Although these results support the importance of detecting and treating P. falciparum sub-
microscopic infections for successful elimination strategies [46,184], implementing 
FSAT using PCR as routine strategy in well identified hotspots may not be feasible since 
current PCR tests are resource-intensive, time-consuming and expensive [113]. However, 
recent studies have shown high sensitivity of non-conventional molecular tests based on 
loop-mediated isothermal amplification (LAMP) and which do not require specialized 
staff or equipment [185]. Although, recent field studies carried out in in Zanzibar [203] 
and Colombia [204] have shown promising results with sensitivities above 97%,  the 
LAMP assays still need further optimization in order to be used as true point of care tests.  
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CONCLUSIONS AND PERSPECTIVES 
 
A key challenge faced by the Peruvian NMCP is the ability to efficiently target a human 
malaria infectious reservoir which remains largely undetected by the standard diagnostic 
tools. The use of PCR to detect current malaria infections and serology to identify past 
malaria exposure have repeatedly proved their added value in accurately understanding the 
local epidemiology, determining risk factors for malaria, describing spatial heterogeneity in 
transmission, and identifying recent changes in malaria transmission in the study areas of the 
northern coast and the Amazon region.  
The uncovered asymptomatic and sub-patent reservoir calls for an immediate shift in the 
malaria control policy in Peru from detecting and controlling clinical malaria to targeting and 
eliminating all malaria infections (both asymptomatic and symptomatic infections). The high 
heterogeneity in malaria transmission in the northern coast and Amazon region creates 
opportunities for targeted interventions as focal screening and treatment (FSAT) or mass drug 
administration (MDA) with effective treatment combinations (including  single-dose 
primaquine for P. falciparum), however, hotspots of malaria transmission need to be first 
accurately identified.  Serological metrics have proven to be reliable tools to detect future 
malaria hotspots of clinical malaria cases in the northern coast, but they need to be evaluated 
in other ecological areas. Furthermore, serological tools should also be tested for their ability 
to predict clusters with high risk of asymptomatic and sub-patent infections.   
Since the financial resources available to control malaria are currently limited, it is important 
for the NMCP to know what will be the contribution of new surveillance and control 
strategies aimed to target the asymptomatic and sub-patent reservoir, including the 
assessment of their cost-effectiveness.  Trying always to keep the principle of parsimony, our 
current P. falciparum model can be further improved by including particularities of both the 
malaria dynamics and the targeted interventions, such as: the human mobility patterns (i.e, 
migration and visitation); the heterogeneity in transmission parameters between human sub-
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populations by age (children, adults), occupation (farmers, loggers, fishers), and treatment 
behaviour practices (i.e., treatment seeking behaviour, treatment adherence, use of preventive 
malaria measures, etc.); the different levels of gametocyte infectiousness according to the age 
of the gametocyte carrier state; the variable duration of case detection interventions according 
to the size of the target population, the malaria diagnostic tool used, and the available human 
and logistic resources; the addition of a single dose primaquine  to the treatment for 
uncomplicated P. falciparum malaria.   New research lines should include the development 
of more complex models for P. vivax transmission using data of cohorts carried out in the 
Peruvian Amazon to better define the operational criteria for FSAT interventions to maximize 
the impact of the intervention on both species. In addition, models would also allow for 
evaluating the cost-effectiveness highly sensitive diagnostic tests such as loop-mediated 
isothermal amplification (LAMP) in active case detection interventions, as well as, to assess 
innovative malaria elimination strategies in countries where P. falciparum and P. vivax are 
co-endemic, such as the treatment of all individuals with confirmed infections by LAMP 
(treatment according to the identified species) plus the additional treatment of probable P. 
vivax hypnozoite carriers (e.g. P. vivax seropositive individuals).  Considering MDA as a 
potential elimination strategy in well delimited areas, models can be adapted to simulate the 
impact of using a unique treatment based on ACT and primaquine (or tafenoquine when 
available) for treating both P. falciparum and P. vivax infections.  
The significant reduction in malaria cases and deaths over the past decade in the Americas 
with many endemic countries close to eliminate malaria from their territories (i.e., Argentina, 
Belize, Costa Rica, Ecuador, El Salvador, Mexico, and Paraguay) has recently encouraged 
consultations in Peru between the research community and decision-makers on the relevance 
and feasibility of a national malaria elimination program. The good news is that malaria 
elimination in the country is not perceived as unachievable, but it will require in addition to 
political and financial commitment, the involvement of key stakeholders and experts at every 
level of government, as well as, integrated research activities to evaluate and implement 
sustainable interventions and tools in endemic regions.  
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Annexes chapter 2.   
 
Text S2.1. R-code for basic malaria models 
 
#1#Ross model 
 
library(deSolve) 
 
#Parameters 
Nt <-500      #Total human population 
Mt<- 15000     #Total mosquito population 
m <- Mt/Nt    # m is equilibrium mosquito density per human.  
a <- 0.2      # expected number of bites on humans per mosquito. 
b <- 0.2      #transmission efficiency from infectious mosquito to susceptible human 
c<- 0.5       #probability of infection of an uninfected mosquito by biting an infectious 
human 
g<- 0.2      #daily force of mosquito mortality 
r<- 1/210     #daily recovery rate 
tim<-365*1.5      #time in days 
 
#Initial population number 
Io<-1 
So<-Nt-Io 
Vo<-0 
Uo<-Mt-Vo 
 
#Function 
mal1.dyn <- function(t,var,par) { 
  # Rename the variables and parameters 
  S<- var[1] 
  I<- var[2] 
  U<-var[3] 
  V<- var[4] 
  N<-S+I 
  M<-U+V 
  m <- par[1] 
  a <- par[2] 
  b <- par[3] 
  c<- par[4] 
  g<- par[5] 
  r<- par[6] 
   
  # Derivatives 
  dS <- -m*a*b*V/M*S+r*I 
  dI <- m*a*b*V/M*S-r*I 
  dU <- -a*c*I/N*U+g*V 
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  dV <- a*c*I/N*U-g*V 
   
  list(c(dS,dI,dU,dV))}  # Return the 5 values 
 
#Preparing the numerical solution 
par <- c(m,a,b,c,g,r) 
init <- c(So,Io,Uo,Vo)  #Initial population  
time <- seq(0,tim,by=0.1) 
 
#Numerical solution 
# lsoda(var,t,function,par) 
 
mal1.sol <- lsoda(init,time,mal1.dyn,par)  # obtain a matrix with 5 columns (time, S,I,U, 
V) 
 
#Relabeling the variables 
TIME <- mal1.sol[,1] 
S1 <- mal1.sol[,2] 
I1 <- mal1.sol[,3] 
U1 <- mal1.sol[,4] 
V1 <- mal1.sol[,5] 
N1 <- S1+I1 
M1 <- V1+U1 
 
#Plots  
windows() 
 
par(mfrow=c(2,1), xaxs='i', yaxs='i') 
 
plot(TIME,S1/Nt,type='l',main=paste('Ross model - Differential 
equation'),xlab='time',ylab='Human population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,I1/Nt, type='l',col='red', lwd=3) 
legend("topright", c("S", "I"), col=c("blue","red"),lty=c(1,1),inset=0.1) 
 
plot(TIME,U1/Mt,type='l', main=paste('Ross model - Differential equation'), 
xlab='time',ylab='Vector population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,V1/Mt, type='l',col='red', lwd=3) 
legend("topright", c("U", "V"), col=c("blue","red"),lty=c(1,1),  inset=0.1) 
 
 
#2#Mc Donald model## 
 
library(deSolve) 
 
#Parameters 
Nt <-500      #Total human population 
Mt<- 15000     #Total mosquito population 
m <- Mt/Nt    # m is equilibrium mosquito density per human.  
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a <- 0.2      # expected number of bites on humans per mosquito. 
b <- 0.2      #transmission efficiency from infectious mosquito to susceptible human 
c<- 0.5       #probability of infection of an uninfected mosquito by biting an infectious 
human 
g<- 0.2      #daily force of mosquito mortality 
r<- 1/210     #daily recovery rate 
n<- 10        #mosquito incubation period 
tim<-365*1.5      #time in days 
 
#Initial population number 
Io<-1 
So<-Nt-Io 
Vo<-0 
Lo<-0 
Uo<-Mt-Vo-Lo 
 
#Function 
mal1.dyn <- function(t,var,par) { 
   
  #Setting the lag for mosquito incubation period 
  lagM <- t - n 
  if (lagM <= 0) 
    varlagM <- c(So,Io,Uo,Lo,Vo)  #"n" past values of compartments before time 0   
  else  
    varlagM <- lagvalue(lagM)   
   
  # Rename the variables and parameters 
  S<- var[1] 
  I<- var[2] 
  U<-var[3] 
  L<-var[4] 
  V<- var[5] 
  N<-S+I 
  M<-U+L+V 
  m <- par[1] 
  a <- par[2] 
  b <- par[3] 
  c<- par[4] 
  g<- par[5] 
  r<- par[6] 
  n<-par[7] 
  I_lagM<-varlagM[2] 
  U_lagM<-varlagM[3] 
   
  # Derivatives 
  dS <- -m*a*b*(V/M)*S+r*I 
  dI <- m*a*b*(V/M)*S-r*I 
  dU <- -a*c*(I/N)*U+g*(V+L) 
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  dL <- a*c*(I/N)*U - a*c*(I_lagM/N)*U_lagM*exp(-g*n)-g*L 
  dV <- a*c*(I_lagM/N)*U_lagM*exp(-g*n)-g*V 
   
  list(c(dS,dI,dU,dL,dV))}  # Return the 6 values 
 
#Preparing the numerical solution 
par <- c(m,a,b,c,g,r,n) 
init <- c(So,Io,Uo,Lo,Vo)  #Initial population  
time <- seq(0,tim,by=0.1) 
 
#Numerical solution 
# lsoda(var,t,function,par) 
mal1.sol <- dede(init,time,mal1.dyn,par)  # obtain a matrix with 6 columns (time, 
S,I,U,L,V) 
 
#Relabeling the variables 
TIME <- mal1.sol[,1] 
S2 <- mal1.sol[,2] 
I2 <- mal1.sol[,3] 
U2 <- mal1.sol[,4] 
L2 <- mal1.sol[,5] 
V2 <- mal1.sol[,6] 
N2 <- S2+I2 
M2 <- V2+L2+U2 
 
#Plots  
windows() 
par(mfrow=c(2,1), xaxs='i', yaxs='i') 
plot(TIME,S2/Nt,type='l',main=paste('Mac Donald model - Differential 
equation'),xlab='time',ylab='Human population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,I2/Nt, type='l',col='red', lwd=3) 
legend("topright", c("S", "I"), col=c("blue","red"),lty=c(1,1),inset=0.1) 
 
plot(TIME,U2/Mt,type='l', main=paste('Mac Donald model - Differential equation'), 
xlab='time',ylab='Vector population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,L2/Mt, type='l',col='orange', lwd=3) 
lines(TIME,V2/Mt, type='l',col='red', lwd=3) 
legend("topright", c("U","L","V"), col=c("blue","orange","red"),lty=c(1,1,1),  inset=0.1) 
 
#3#Anderson & May model# 
 
library(deSolve) 
 
#Parameters 
Nt <-500      #Total human population 
Mt<- 15000     #Total mosquito population 
m <- Mt/Nt    # m is equilibrium mosquito density per human.  
a <- 0.2      # expected number of bites on humans per mosquito. 
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b <- 0.2      #transmission efficiency from infectious mosquito to susceptible human 
c<- 0.5       #probability of infection of an uninfected mosquito by biting an infectious 
human 
g<- 0.2       #daily force of mosquito mortality 
r<- 1/210     #daily recovery rate 
n<- 10        #mosquito incubation period 
h<-0.00005    #daily force of human mortality 
l<- 21        #human incubation period 
 
tim<-365*1.5      #time in days 
 
#Initial population number 
Io<-1 
Eo<-0 
So<-Nt-Io-Eo 
Vo<-0 
Lo<-0 
Uo<-Mt-Vo-Lo 
 
#Function 
mal1.dyn <- function(t,var,par) { 
   
  #Setting the lag for mosquito latent period 
  lagM <- t - n 
  if (lagM <= 0) 
    varlagM <- c(So,Eo,Io,Uo,Lo,Vo)  #"n" past values of compartments before time 0 # 
Put Io-Io to have the same curve of the paper  
  else  
    varlagM <- lagvalue(lagM)    
   
  #Setting the lag for human latent period 
  lagH <- t - l 
  if (lagH <= 0) 
    varlagH <- c(So,Eo,Io,Uo,Lo,Vo)  #"l" past values of compartments before time 0   
  else  
    varlagH <- lagvalue(lagH)  
   
  # Rename the variables and parameters 
  S<- var[1] 
  E<- var[2] 
  I<- var[3] 
   
  U<-var[4] 
  L<-var[5] 
  V<- var[6] 
  N<-S+E+I 
  M<-U+L+V 
  m <- par[1] 
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  a <- par[2] 
  b <- par[3] 
  c<- par[4] 
  g<- par[5] 
  r<- par[6] 
  n<-par[7] 
  h<-par[8] 
  l<-par[9] 
   
  S_lagM<-varlagM[1] 
  E_lagM<-varlagM[2] 
  I_lagM<-varlagM[3] 
  U_lagM<-varlagM[4] 
  L_lagM<-varlagM[5] 
  V_lagM<-varlagM[6] 
   
  S_lagH<-varlagH[1] 
  E_lagH<-varlagH[2] 
  I_lagH<-varlagH[3] 
  U_lagH<-varlagH[4] 
  L_lagH<-varlagH[5] 
  V_lagH<-varlagH[6] 
   
  # Derivatives 
  dS <- -m*a*b*(V/M)*S+r*I+r*E-h*S+h*(S+I+E) 
  dE <-  m*a*b*(V/M)*S-m*a*b*(V_lagH/M)*S_lagH*exp(-l*(r+h))-r*E-h*E 
  dI <-  m*a*b*(V_lagH/M)*S_lagH*exp(-l*(r+h))-r*I-h*I 
   
  dU <- -a*c*(I/N)*U+g*(V+L) 
  dL <- a*c*(I/N)*U - a*c*(I_lagM/N)*U_lagM*exp(-g*n)-g*L 
  dV <- a*c*(I_lagM/N)*U_lagM*exp(-g*n)-g*V 
   
  list(c(dS,dE,dI,dU,dL,dV))}  # Return the 7 values 
 
#Preparing the numerical solution 
par <- c(m,a,b,c,g,r,n,h,l) 
init <- c(So,Eo,Io,Uo,Lo,Vo)  #Initial population  
time <- seq(0,tim,by=0.1) 
 
#Numerical solution 
# lsoda(var,t,function,par) 
mal1.sol <- dede(init,time,mal1.dyn,par)  # obtain a matrix with 7 columns (time, 
S,E,I,U,L,V) 
 
#Relabeling the variables 
TIME <- mal1.sol[,1] 
S3 <- mal1.sol[,2] 
E3 <- mal1.sol[,3] 
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I3 <- mal1.sol[,4] 
U3 <- mal1.sol[,5] 
L3 <- mal1.sol[,6] 
V3 <- mal1.sol[,7] 
N3 <- S3+E3+I3 
M3 <- V3+L3+U3 
 
#Plots  
windows() 
par(mfrow=c(2,1), xaxs='i', yaxs='i') 
plot(TIME,S3/Nt,type='l',main=paste('Anderson & May model - Differential 
equation'),xlab='time',ylab='Human population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,E3/Nt, type='l',col='orange', lwd=3) 
lines(TIME,I3/Nt, type='l',col='red', lwd=3) 
legend("topright", c("S","E", "I"), col=c("blue","orange","red"),lty=c(1,1,1),inset=0.01, 
cex=0.5) 
 
plot(TIME,U3/Mt,type='l', main=paste('Anderson & May model - Differential 
equation'), xlab='time',ylab='Vector population',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,L3/Mt, type='l',col='orange', lwd=3) 
lines(TIME,V3/Mt, type='l',col='red', lwd=3) 
legend("topright", c("U","L","V"), col=c("blue","orange","red"),lty=c(1,1,1),  
inset=0.01, cex=0.5) 
 
 
#####COMPARISON 
 
windows() 
plot(TIME,I1/Nt,type='l',xlab='time',ylab='Prevalence (I or 
V)',col='blue',lwd=3,ylim=c(0,1)) 
lines(TIME,I2/Nt, type='l',col='green', lwd=3) 
lines(TIME,I3/Nt, type='l',col='red', lwd=3) 
lines(TIME,V1/Mt, type='l',col='blue', lwd=3, lty=3) 
lines(TIME,V2/Mt, type='l',col='green', lwd=3, lty=3) 
lines(TIME,V3/Mt, type='l',col='red', lwd=3, lty=3) 
legend("right", c("Ross","Mac Donald","Anderson & May"), 
col=c("blue","green","red"),lty=c(1,1,1),lwd=c(3,3,3),,inset=0.01, cex=1.1) 
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Annexes chapter 3.  
 
Table S3.1. Prevalence of P. vivax infections by age-groups and occupation 
 
 Prevalence n N  % 95% CI   
Age groups (years)* 
 0.5-5 0.89 [0.34,2.36] 4 447 
6-10 0.60 [0.15,2.36] 2 335 
11-14 1.30 [0.49,3.43] 4 307 
15-19 1.19 [0.38,3.60] 3 253 
20-29 1.17 [0.49,2.77] 5 429 
30-39 1.09 [0.45,2.58] 5 460 
40-49 0.40 [0.06,2.81] 1 249 
≥50 0.53 [0.07,3.71] 1 187 
Total 0.94 [0.63,1.40] 25 2667 
Occupation as farmer°* 
 No 0.95 [0.54,1.66] 12 1269 
Yes 0.00  0 56 
Total 0.91 [0.52,1.59] 12 1325 
Occupation as moto-taxi driver°* 
 No 0.87 [0.48,1.57] 11 1260 
Yes 1.54 [0.22,10.18] 1 65 
Total 0.91 [0.52,1.59] 12 1325 
     
* No differences between groups (p > 0.05); ° in the past 12 months in individual ≥ 20 years; 
 
 
 
Table S3.2. P. falciparum  seropositivity  by occupation as moto-taxi driver  
 
 Prevalence n N 
 % 95% CI   
Occupation as moto-taxi 
driver  
 
No 10.96 [9.32,12.85] 138 1259 
Yes 21.54 [13.22,33.09] 14 65 
Total 11.48 [9.84,13.35] 152 1324 
      
* Significant difference between groups (OR=2.2, p<0.008); ° in the past 12 months in individual 
≥ 20 years; 
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Annexes chapter 4.  
 
 
Table S4.1. Survey coverage by site and age group 
Site Age Census Enrolled % 
   
Site A < 6 m 41 ▁ ▁ 
6 m - 6.9 y 146 109 74.7 
7-14.9 y 149 42 28.2 
15-30 y 188 47 25.0 
> 30 y 131 40 30.5 
Total 655 238 36.3 
    
Site B < 6 m 31 ▁ ▁ 
6 m - 6.9 y 105 74 70.5 
7-14.9 y 60 19 31.7 
15-30 y 58 17 29.3 
> 30 y 123 43 35.0 
Total 377 153 40.6 
    
Site C < 6 m 45 ▁ ▁ 
6 m - 6.9 y 169 121 71.6 
7-14.9 y 124 40 32.3 
15-30 y 125 44 35.2 
> 30 y 154 55 35.7 
Total 617 260 42.1 
    
Total < 6 m 117  
6 m - 6.9 y 420 304 72.4 
7-14.9 y 333 101 30.3 
15-30 y 371 108 29.1 
> 30 y 408 138 33.8 
Total 1649 651 39.5 
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Table S4.2. Uni- and multivariate risk factor analysis for individuals included in P. 
falciparum-exposure cluster in site B (N=152) 
  Univariate   Multivariate  
  % n/N    OR        [95% CI] AOR [95% CI]    
Age groups (years)             
 < 7   39.5 27/73  1     -    
 7-14.9 23.9 5/19  0.5  [0.2;1.5]       
15-30 41.9 7/17  1.1  [0.4;2.7]       
> 30 47.8 18/43  1.4  [0.6;3.4]       
Gender             
 Female 31.7 28/76  0.5  [0.2;1.2]   -    
Male 46.5 29/76  1         
Outdoor occupation              
 No 34.3 45/125  1     1    
 Yes 60.0 12/27  2.9 * [1.1;7.8]   4.4 * [1.6;11.8]  
Predominant material 
in roof    
         
 Palm leaf, straw 35.5 29/88  0.7  [0.3;2.0]   -    
 Tin roof 43.6 28/64  1         
Electricity available             
 No 22.1 15/62  1     1    
 Yes 48.2 42/90  3.3 * [1.2;9.1]   4.5 * [1.6;12.9]  
Malaria episode in the 
past 12 months 
            
 No 34.2 44/127  1         
Yes 59.7 13/25  2.9 o [1.0;8.4]   -    
*p<0.05;  o p<0.1 
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Figure S1. Evolution of the annual malaria incidence in San Juan/Iquitos districts: 
2002–2013. 
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Annexes chapter 5. 
 Figure S5.1. Schematic diagram of the human and vector model states including all transmission 
parameters. The total human population (N) is divided into 4 compartments: susceptible (S), infected latent (E), 
infectious treated (T) and infectious untreated (Ι) individuals. The latent period has two sub-states: latent which have 
not yet developed asexual blood-stage parasites (E1) and latent with asexual blood-stage parasites (E2). Before 
becoming recovered, individuals in Ι compartment need to pass through two sub-states: those who have not yet (Ι1) 
and those who have spontaneously cleared the asexual blood stage parasites (Ι2). The total mosquito population (M) 
is divided into three compartments: uninfected (U), infected latent (L) and infectious (V) mosquitoes. The addition 
of FSAT to PCD allows for the detection and treatment of individuals in E2, Ι1 and Ι2 compartments. 
 
 
Table S5.1. P. falciparum malaria prevalence and incidence rate in Ninarumi in 2004. 
  n N % 95% CI 
  
Prevalence by 
microscopy 
February 2004 28 432 6.5 [5.6; 7.4] 
 August 2004 3 269 1.1 [0.3; 2.0] 
Annual incidence  Symptomatic infections 91 - 65.4 - 
 Asymptomatic microscopically 
confirmed infections
29 - 20.9 - 
 Asymptomatic sub-microscopic 
infections
19 - 13.7 - 
 Total 
 
13
9
- 100.
0
- 
Annual P. 
falciparum 
parasitological index  
278 P. falciparum cases per 
1000 inhabitants 
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Text S5.1. Description of transmission parameters for baseline model. 
 
The susceptibility of an individual to infection (b) was assumed to be 0.05 based on estimates 
of two malariometric indices in Ninarumi: the annual P. falciparum force of infection in 2004 
(Pf-FOI = 0.28 P. falciparum infections/person/year) and the annual P. falciparum 
entomological inoculation rate (Pf-EIR = 5.57 infective bites/person/year).  The annual Pf-
EIR was calculated by multiplying the annual-average An. darlingi human biting rate (Ad-
HBR) by the P. falciparum sporozoite rate in An. darlingi mosquitoes (Pf-SR) and the number 
of days in a year (365). The annual Ad-HBR was estimated at 15.25 An.darlingi 
bites/person/night from mosquito collections undertaken in Ninarumi along 2003 [1].  Pf-SR 
was conservatively assumed to be 0.001 (0.1%), as observed in two entomological surveys 
carried out in 2008 in another area near Iquitos in the Peruvian Amazon [2].  
The average human latent period (l) was set to 21 days based on previous reports about the 
biology of P. falciparum transmission stages [3].  The probability for an individual to develop 
symptoms upon infection and being detected by PCD was assumed to be 65% (y=0.65) based 
on results of the monitoring of symptoms in asymptomatic infections as part of the cohort 
study in Ninarumi [1].   ACT treatment effectiveness was assumed to be 98% (ε=0.98) 
according to an efficacy and effectiveness study of MQ-AS combination therapy for P. 
falciparum malaria in the Peruvian Amazon [4].  Daily recovery rate without treatment (r2) 
for P. falciparum was set to 1/200 based on case data compiled by Macdonald from several 
previous studies [5]. Daily recovery rate with ACT (r1) was conservatively assumed to be 
1/14 according to antimalarial trials which measured gametocyte clearance from blood after 
treatment with MQ-AS [6-8] .   
Susceptibility of An. darlingi was conservatively assumed to be 0.41 for P. falciparum based 
on published data for membrane-fed An. darlingi caught in Belize [9]. Considering an 
average annual temperature of 28°C for the Loreto region [10], the latent period for mosquito 
(n) (i.e. the sporogonic period) was estimated at 11 days for P. falciparum based on data from 
various experimental studies compiled and plotted against ambient temperature by 
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Macdonald [11]. While daily human mortality rate (h) was set to 0.00005 considering an 
expected lifespan of 50 years at the median age of the population [12]; daily mosquito 
mortality rate (g) was assumed to be 0.16, after its estimation from the average parous rate 
[13] of An. darlingi in the Upper-Maroni forest region of French Guiana [14].   
Basic malaria models have usually assumed arbitrary values between 1 and 100 for the 
mosquito density (m) (15), while the human feeding rate (a) is estimated by dividing the 
human blood index (proportion of mosquito-blood meals obtained from humans) by the 
duration of gonotrophic cycle in time units [16].  Due to large variations in values for both 
parameters, these were estimated by fitting the parameterized model to the observed monthly 
incidence of symptomatic P. falciparum infections in 2004 in Ninarumi. Setting a constant 
mosquito density (m) to 75, allowed the model to estimate monthly values of the human 
feeding rate (a) between 0.035 to 0.32 bites on humans per An. darlingi per day; a range 
considered realistic considering previously reported data on human blood indices (between 
0.15 and 0.72 [17, 18]), and gonotrophic cycle periods (between 2.19 and 4.4 days [19, 20]) 
for An. darlingi in the Brazilian Amazon.  Therefore, the human feeding rate (a) was the only 
time-dependent parameter in the model which allowed for the assessment of the seasonal 
variations of malaria transmission. 
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Text S5.2. R-code for the baseline model. 
 
library(deSolve) 
 
year<-20 
tim<-360*year #time in days 
time <- seq(0,tim,by=1) 
es <- 1  # number of scenarios.  It is only one scenario: the baseline model.  
 
#Parameters 
 
m <- 75        #mosquito density 
Nt <-500      #total human population 
Mt<- Nt*m  #total mosquito population 
b<- 0.05       #susceptibility of an individual to infection after being bitten by an infectious 
mosquito 
c<- 0.41       #mosquito susceptibility to infection after biting an infectious individual  
e<-0.98        #treatment effectiveness  
y<-0.65       #fraction of symptomatic infections  
r1<-14         #duration of infectious period in treated humans with ACT (in days) 
r2<-200       #duration of infectious period in untreated humans in days (r2= r2a+r2b) 
r2a<-80       #duration of presence of blood asexual parasites in untreated humans in days 
r2b<-120     #duration of infectious period in untreated humans after clearance of blood 
asexual parasites in days   
 
rr1<-1/r1; rr2<-1/r2; rr2a<-1/r2a; rr2b<-1/r2b 
 
n<- 11         #duration of mosquito latent period in days 
l<- 21          #duration of human latent period for P.falciparum in days (l= l1+l2+ne) 
l1<-10         #duration from sporozoite inoculation to development of blood asexual 
parasites in days  
l2<-10         #duration from asexual blood stage infection to development of gametocytes in 
days  
rl2<-1/l2      #daily rate from appearance of blood asexual parasites to development of 
patent blood infection   
ne<-1           #time spent in days (only one day) in a fictitious compartment called "New".  
“New” allows calculating daily incidence 
rnew<-1/ne  #rate to enter/leave the fictitious compartment   
h<- 1/(70*360)   #daily human mortality rate  
g<-0.16              #daily mosquito mortality rate 
v<-1              #duration of FSAT in days 
vv<-1/v 
cov<-1          #coverage of intervention 
sm1<-0.5      #sensitivity of microscopy for detecting asexual parasites 
sp1<-0.95     #sensitivity of PCR for detecting asexual parasites 
sm2<-0.1      #sensitivity of microscopy for gametocytes 
sp2<-0.8       #sensitivity of PCR for detecting gametocytes 
Annexes 
 
174 
 
 
# monthly values of the human feeding rate (expected number of bites on humans per 
mosquito)  
a<rep(c(rep(0.32,30),rep(0.19,30),rep(0.04732,30),rep(0.12,30),rep(0.07,30),rep(0.095,30),
rep(0.035,30), rep(0.035,30),rep(0.035,30), 
rep(0.035,30),rep(0.035,30),rep(0.035,30)),year) 
a.t<-c(0,a) 
A.t<-function(i) a.t[i] 
 
# Scenario: Only passive case detection (PCD) 
# Timing for the intervention 
t1<-array(0,c(es,length(time)))   
t1[1,]<-c(0,rep(0,360*year))  
 
#Initial population number 
To<-4 
I1o<-9 
I2o<-7 
NEWo<-0 
E1o<-0 
E2o<-0 
So<-Nt-I1o-I2o-E1o-E2o-To-NEWo 
Vo<-0.001*Mt 
Lo<-0 
Uo<-Mt-Vo-Lo 
 
#For storage 
TIME<- array(0,c(es,length(time))) 
Sx<- array(0,c(es,length(time))) 
E1x<- array(0,c(es,length(time))) 
NEWx<-array(0,c(es,length(time))) 
E2x<- array(0,c(es,length(time))) 
Tx<- array(0,c(es,length(time))) 
I1x<- array(0,c(es,length(time))) 
I2x<- array(0,c(es,length(time))) 
Ux<- array(0,c(es,length(time))) 
Lx<- array(0,c(es,length(time))) 
Vx<- array(0,c(es,length(time))) 
Nx<- array(0,c(es,length(time))) 
Mx<- array(0,c(es,length(time))) 
 
ITm<-array(0,c(es,((length(time)-1)/30))) 
 
#Loop for scenarios 
for(j in 1:es) 
{ 
  t1.t<-function(i) t1[j,][i]   
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#Function 
mal1.dyn <- function(t,var,par) { 
   
  #Setting the lag for mosquito latent period 
  lagM <- t - n 
  if (lagM <= 0) 
    varlagM <- c(0,0,0,0,0,0,0,0,0,0)  #"n" past values of compartments before time 0  
  else  
    varlagM <- lagvalue(lagM)    
   
  #Setting the lag for human latent period1 
  lagH <- t - l1 
  if (lagH <= 0) 
    varlagH <- c(0,0,0,0,0,0,0,0,0,0)  #"l1" past values of compartments before time 0   
  else  
    varlagH <- lagvalue(lagH)  
   
  #Setting the time dependent gonotrophic cycle for a mosquito  
  a <- A.t(t+1) 
   
  #Setting the lag for gonotrophic cycle for a mosquito  
  if (lagM <= 0) 
    a_lagM <- 0 
  else  
    a_lagM <- A.t(t+1-n)  
   
  #Setting the lag for human latent period1  
  if (lagH <= 0) 
    a_lagH <- 0 
  else  
    a_lagH <- A.t(t+1-l1)  
   
  # Rename the variables and parameters 
  S<- var[1] 
  E1<- var[2] 
  NEW<- var[3] 
  E2<- var[4] 
  I1<- var[5] 
  I2<- var[6] 
  T<- var[7] 
  U<-var[8] 
  L<-var[9] 
  V<- var[10] 
   
  N<-S+E1+NEW+E2+NEW+I1+I2+T 
  M<-U+L+V 
   
  m <- par[1]   
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  b <- par[2] 
  c<- par[3]   
  rr1<- par[4] 
  rr2a<- par[5] 
  rr2b<- par[6] 
  n<-par[7] 
  h<-par[8] 
  l1<-par[9] 
  l2<-par[10] 
  y<-par[11] 
  sm1<-par[12] 
  sp1<-par[13] 
  sm2<-par[14] 
  sp2<-par[15] 
  vv<-par[16]  
  g<-par[17] 
  e<-par[18] 
  cov<-par[19] 
  rnew<-par[20] 
  rl2<-par[21] 
     
  #Time dependent timing for the intervention 
 t1 <- t1.t(t+1) 
   
  # Rename Lags for mosquito and human latent period   
  S_lagM<-varlagM[1] 
  E1_lagM<-varlagM[2] 
  NEW_lagM<-varlagM[3] 
  E2_lagM<-varlagM[4] 
  I1_lagM<-varlagM[5] 
  I2_lagM<-varlagM[6] 
  T_lagM<-varlagM[7] 
  U_lagM<-varlagM[8] 
  L_lagM<-varlagM[9] 
  V_lagM<-varlagM[10] 
   
  S_lagH<-varlagH[1] 
  E1_lagH<-varlagH[2] 
  NEW_lagH<-varlagH[3] 
  E2_lagH<-varlagH[4] 
   
  I1_lagH<-varlagH[5] 
  I2_lagH<-varlagH[6] 
  T_lagH<-varlagH[7] 
  U_lagH<-varlagH[8] 
  L_lagH<-varlagH[9] 
  V_lagH<-varlagH[10] 
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  # Derivatives 
  dS <- -m*a*b*(V/M)*S+rr1*T+rr2b*I2-h*S+h*(S+E2+E1+I1+I2+T) 
  dE1 <-  m*a*b*(V/M)*S-m*(a_lagH)*b*(V_lagH/M)*S_lagH*exp(-l1*h)-h*E1 
  dNEW <- m*(a_lagH)*b*(V_lagH/M)*S_lagH*exp(-l1*h)-NEW*rnew  
  dE2 <-  NEW*rnew-rl2*E2-h*E2-(sm1+sp1)*t1*cov*vv*e*E2 
  dI1 <-  rl2*E2*(1-y*e)-rr2a*I1-h*I1-(sm1+sp1)*t1*cov*vv*e*I1   
  dI2 <-  I1*rr2a-rr2b*I2-h*I2-(sm2+sp2)*t1*cov*vv*e*I2   
  dT <-   rl2*E2*(y*e)-rr1*T-
h*T+(sm1+sp1)*t1*cov*vv*e*E2+(sm1+sp1)*t1*cov*vv*e*I1+(sm2+sp2)*t1*cov*vv*e*
I2   
   
  dU <- -a*c*((I1+I2+T)/N)*U+g*(V+L) 
  dL <- a*c*((I1+I2+T)/N)*U-
(a_lagM)*c*((I1_lagM+I2_lagM+T_lagM)/N)*U_lagM*exp(-g*n)-g*L 
  dV <- (a_lagM)*c*((I1_lagM+I2_lagM+T_lagM)/N)*U_lagM*exp(-g*n)-g*V 
     
  list(c(dS,dE1,dNEW,dE2,dI1,dI2,dT,dU,dL,dV))}  # Return the 10 values 
 
#Preparing the numerical solution 
par <- c(m,b,c,rr1,rr2a,rr2b,n,h,l1,l2,y,sm1,sp1,sm2,sp2,vv,g,e,cov,rnew,rl2) 
init <- c(So,E1o,NEWo,E2o,I1o,I2o,To,Uo,Lo,Vo)  #Initial population  
time <- seq(0,tim,by=1) 
 
#Numerical solution 
mal1.sol <- dede(init,time,mal1.dyn,par)   
 
#Relabeling the variables 
TIME[j,]<- mal1.sol[,1] 
Sx[j,]<- mal1.sol[,2] 
E1x[j,] <- mal1.sol[,3] 
NEWx[j,]<-mal1.sol[,4] 
E2x[j,] <- mal1.sol[,5] 
I1x[j,]<- mal1.sol[,6] 
I2x[j,]<- mal1.sol[,7] 
Tx[j,]<- mal1.sol[,8] 
Ux[j,]<- mal1.sol[,9] 
Lx[j,]<- mal1.sol[,10] 
Vx[j,]<- mal1.sol[,11] 
Nx[j,]<- Sx[j,]+E1x[j,]+E2x[j,]+NEWx[j,]+I1x[j,]+I2x[j,]+Tx[j,] 
Mx[j,]<- Vx[j,]+Lx[j,]+Ux[j,] 
 
#Monthly incidence calculation 
for (x2 in 1:((length(time)-1)/30)) 
{ 
  ITm[j,x2]<-sum(mal1.sol[2:(length(time)),4][(30*(x2-1)+1):(30*x2)])  
} 
} 
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#Plots  
# 1. Prevalence of compartments  
windows() 
par(mfrow=c(2,1), xaxs='i', yaxs='i') 
plot(Sx[1,]/Nt,type='l',xlab='time',main=paste('Prevalence'), ylab='Human 
population',col='blue',lwd=3,ylim=c(0,1)) 
lines((E1x[1,]+E1x[1,])/Nt, type='l',col='yellow', lwd=3) 
lines((I1x[1,]+I2x[1,])/Nt, type='l',col='red', lwd=3) 
lines(Tx[1,]/Nt, type='l',col='green', lwd=3) 
legend("right", c("S","E","I","T"), 
col=c("blue","yellow","red","green"),lty=c(1,1,1,1),inset=0.01, cex=0.5) 
 
plot(Ux[1,]/Mt,type='l', xlab='time',ylab='Vector 
population',col='green',lwd=3,ylim=c(0,1)) 
lines(Lx[1,]/Mt, type='l',col='purple', lwd=3) 
lines(Vx[1,]/Mt, type='l',col='orange', lwd=3) 
legend("right", c("U","L","V"), col=c("green","purple","orange"),lty=c(1,1,1),  inset=0.01, 
cex=0.5) 
 
 
###Figure 2...exported to TIFF file 
 
##2.  Prevalence and incidence by P. falciparum only 3 years 
tiff(file = "PCDBaselineMAR1.tiff", width = 360*6, height = 360*6, units = "px", pointsize 
=6, res = 360)  
par(mfrow=c(2,1)) 
par(mar=c(4,4.5,1,1)) 
 
 
# Figure 2A Incidence 
observed<-rep(c(7,32,15,7,11,8,6,1,1,1,1,1),3)  # Observed monthly incidence in Ninarumi   
 
ax1<-seq(1,3*12,3)  
ay1<-c("Y1 Jan","Apr","Jul","Oct","Y2 Jan","Apr","Jul","Oct","Y3 
Jan","Apr","Jul","Oct") 
leg<-c("Model-predicted overall incidence             ","Model-predicted symptomatic 
incidence             ", 
       "Observed symptomatic incidence") 
 
INC<-ITm[1,(12*10+1):(12*(year-7))] 
 
par(mar=c(4,4.5,1,1)) 
plot(INC*y, type="l",lty=1,lwd=2, col="blue", xaxt="n", xlab="", ylab="P.falciparum 
monthly incidence", ylim=c(0,max(INC*1.23)),cex=2) 
text(1, max(INC*1.2),"A", cex=2, col="black",  font=2) 
lines(ITm[1,(12*10+1):(12*(year-7))],type="l", lty=1, lwd=2, col="dark gray") 
lines(observed, type="l", lty=2, lwd=2, col="black") 
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legend(3.5,max(INC*1.24), leg, inset=0.004, cex = 1.1,lty = c(1,1,3), lwd=2, col=c("dark 
gray","blue","black"), horiz=F, y.intersp=1, box.col="white",ncol=2) 
axis(1, at=ax1,labels=ay1, las=2, cex.axis=0.8, tck=-.02)  
 
# Figure 2B  Prevalence 
 
ax1<-seq(1,3*360,13*7)  
ay1<-c("Y1 Jan","Apr","Jul","Oct","Y2 Jan","Apr","Jul","Oct","Y3 
Jan","Apr","Jul","Oct") 
 
leg1<-c("Observed prevalence by microscopy","Model-predicted overall prevalence 
","Model-predicted prevalence by microscopy") 
 
leg2<-c("Model-predicted asymptomatic prevalence", "Model-predicted asymptomatic sub-
microscopic  prevalence", 
        "Model-predicted symptomatic prevalence") 
 
cu<-(360*10+1):(360*(year-7)) 
 
prevPCD<-(E2x[1,cu]+I1x[1,cu]+I2x[1,cu]+Tx[1,cu])/Nt 
 
eo<-c(rep(NA,360),rep(NA,60),6.5/100,rep(NA,29+180),1.1/100, 
rep(NA,89),rep(NA,360)) #Observed prevalence in Ninarumi 
 
plot(prevPCD,type='l',xaxt="n", xlab="", lty=1, ylab='P.falciparum   prevalence',col='dark 
gray',lwd=2,ylim=c(0,1.25*max(prevPCD)), cex=2) 
 
text(0,1.23*max(prevPCD),"B", cex=2, col="black",  font=2) 
lines((E2x[1,cu]*0.5+I1x[1,cu]*0.5+I2x[1,cu]*0.1+Tx[1,cu])/Nt, type='l',col='dark gray', 
lty=2, lwd=2) #Microscopy prevalence 
lines((E2x[1,cu]*0.35+I1x[1,cu]+I2x[1,cu])/Nt, type='l',col='red', lty=1, lwd=1.5)         # 
Asymptomatic   prevalence 
lines((E2x[1,cu]*0.35*0.5+I1x[1,cu]*0.5+I2x[1,cu]*0.9)/Nt, type='l',col='red', lty=2, 
lwd=1.5) # Asymptomatic sub-microscopic  prevalence 
lines((E2x[1,cu]*0.65+Tx[1,cu])/Nt, type='l',col='blue', lty=1, lwd=1.5) #Symptomatic 
prevalence 
#lines(NEWx[1,cu]/Nt, type='l',col='black', lwd=3.5) 
points(1:(360*3),eo, pch ="*", bg = "black",cex=2) 
 
legend(100,1.29*max(prevPCD), leg1, col=c("black","dark gray","dark 
gray"),lty=c(NA,1,3), pch=c("*",NA,NA),  
       inset=0.004, lwd=c(NA,2,2), cex=1.1, box.col="white",y.intersp=1, ncol=1) 
legend(360*1.5,1.29*max(prevPCD), leg2, col=c("red","red","blue"),lty=c(1,3,1),   
       inset=0.004, lwd=c(2,2,2), cex=1.1, box.col="white",y.intersp=1, ncol=1) 
axis(1, at=ax1,labels=ay1, las=2, cex.axis=0.8, tck=-.02)  
text(c(460,675),c(0.065,0.01),c(0.065,0.01),cex = 1) 
 
dev.off() 
Annexes 
 
180 
 
Curriculum vitae 
 
181 
 
SCIENTIFIC CURRICULUM VITAE 
 
 
Angel Rosas-Aguirre is a medical doctor with substantial work experience managing malaria 
control projects in South America. Because of the importance of the evidence-based decision 
making, his professional career has always been continuously interwoven with teaching and 
research activities. His current research aims to understand malaria transmission dynamics in 
Peruvian endemic areas and to generate evidence for improving case detection and treatment 
strategies for the malaria control and elimination. 
 
Positions and Employment 
1999 -2001 Research Assistant, Universidad Peruana Cayetano Heredia (UPCH) – 
Faculty of Public Health and Administration (FPHA). Health Management 
Research Unit. 
2000 – 2001 Medical assistant/ Medical Epidemiologist, Ministry of Health, Regional 
Direction of Pasco, Villa Rica Hospital.   
2002 - 2006 Malaria Advisor, VIGIA Project “Addressing the Threats of Emerging and 
Re-emerging Infectious Diseases”, Ministry of Health/ United States 
Agency for International Development (MOH/USAID), Lima-Peru. 
2007 Malaria Advisor for “Diagnosis and design of Entomological Surveillance 
and Vector Control Systems in Peru” consulting, Ministry of Health, Lima-
Peru. 
2006 - 2011 Multi-Country Project Technical Coordinator, Global Fund Multi-Country 
Malaria Project “Malaria control on the cross border areas of the Andean 
Region: A community based approach”-PAMAFRO/ Organismo Andino de 
Salud- Convenio Hipolito Unanue (ORAS-CONHU), Lima-Peru. 
2009 - 2011 Tutor, Diploma in Health and Local Development, Panamerican Health 
Organization (PAHO), Washington (US)/Lima (Peru). 
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2011 Academic coordinator, International Diploma in malaria control, 
UPCH/MCDI/Marathon Oil, Lima-Peru.  
2011 - 2012 Coordinator, Course Control of malaria and other vector transmitted 
diseases, Master in Control of Tropical Infectious Diseases,UPCH Lima-
Peru. 
2012 - 2013 Principal Consultant/Advisor “Assessment of the diagnosis and treatment in 
areas of low malaria transmission in Peru”, Systems for Improved Access 
to Pharmaceuticals and Services (SIAPS)- Management Sciences for Health 
(MSH), Washington DC. 
2006 - now Associated Researcher, Malaria Research Group, Institute of Tropical 
Medicine Alexander von Humboldt, UPCH, Lima-Peru. 
 
 
Honors 
2000 Sixth (6th) of 121 students at Medical School. Universidad Peruana 
Cayetano Heredia. Lima-Peru, 2000. 
2006 Grant for research project from Macro International Inc./USAID – Peruvian 
National Institute of Statistical and Informatics 
2007 Third (3rd) place in Induquimica Prize Award 2007.  “Validity of 
Parascreen® as malaria rapid diagnostic test”. X Meeting of Peruvian 
Society of Tropical and Infectious Diseases (PSTID). 
2007 Fifth (5th) place in Induquimica Prize Award 2007. “Associated factors to 
homes with malaria during the last year in communities of Loreto Region-
Peru”. X Meeting of PSTID. 
2007 Travel grant for Regional Meeting of Health and Local Development. 
PAHO. 
2009 Travel grant for Vivax Malaria Research III 2009 and Beyond Conference. 
USF Health, Gates Foundation, Welcome Trust. 
2009 Scholarship for attending Diploma in “Quantitative Risk Analysis” Belgian 
Technical Cooperation (BTC). Institute of Tropical Medicine (ITM), 
Antwerp, Belgium.  Sep-Dec 2009. 
2009 Malaria Champion of the Americas” award to PAMAFRO project from 
PAHO.   
2011 Scholarship for PhD studies. BTC. ITM Antwerp - Université catholique de 
Louvain, Antwerp-Brussels, Belgium.  January 2011 – June 2015. 
2013 Scholarship for attending “Mathematical Models for Infectious Disease 
Dynamics” course. The Welcome Trust. Cambridge, UK. February 2013. 
2013 Scholarship for “Science of Eradication: Malaria leadership development 
course” participation. ISGlobal/Barcelona Institute for Global Health/ Swiss 
Tropical & Public Health Institute/ Harvard School of Public Health 
Barcelona, Spain.  May 2013. 
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Contribution to Science 
 
1. His publications are mainly intended to understand the malaria transmission in Peruvian 
endemic areas and to generate evidence for the design and implementation of malaria 
control strategies, particularly: preventive and malaria case detection and treatment 
strategies in the perspective of low transmission.  Many study findings have been used 
for the design of new research studies and for adjusting malaria control strategies at 
regional and national level. He served as the primary investigator or co-investigator in 
all of these studies.  
 
a. Rosas-Aguirre Á, Gamboa D, Rodriguez H, Llanos-Zavalaga F, Aguirre K, Llanos-
Cuentas A. [Use of standardized blood smear slide sets for competency assessment in 
the malaria microscopic diagnosis in the Peruvian Amazon]. Rev Peru Med Exp Salud 
Publica. 2010 Oct-Dec;27(4):540-7. 
b. Rosas-Aguirre A, Guzmán-Guzmán M, Moreno-Gutierrez D, Rodriguez-Ferrucci H, 
Vargas-Pacherrez D, Acuña-González Y. [Long-lasting insecticide - treated bednet 
ownership, retention and usage one year after their distribution in Loreto, Peru]. Rev 
Peru Med Exp Salud Publica. 2011 Jun;28(2):228-36 
c. Arevalo-Herrera M, Quiñones ML, Guerra C, Céspedes N, Giron S, Ahumada M, 
Piñeros JG, Padilla N, Terrientes Z, Rosas A, Padilla JC, Escalante AA, Beier JC, 
Herrera S. Malaria in selected non-Amazonian countries of Latin America. Acta Trop. 
2012 Mar;121(3):303-14.  
d. Grietens KP, Muela Ribera J, Soto V, Tenorio A, Hoibak S, Aguirre AR, Toomer E, 
Rodriguez H, Llanos Cuentas A, D'Alessandro U, Gamboa D, Erhart A. Traditional nets 
interfere with the uptake of long-lasting insecticidal nets in the Peruvian Amazon: the 
relevance of net preference for achieving high coverage and use. PLoS One. 
2013;8(1):e50294.  
e. Rosas-Aguirre A, Llanos-Cuentas A, Speybroeck N, Cook J, Contreras-Mancilla J, Soto 
V, Gamboa D, Pozo E, Ponce OJ, Pereira MO, Soares IS, Theisen M, D'Alessandro U, 
Erhart A. Assessing malaria transmission in a low endemicity area of north-western 
Peru. Malar J. 2013 Sep 22;12:339.  
f. Delgado-Ratto C, Soto-Calle VE, Van den Eede P, Gamboa D, Rosas A, Abatih EN, 
Rodriguez Ferrucci H, Llanos-Cuentas A, Van Geertruyden JP, Erhart A, D'Alessandro 
U. Population structure and spatio-temporal transmission dynamics of Plasmodium vivax 
after radical cure treatment in a rural village of the Peruvian Amazon. Malar J. 2014 Jan 
6;13:8.  
g. Rosas-Aguirre A, Ponce OJ, Carrasco-Escobar G, Speybroeck N, Contreras-Mancilla J, 
Gamboa D, Pozo E, Herrera S, Llanos-Cuentas A. Plasmodium vivax malaria at 
households: spatial clustering and risk factors in a low endemicity urban area of the 
northwestern Peruvian coast. Malar J. 2015 Apr 24;14:176.  
h. Rosas-Aguirre A, Erhart A, Llanos-Cuentas A, Branch O, Berkvens D, Abatih E, 
Lambert P, Frasso G, Rodriguez H, Gamboa D, Sihuincha M, Rosanas-Urgell A, 
D'Alessandro U, Speybroeck N. Modelling the potential of focal screening and treatment 
as elimination strategy for Plasmodium falciparum malaria in the Peruvian Amazon 
Region. Parasit Vectors. 2015 May 7;8:261.  
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2. In addition to the contributions related to malaria case detection interventions described 
above, he participated in scientific and operative studies aimed to generate evidence to 
support the value of community-based malaria diagnosis using malaria rapid diagnostic 
tests (RDTs). Studies assessed the performance of the diagnostic test for use with local 
parasite strains (including the first report of low sensitivity of one HRP2 based-RDT to 
detect P. falciparum in Peru), documented the delays caused by microscopy and the time 
saved by RDT use, and demonstrated that promotores (volunteers community agents 
with limited training) could use the tests safely and effectively. Then, a cost-
effectiveness study strongly suggested that RDT use would generate savings for Ministry 
of Health by greatly reducing complicated cases and reducing overtreatment in 
Amazonian communities with limited access to health facilities.  
 
a. Llanos F, Huayta E, Mendoza D, Rosas A, Contreras C, et al. [Knowledge and 
perceptions of health workers about the malaria rapid diagnostic test Parasight in a 
malaria endemic area of Peru]. Revista Medica Herediana. 2000; 11(4):115-21. 
b. Casapía M, Vásquez L, Rosas A, Pinedo-Ríos N, Cabezas C, et al. [Improvements in 
timely malaria diagnosis and appropriate therapy with the use of rapid tests by health 
promoters in Peruvian Amazon Region]. Revista peruana de medicina experimental y 
salud pública. 2008; 25(4):540-47 
c. Rosas Aguirre AM, Llanos Zavalaga LF, Trelles de Belaunde M. [Cost-effectiveness 
ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon]. Rev Panam 
Salud Publica. 2009 May;25(5):377-88.  
d. Bendezu J, Rosas A, Grande T, Rodriguez H, Llanos-Cuentas A, Escobedo J, Gamboa 
D. Field evaluation of a rapid diagnostic test (Parascreen) for malaria diagnosis in the 
Peruvian Amazon. Malar J. 2010 Jun 7;9:154.  
e. Mendoza NM, Rosas AM, Burgos JD. [Evaluation of rapid diagnostic tests for malaria 
in Colombia as an integral part of the disease control strategy]. Biomedica. 2011 
Mar;31(1):55-69. 
 
3. However the interest in research whose results can be directly applied for improving 
health policies and programs was not only limited to the malaria control.  He has also 
participated in evaluations that have allowed the adjustment of important public social 
and health programs in Peru, such as: maternal and child care program, and food and 
nutrition program.  
 
a. Rojas C, Montes C, Segura L, Rosas A, Llanos-Zavalaga F, et al. [Approach to the 
effect of a School Breakfast Program on the intellectual performance of children in 
elementary and primary schools of Peru]. Revista peruana de medicina experimental y 
salud pública. 2003; 20(1):31-38. 
b. Mispireta M, Rosas A, Velásquez J, Lescano A, Claudio L. [Nutrition transition in 
Peru, 1991-2005]. Revista peruana de medicina experimental y salud pública. 2007; 
24(2):129-35. 
c. Velásquez Hurtado JE, Kusunoki Fuero L, Paredes Quiliche TG, Hurtado La Rosa R, 
Rosas Aguirre ÁM, Vigo Valdez WE. [Neonatal mortality, analysis of surveillance 
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registers, and neonatal medical histories of 2011 in Huanuco and Ucayali, Peru]. Rev 
Peru Med Exp Salud Publica. 2014 Apr;31(2):228-36. 
d. Velásquez Hurtado JE, Solís Alcedo L, Vigo Valdez WE, Rosas Aguirre AM, Giusti 
Hundskopf P, Alfaro Fernandez P, Cabrera Arredondo H. [Evaluating maternal child 
care practices in extreme poverty areas in Peru, 2012]. Rev Peru Med Exp Salud 
Publica. 2014 Apr;31(2):243-53.  
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Period: 2010-2017 
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Project: Research Circle “Towards the elimination of malaria in Peru” 
Role: Principal investigator in two of the four project studies         
Period: 2014-2018 
Agency: Peruvian National Council for Science and Technology (CONCYTEC) 
Objective: Generate solid scientific evidence about strategies of detection and 
treatment of asymptomatic malaria infections, in order to support the 
decision-making in the malaria control and to facilitate the way to its 
elimination in the Peruvian Amazon.    
 
Project: Strengthening the diagnosis, treatment and surveillance strategies for 
the malaria control and elimination in the Peruvian Amazon 
Role: Local principal investigator                                                              
Period: 2014-2019 
Agency: L’Académie Belge de Recherche et d’Enseignement supérieur- 
Commission de la Coopération au Développement (ARES-CCD) 
Objective: To strengthen local capacity for malaria diagnosis, treatment, 
surveillance and research in the Peruvian Amazon Region. 
 
 
 
